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CHAPTER I
INTRODUCTION
Addiction is a chronic, relapsing disorder for which strikingly few effective
therapies exist, and there are no FDA-approved pharmacotherapies for
psychostimulant addiction.

There is an immense need to identify the

neurobiological underpinnings of stimulant addiction and develop efficacious
pharmacotherapies

to

compliment

the

current

mainstay

treatment

of

behavioral/cognitive therapy. Several theories of addiction exist. However, the
propensity of drug-associated cues to increase neuronal activity (Childress et al.,
1999; Hotsenpiller et al., 2001; Hotsenpiller and Wolf, 2002; Rebec and Sun,
2005; Maas et al., 1998) and elicit drug-craving and seeking (Grant et al., 1996;
Bonson et al., 2002; Ehrman et al., 1992) suggests a considerable contribution of
maladaptive associative learning processes in the underlying neuropathology of
addiction. The association between the rewarding effects of abused substances
and contextual cues can be profound and long-lasting. Even after long-periods
of abstinence, cues associated with drug-use can precipitate drug-craving, drugseeking and relapse to drug-taking (Ehrman et al., 1992; Hartz et al., 2001;
O'Brien et al., 1992). In the laboratory, conditioned place preference (CPP) is
demonstrated by rodents (Tzschentke, 1998; Tzschentke, 2007) and humans
(Childs and deWit H., 2009) whereby subjects will choose to spend time in a
1
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context previously associated with a rewarding substance; a behavior which is
thought to reflect the increased salience attributed to drug-associated cues. Thus
CPP is a valuable research tool to evaluate the neuronal adaptations associated
with drug-induced associative learning and provides a means to evaluate the
utility of potential pharmacotherapies to reduce the salience of drug-associated
cues.

Methamphetamine (Meth) is a powerful psychostimulant which reliably produces
CPP (Tzschentke, 2007; Tzschentke, 1998). This behavior reflects molecular,
cellular, and circuit adaptations that occur as a consequence of repeated
psychostimulant administration (Hyman et al., 2006; Nestler, 2004) as well as the
adaptations that underlie acquisition, maintenance, and expression of the Methcontext association (Alberini, 2009; Bailey et al., 1996). Human imaging studies
demonstrate that basal neuronal activity is decreased in the cortex after chronic
cocaine use (Bolla et al., 2004; Goldstein and Volkow, 2002; Volkow et al.,
1992). However, the brain is hyper-responsive to stimuli, including unconditioned
stimuli (subsequent drug-injections) (Sax and Strakowski, 2001; Pierce and
Kalivas, 1997; McDaid et al., 2007; McDaid et al., 2006b) as well as conditioned
stimuli (e.g., drug-associated cues) (Hotsenpiller et al., 2001; Rebec and Sun,
2005; Rebec and Sun, 2005; Hotsenpiller and Wolf, 2002).

This hyper-

responsivity may be a mechanism underlying cue-induced drug-craving and seeking in humans (Childress et al., 1999; O'Brien et al., 1998; Childress et al.,
1999; Ehrman et al., 1992) and rodents (Crombag et al., 2008).

While the
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hyper-excitable brain state is likely the consequence of maladaptations in a
number of neurotransmitter systems such as down-stream signaling proteins,
gene expression patterns, and neuronal function, decreased function of the γamino butyric acid (GABA) system, the major inhibitory neurotransmitter in the
central nervous system, may significantly contribute to the hyper-responsive
brain state.

The metabotropic GABAB receptor (GABABR) system is down-

regulated by psychostimulant administration.

Such down-regulation includes

decreases in GABABR expression (Frankowska et al., 2008b; Frankowska et al.,
2008a), G-protein expression (i.e., Gi/o) (Nestler et al., 1990), and functional
coupling of the receptor to the G-protein (Xi et al., 2003; Zhang et al., 2000).
However, it is not clear if this down-regulation occurs at a time when Methconditioned behaviors are expressed or if a decrease in GABA BR signaling
during withdrawal might contribute to the maintenance of the mal-adapted brain
state and behaviors.

This dissertation project evaluated GABABR

expression and distribution at a time when rats demonstrate Meth-induced
behaviors (e.g., CPP).

The GABABR system has recently emerged as a potential therapeutic target for
drug addiction (Brebner et al., 2002; Cousins et al., 2002; Rose and Grant, 2008;
Xi and Gardner, 2008).

Pharmacological augmentation of GABABR signaling

inhibits the development and expression of many psychostimulant-induced
behaviors including CPP (Li et al., 2001), conditioned locomotion (Hotsenpiller
and Wolf, 2003), motor sensitization (Bartoletti et al., 2005; Bartoletti et al., 2004;
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Frankowska et al., 2009; Lhuillier et al., 2007), and self-administration (Brebner
et al., 2005; Campbell et al., 1999; Filip et al., 2007; Filip and Frankowska, 2007;
Ranaldi and Poeggel, 2002; Roberts et al., 1996; Roberts and Andrews, 1997;
Shoaib et al., 1998; Smith et al., 2004; Weerts et al., 2007).

These results

demonstrate a role of the GABABR in drug-induced processes, but to better
emulate the clinical scenario we wanted to determine the capacity of GABA BR
ligands to modify the maintenance of a previously established psychostimulantinduced behavior. To date, only Bartoletti and colleges have demonstrated the
capacity of the GABABR agonist baclofen to inhibit the maintenance of a
previously established psychostimulant-induced behavior; they demonstrated
that 10 once-daily injections of baclofen inhibited the maintenance of
amphetamine-induced motor sensitization (Bartoletti et al., 2004). We proposed
that pharmacologically augmenting GABABR signaling would disrupt
mnemonic processes necessary to maintain and subsequently express
previously acquired Meth-induced CPP. Furthermore, during the hours, days,
and weeks following psychostimulant administration and memory acquisition, the
brain is highly dynamic with withdrawal-time-dependent effects being observed in
the GABABR system (Zhang et al., 2000; Jayaram and Steketee, 2005) and
withdrawal time-dependent behavioral effects are reported in humans (McGregor
et al., 2005). Thus, we hypothesized that withdrawal time dependent effects
on GABABR expression/distribution and/or function may be reflected as a
change in the capacity of GABABR ligands to disrupt the maintenance of
Meth-induced associative learning.
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Baclofen is a direct-acting (i.e., orthosteric) GABABR agonist, and it produces
substantial undesirable side effects, including sedation and motor impairment,
that may limit its clinical usefulness (Cryan et al., 2004; Jacobson and Cryan,
2005; Heinzerling et al., 2006; Ling et al., 1998; Shoptaw et al., 2003). Positive
allosteric modulators (PAMs) of the GABABR provide an alternative means to
augment GABAergic signaling.

GABABR PAMs do not directly activate

receptors; instead they increase the efficacy of endogenous GABA (Bettler et al.,
2004; Urwyler et al., 2001; Urwyler et al., 2005; Gjoni et al., 2006).

This

dependence on endogenous GABA release makes PAMs regionally and
temporally specific in contrast to direct acting GABABR agonists which bind to
and activate all GABABRs regardless of endogenous GABAergic tone. These
attributes of PAMs result in fewer unwanted side effects than those typically
observed with direct acting agonists, like baclofen (Cryan et al., 2004).
Substantiating the idea that these drugs may be useful for addiction therapy,
PAMs have been shown in laboratory rodents to successfully reduce cocaine
self-administration (Smith et al., 2004) and prevent molecular adaptations
resulting from psychostimulant administration (Lhuillier et al., 2007).

We

hypothesized that systemic administration of the GABABR PAMs would
antagonize the maintenance of Meth-induced CPP without the side effects
associated with the GABABR agonist baclofen.
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One region that might be particularly important in mediating the effects of
systemically administered GABABR ligands is the medial dorsal thalamus (MDT).
The MDT expresses moderate to high levels of GABABR (Margeta-Mitrovic et al.,
1999; Charles et al., 2003) and via afferent and efferent projections modulates
and

is

modulated

by

brain

regions

important

for

the

regulation

of

psychostimulant-induced behaviors and mnemonic processes. Indeed, baclofen
(Romanides et al., 1999) or lidocaine (Floresco et al., 1999) injected into the
MDT inhibits working memory.

The role of the MDT in the maintenance of

psychostimulant-induced associative learning is unclear. To fill this gap, the
present dissertation project evaluated the role of GABABRs in the MDT as
critical regulators of the maintenance of Meth-induced CPP.

A stand alone pharmacotherapy may not be the most effective approach to
reduce the propensity of cue-elicited relapse; likewise, behavioral/cognitive
therapy (i.e., extinction therapy) has not been particularly efficacious in reducing
relapse in abstinent drug-dependent humans (Conklin and Tiffany, 2002) or in
rodent models of addiction (Crombag and Shaham, 2002; Di Ciano P. and
Everitt, 2004).

There is convincing evidence which suggests that combining

extinction therapy with a pharmacotherapy may be more efficacious in reducing
cue-elicited responses in humans (O'Brien et al., 1990) and rodents (Heinrichs et
al., 2010) than with either strategy alone.

Thus, we proposed that the

GABABR agonist, baclofen would promote extinction training.
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These experiments will 1) shed light on the role of GABABRs in the maintenance
of Meth-induced associative learning, 2) provide insight into the role of the MDT
in the maintenance of associative memories, and 3) evaluate the utility of
GABABR activators to reduce the salience of psychostimulant-associated cues.

CHAPTER II
LITERATURE REVIEW
Methamphetamine Addiction
Meth, a highly addictive psychostimulant, is one of the most abused substances
world-wide (United Nations Office on Drugs and crime, 2009) with Meth use
disturbingly high in certain regions in the United States including Hawaii, San
Diego, Los Angeles, San Francisco, and Phoenix (National Institute on Drug
Abuse, 2009). The euphorogenic effects of amphetamines (including Meth), is
the consequence of elevated extracellular concentrations of the monoamines
serotonin (5-HT), dopamine (DA), and norepinephrine (NE) (Baumann et al.,
2002b; Baumann et al., 2002a; Kuczenski et al., 1995; Melega et al., 1995;
Rothman et al., 2001).

The massive increase in synaptic monoamine

concentrations is achieved via multiple mechanisms including inhibition of
reuptake transporters for dopamine (DAT), norepinephrine (NET), and serotonin
(SERT) as well as the vesicular monoamine transporter 2 (VMAT-2) (Amara and
Kuhar, 1993; Rothman and Baumann, 2003; Rudnick and Clark, 1993; Sulzer et
al., 2005).

These mechanisms of Meth function to increase monoamine

concentrations in the synapse.

By virtue of Meth increasing the synaptic

concentrations of the monoamines Meth can be considered an indirect agonist at
DA, NE, and 5-HT receptors. In addition, Meth decreases monoamine
8
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concentration of monoamines achieved as a consequence of these multiple
mechanisms exceeds that achieved by, e.g., cocaine which only inhibits reuptake
transporters (i.e., DAT, NET, SERT) (Hyman and Malenka, 2001). Thus, the
effects of Meth are more profound and long lasting than those observed after
cocaine administration (Fowler et al., 2008) which is thought to underlie the
extraordinarily high abuse liability of Meth.

Withdrawal from psychostimulant administration
The massive efflux of synaptic monoamines observed during psychostimulant
administration activates a number of neurotransmitter receptors to initiate a
cascade of down-stream signaling events that result in neuronal adaptations
which change over the course of hours, days, and weeks after exposure (Zhang
et al., 2001; Ernst and Chang, 2008; McGregor et al., 2005; Camp et al., 1997;
McDaid et al., 2006b; Zhang et al., 2000; Jayaram and Steketee, 2005). These
adaptations can persist long after terminating psychostimulant use, and thus may
underlie the subjective states (e.g., negative affect) that occur during withdrawal
as observed by McGregor and colleagues in Meth withdrawn addicts (McGregor
et al., 2005). Studies demonstrate that basal neuronal activity is decreased in
the cortex during withdrawal from chronic cocaine use in humans (Bolla et al.,
2004;

Goldstein and

Volkow,

2002; Volkow et

al.,

1992)

and after

psychostimulant administration in rodents (Kalivas and Hu, 2006), however the
brain is hyper-responsive to stimuli including re-exposure to cocaine or cocaineassociated cues (Hotsenpiller et al., 2001; Rebec and Sun, 2005; Rebec and
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Sun, 2005; Hotsenpiller and Wolf, 2002; Febo et al., 2004; Ferris et al., 2005;
Sun and Rebec, 2006; Kalivas and Hu, 2006).

As withdrawal time and

contextual cues are important factors in determining neuronal function, brain
state, and subjective behavioral effects, a better understanding of the underlying
neuronal adaptations may aid in developing anti-addiction pharmacotherapies.

Psychostimulant-induced associative learning
Persistent adaptations in neuronal function likely contribute to the behavioral
hallmarks of withdrawal from drug addiction including compulsive drug-seeking,
the inability to stop using the drug even when desired, and high propensity to
relapse to drug-use even after long-periods of withdrawal (American Psychiatric
Association, 2000).
behaviors;

however,

There are several theories why individuals exhibit these
the

association

which

forms

between

the

drug

(unconditioned stimulus) and contextual cues (conditioned stimulus) appears to
be a credible candidate. Repeated administration of psychostimulants creates
persistent molecular and cellular adaptations (Everitt and Wolf, 2002; Hyman and
Malenka, 2001; Hyman et al., 2006; Nestler, 2004).

The stimulant-induced

effects are similar to those that are engaged during mnemonic processes (i.e.,
learning and memory) (Abel and Kandel, 1998; Bailey et al., 1996).

These

overlapping mechanisms (Hyman et al., 2006; Kelley, 2004) include effects on
kinases (e.g., PKA) (Chen et al., 2009; Selcher et al., 2002) and transcription
factors (e.g., CREB) (Carlezon et al., 2005; Lonze and Ginty, 2002). Adaptations
such as these may contribute to cue-elicited neuronal hyper-responsivity

11
observed in brain regions such as the prefrontal cortex (especially the
orbitofrontal and anterior cingulate cortices), amygdala, and thalamus (Childress
et al., 1999; Childress et al., 2008; Kilts et al., 2001; Kilts et al., 2004; Brown et
al., 1992; Zombeck et al., 2008; Ciccocioppo et al., 2001; Rhodes et al., 2005;
Franklin and Druhan, 2000), cue-induced drug-craving (Ehrman et al., 1992;
Hartz et al., 2001; O'Brien et al., 1992), and drug-seeking (Ciccocioppo et al.,
2001; Filip and Frankowska, 2007).

Drug-induced associative learning (i.e.,

drug-induced conditioned place preference, CPP) is the process where an
association

is

learned

between

the

unconditioned

stimulus

(e.g.,

the

psychostimulant) and the context (e.g., place) where the drug was administrated,
i.e., the conditioned stimulus) wherein drug-free laboratory animals (Tzschentke,
1998; Tzschentke, 2007) and humans (Childs and deWit H., 2009) tend to spend
more time in a previously drug-paired context than in one not associated with the
rewarding effects of abused substances. Conditioned place preference can be
induced with a wide range of substances including the Meth (Tzschentke, 1998;
Tzschentke, 2007). Thus, CPP is an efficient and effective means to model the
enhanced salience of Meth-associated cues (i.e., the increased significance
attributed to Meth-associated cues) that occurs during addiction.

Memory that results from associative learning processes (such as that engaged
during CPP) can be divided into short-term (also known as working memory) and
long-term memory. Short- and long-term memories involve distinct processes.
Long-term memory requires a complex interplay of kinases and protein
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transcription in order for learned events to be consolidated, retained, and
subsequently recalled.

Processes necessary for consolidation of long-term

memory (events which occur soon after learning) and reconsolidation (events
necessary to retain a memory following recall) also involve kinases (e.g., PKA)
and protein expression in a time dependent manner within particular brain
regions such as the hippocampus, frontal cortex, and amygdala (McGaugh,
2000). Recall (also known as memory expression) requires glutamate receptors.
The maintenance phase of long-term memory is a relatively un-explored area,
and while it is clear that memory maintenance is highly dynamic (Abel and
Kandel, 1998; Alberini, 2009; Bailey et al., 1996), the exact mechanisms remain
to be elucidated.

Associative learning established during CPP can be broken down into several
distinct phases including development, maintenance, and expression.

The

development of CPP refers to the time when the association between the drug
and the context memory is being acquired (i.e., during conditioning) and
expression is when the learned association is recalled and is demonstrated
behaviorally. The maintenance of CPP refers to the time between when the
drug-cue memory is acquired and when it is subsequently recalled.

This

dynamic phase is a potential point of therapeutic intervention to disrupt unwanted
memories after they have been established. This disruption can occur as a result
of a pharmacologic intervention modifying processes that are necessary to
maintain memory or via extinction training wherein an unwanted memory is
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replaced or over ridden by a new memory.

Applications of these memory

maintenance disrupting approaches are considered in this dissertation.

The GABAB receptor and psychostimulant administration
GABA is the major inhibitory neurotransmitter in the central nervous system.
Ionotropic GABAA receptors mediate fast, robust neuronal inhibition via activation
of chloride channels whereas GABABRs modulate neuronal activity via G-protein
(Gi/o)-dependent mechanisms including inhibition of high voltage activated
calcium (Ca++) channels, activation of inwardly rectifying potassium channels
(GIRKs), and inhibition of cAMP production (Bowery, 1993; Mott and Lewis,
1994). These mechanisms blunt both pre- and post-synaptic neuronal activity.
In order for the GABABR to efficiently mediate these inhibitory effects, the
GABABR must function as an obligate heterodimer complex containing both the
GABABR1 and the GABABR2 receptor (Jones et al., 1998; Kaupmann et al.,
1998; Kuner et al., 1999; White et al., 1998). The GABABR1 receptor subtype
cannot be trafficked to the neuronal surface due to the presence of an
endoplasmic reticulum (ER) retention signal.

This ‘signal’ is found in both

isoforms of the GABABR1, the GABABR1a and the GABABR1b, which differ from
each other by the presence or absence of a sushi domain. Dimerization of the
GABABR1 with the GABABR2 masks the ER retention signal which allows the
receptor dimer to traffic to the neuronal surface (Jones et al., 1998; Kaupmann et
al., 1998; Kuner et al., 1999; White et al., 1998).

Following insertion, the

GABABR1 is responsible for binding to the ligand whereas the GABABR2 is
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responsible for binding of the receptor to the G-protein. Thus, both GABABR
subunits are necessary for ligand-mediated signal transduction (Bettler et al.,
2004; Bowery et al., 2002).

Psychostimulant-induced brain adaptations are highly dynamic and contribute to
withdrawal-time and context-dependent brain states, which involve multiple
neurotransmitter systems and downstream signaling molecules (Nestler, 2001;
Chao and Nestler, 2004). One component contributing to the maladapted brain
state may be the GABABR system.

Specific adaptations are influenced by

neuronal phenotype, number of drug exposures, and withdrawal duration;
however, in general the GABABR system is down-regulated after psychostimulant
administration in a brain region and withdrawal-time dependent manner. The
down-regulation includes decreased GABABR expression (Frankowska et al.,
2008b; Frankowska et al., 2008a), decreased G-protein expression (Gi/o) (Nestler
et al., 1990; Striplin and Kalivas, 1993), and decreased GABABR/G-protein
coupling (Kushner and Unterwald, 2001; Zhang et al., 2000).

Furthermore,

increased basal GABAergic tone (Jayaram and Steketee, 2005; Xi et al., 2003)
and evoked GABA release (Bustamante et al., 2002) is observed after
psychostimulant administration which would be consistent with the apparent
down-regulation of the GABABR system if the brain is attempting to blunt
neuronal activity (i.e., return the brain to a pre-psychostimulant state).
Decreased function of the GABABR system may contribute to the hyper-excitable
brain state observed in subjects during re-exposure to drug stimuli.

15

Withdrawal from psychostimulant administration results in region-specific
changes in brain states that vary during the hours, days, and weeks following
psychostimulant administration.

Examples include, decreased Gi/o G-protein

expression at 14 days, but not at one day, of withdrawal from repeated cocaine
administration (Striplin and Kalivas, 1993), functional coupling of the GABABR to
the G-protein is decreased in the cortex at 14 days withdrawal from repeated
amphetamine, an effect that is not observed at one day withdrawal (Zhang et al.,
2000), and extracellular GABA concentrations are elevated at one and seven, but
not 28 days of withdrawal from repeated cocaine administration (Jayaram and
Steketee, 2005). These studies demonstrate withdrawal time-dependent effects
of psychostimulant administration on the GABABR which may significantly alter
neuronal excitability. Furthermore, changes such as these may render the brain
more vulnerable to pharmacological interventions at certain withdrawal times
than at others. The studies in this dissertation are designed to evaluate these
withdrawal phase-dependent effects.

The GABAB receptor: drug-induced behaviors and mnemonic processes
Pharmacologically augmenting GABABR signaling (via systemic administration of
a GABABR agonist) blunts psychostimulant-induced behaviors, including CPP (Li
et al., 2001), motor sensitization (Bartoletti et al., 2004; Frankowska et al., 2009;
Lhuillier et al., 2007; Hotsenpiller and Wolf, 2003), and self-administration
(Ranaldi and Poeggel, 2002; Brebner et al., 2005; Campbell et al., 1999; Filip et
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al., 2007; Roberts and Andrews, 1997; Smith et al., 2004; Weerts et al., 2007).
These findings lend credibility to the idea that the GABABR system influences
psychostimulant-induced behaviors.

Furthermore, systemic administration of

GABABR agonists negatively regulates mnemonic processes (Castellano et al.,
1989; Levin et al., 2004; McNamara and Skelton, 1996; Nakagawa et al., 1995;
Swartzwelder et al., 1987; Zarrindast et al., 2004; Zarrindast et al., 2001);
however, memory-improving effects have also been observed (Georgiev et al.,
1988; Saha et al., 1993). Therefore, it is not clear what effect pharmacological
augmentation of GABABR signaling might have on the maintenance of learned
associations between Meth and the contextual cues.

The GABABR modulates neuronal excitability, signal transduction, and protein
expression; thus, changes in the GABABR system will significantly affect brain
function. Effects on neuronal excitability are mediated by G-protein-dependent
activation of inwardly rectifying K+ channels and inhibition of high voltage
activated Ca++ channels (i.e., P/Q- and N-type) (Bowery, 1993; Mott and Lewis,
1994). The GABABR is located both pre- and post-synaptically (Bowery, 1993;
Chen et al., 2004; Wirtshafter and Sheppard, 2001) regulating neuronal activity
and the release of other neurotransmitters including dopamine (Gong et al.,
1998; Kalivas, 1993; Santiago et al., 1993a; Santiago et al., 1993c; Smolders et
al., 1995), and glutamate (Bonanno et al., 1997; Huston et al., 1990). Dopamine
and glutamate are critical regulators of drug-induced behaviors, and learning and
memory.

In addition, GABABRs negatively regulate protein expression and
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signal transduction via a G-protein-dependent mechanism (e.g., inhibition of
cAMP) to regulate the activity of the transcriptional regulator cAMP response
element binding protein (CREB) (Barthel et al., 1996; Bettler et al., 2004; Mott
and Lewis, 1994; Lhuillier et al., 2007; Yin et al., 2006). In addition, a G-proteinindependent mechanism exists wherein transcription factors (e.g., ATF4/CREB2)
bind directly to the carboxyl terminus of the receptor (Bettler et al., 2004; White et
al., 2000; Nehring et al., 2000).

Thus, processes that are critical for the

maintenance of Meth-induced behaviors may be disrupted by pharmacologically
augmenting GABABR signaling.

GABAB receptor positive allosteric modulators
Stimulation of the GABABR by the direct acting agonist baclofen causes
significant side effects including hypothermia, sedation, and motor impairment
(Cryan et al., 2004; Jacobson and Cryan, 2005; Heinzerling et al., 2006; Ling et
al., 1998; Paredes and Agmo, 1995; Shoptaw et al., 2003). Baclofen binds to the
orthosteric site, which is located in the large extracellular region of the receptor,
and activate all GABABRs regardless of endogenous GABAergic tone.

In

contrast, positive allosteric modulators (PAMs) of the GABABR bind to a
transmembrane site of the receptor which is distinct from the orthosteric binding
site. Binding of the PAM to the transmembrane site has minimal or no effect on
GABABR signaling in the absence of an agonist.

Rather, PAMs induce a

conformational change which enhances coupling of the receptor to the G-protein
as well as increases the affinity of the receptor for the ligand (i.e., agonist
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binding). Consequently, PAMs increase the potency and maximum efficacy of
endogenous GABA (Bettler et al., 2004; Gjoni et al., 2006; Urwyler et al., 2001).
The enhancement of GABABR signaling only in brain regions / active synapses
where GABA is endogenously released likely underlies the fact that these drugs
have fewer side effects than baclofen and therefore may be an alternative to
baclofen (Bettler et al., 2004; Cryan et al., 2004; Paredes and Agmo, 1995).
Furthermore, the desensitization that can occur during baclofen administration is
not observed with PAMs (Gjoni and Urwyler, 2009; Gjoni and Urwyler, 2008).
Modulation of GABABRs may be a way to modify the maintenance of CPP
without the associated side effects of direct acting agonists such as baclofen.

The medial dorsal thalamus: drug-induced behaviors and mnemonic
processes
Mnemonic processes engage numerous brain regions; however, those which
have been very well characterized are the hippocampus (HC) and the prefrontal
cortex (PFC).

The HC is critically involved in the early phases of memory

consolidation. Memories are subsequently transferred to the PFC for long-term
storage.

Other regions have also been implicated in learning and memory

processes such as the amygdala and the more recently identified medial dorsal
thalamus (MDT). The thalamus has typically been considered a relay region
between the limbic system and the cortex; however, recently the role of the MDT
has been recognized as an important regulator of learning and memory. The
MDT is connected with the PFC, NAc, and VP via glutamatergic (Pirot et al.,

19
1994; Kuroda et al., 1995; Kuroda et al., 1998) and GABAergic projections
(Churchill et al., 1996b; Groenewegen, 1988; Mogenson et al., 1987; Zahm et al.,
1996) via efferent and afferent projections.

A primary source of glutamatergic

afferents to the PFC (a region important for executive control and memory) is the
MDT (Giguere and Goldman-Rakic, 1988; Pirot et al., 1995).

Based on this

anatomy it is not surprising that the MDT is important for associative processes.
Oyoshi et al. revealed that the MDT (particularly the medial portion) is engaged
during conditioned associative tasks (Oyoshi et al., 1996). Furthermore, lesions
of the MDT inhibit the acquisition of sucrose-induced CPP (McAlonan et al.,
1993)

The thalamus, including the MDT, expresses moderate to high levels of
GABABRs (Margeta-Mitrovic et al., 1999; Charles et al., 2003). Following at least
10 days of stable cocaine self-administration, GABABR expression is significantly
reduced throughout the rat brain including in the MDT (Frankowska et al., 2008b;
Frankowska et al., 2008a). Although this change occurs as a consequence of
cocaine self-administration it is not clear if it is driving the self-administration
behavior. Studies have shown that modifying GABA BR signaling within the MDT
modifies behavior; augmenting GABABR signaling within the MDT by intracerebral injections of baclofen dose-dependently increases spontaneous motor
activity (Churchill et al., 1996a) and disrupts working memory (Floresco et al.,
1999; Romanides et al., 1999). The status of GABABRs in the MDT at a time
when Meth-induced associative learning is expressed is unknown. Furthermore,
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the effect of locally augmenting GABABR signaling during the maintenance of
Meth-induced associative learning has not been explored. The experiments in
this project fill in these gaps in the literature.

Significance and therapeutic implications
Addiction is a chronic and relapsing condition. Costs associated with addiction
are an enormous burden on society and the families of the addicted individual.
Thus, there is a huge incentive to determine the underlying neuronal adaptations
and develop effective therapies to reduce the propensity of cue-elicited relapse.
Currently, there are no FDA-approved pharmacotherapies for Meth addiction and
the incidence of relapse is remarkably high following behavioral/cognitive
therapy. Relapse to using abused drugs remains a major challenge for abstinent
addicts. Therefore, determining a way to reduce the salience of drug-associated
memories will be of value to reduce cue-elicited relapse and we propose that the
GABABR may be viable pharmacotherapy target.

CHAPTER III
RATIONALE FOR EXPERIMENTAL DESIGN
AND METHODOLOGY
The studies contained in this dissertation are designed to explore the role of the
GABABR in the maintenance of Meth-induced learned associations.

Several

different CPP paradigms were used to evaluate treatment duration and
withdrawal-time dependent effects of GABABR ligands on the maintenance of
Meth-induced CPP. We further explored combining a GABABR pharmacotherapy
with extinction training as a potential means to rapidly mitigate the maintenance
and subsequent expression of learned associations between the rewarding
effects of Meth and contextual cues.

To better understand the underlying

adaptations contributing to Meth-induced behaviors, the expression and
distribution of the GABABR were evaluated at a time when Meth-induced
behaviors were exhibited. An explanation of selected methodologies is provided
below.

Associative learning is a biological imperative from an evolutionary standpoint.
Animals and humans learn to avoid harmful and stressful situations (conditioned
place aversion, CPA) and to seek out beneficial and pleasurable experiences
(conditioned place preference, CPP). The CPP task measures the associations
that develop between the unconditioned stimulus (e.g., rewarding properties of
21
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psychostimulants) and the unconditioned stimulus (e.g., contextual cues) (Bardo
et al., 1995; Tzschentke, 1998; Tzschentke, 2007).

Place conditioning is a

relatively easy, high-throughput method and it is becoming increasingly used for
evaluations in laboratory rodents; however, the conditioning apparatus,
methodological details, statistical analysis, and even terminology are highly
variable. The merits of the selected CPP paradigms included in this dissertation,
and why these paradigms were selected, are detailed below.

General Methods
Animals

Male Sprague-Dawley rats (Harlan, Indianapolis, IN) weighing 250-300g at the
start of the study were acclimated to the vivarium for at least five days prior to the
onset of the experiments.

Rats were housed in pairs in a climate-controlled

environment (23-25º) on a 12 hr light/dark cycle, and allowed ad libitum access to
food and water. Cage mates were given identical pharmacological treatments.
Housing facilities are accredited through the Association for Assessment and
Accreditation of Laboratory Animal Care, and all experiments were carried out in
accordance with the conditions set forth by the National Institutes of Health
Guide for the Care and Use of Laboratory Animals (National Research Council,
1996) and with the approval of the Loyola University Medical Center or Rush
University Medical Center Institutional Animal Care and Use Committee.

Drugs

23
(+)Methamphetamine HCl (Sigma, St. Louis, MO) was dissolved in 0.9% sterile
saline and administrated as 1mg/ml/kg as the base. Saline was administered as
1ml/kg. All injections were given intraperitoneally (i.p.).

Apparatus for Assessing Conditioned Place Preference
The test room was dimly lit (54-108 lux) with white noise continuously present
(white noise generator, San Diego Instruments, San Diego, CA).

The CPP

apparatus (63cm x 30cm x 30cm) consisted of three chambers divided by
Plexiglas sliding doors (AccuScan Instruments, Inc., Columbus, OH); two large
conditioning chambers (25cm x 30cm x 30cm) separated by a small center
chamber (13cm x 30cm x 30cm). Each chamber had distinct, yet neutral, visual
and tactile cues. Time spent in each chamber and motor activity was monitored
via two sets of photobeams (24 in the horizontal and 12 in the vertical plane).

The rats were transported from the vivarium to the test room at least 30min prior
to the start of the experiment. A 30min pre-test, was used to determine initial
chamber bias and these data were used to assign a Meth-paired chamber (half
were Meth-paired in the chamber in which the greatest amount of time was spent
during the pre-test and half in the chamber in which the least amount of time was
spent during the pre-test). Conditioning was initiated two to three days later.
During the conditioning phase, Meth conditioned rats were given a Meth injection
(1mg/kg, i.p.) every other day (days 1, 3, and 5) and immediately placed into the
appropriate chamber for 45min. On the alternate days (5-day protocol: 2 and 4,
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6-day protocol: 2, 4, and 6), rats were given a saline injection (1ml/kg, i.p.) and
immediately placed into the opposite chamber for 45min. Saline conditioned rats
were given a saline (1ml/kg) for all conditioning sessions. A drug-free CPP test
was performed three days after the last conditioning session (5-day protocol, day
8; 6-day protocol, day 9; termed CPP Test 1). This was accomplished by placing
rats into the center chamber and the sliding doors were immediately removed
allowing free access to the entire CPP box. The test session lasted 30min and
time spent in each chamber was determined.

Elevated Plus Maze
The elevated plus maze (EPM) consisted of two sets of perpendicular arms (50.2
x 10.8cm) located 91.4cm above the floor. The intersection of the arms was 10.8
x 10.8cm. Closed arms had black plastic walls that were 40cm in height on
either side and open arms had no walls. Time spent in each arm and number of
arm entries were (closed vs. open) over 5min were recorded by three trained
observers which were averaged to obtain the value for each rat.

EPM

experiments were conducted under red light conditions.

In order to examine the effects of acute Meth (1mg/kg) administration on anxiety,
a Meth injection was administered 30min prior to the EPM test session. Rats
were then pre-tested, conditioned, and tested as described previously. One day
later, rats were given a drug-free EPM test to determine if Meth-conditioning
altered anxiety.
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Statistics
Conditioned Place Preference: For the pre-test data, time spent in each chamber
was compared using a Paired t-test. CPP was defined as spending significantly
more time in the chamber paired with Meth- vs. time spent in the same chamber
during the pre-test or spending significantly more time in the chamber paired with
Meth- vs. time spent in the saline-paired chamber. These within group analyses
were conducted using a Paired t-test. Between group analyses were conducted
using a Student‟s t-test. Elevated Plus Maze: Time spent in each arm as well as
number of arm entries were compared between Meth- and saline-rats using a
Student‟s t-test.

All data are presented as mean ± standard error of the mean (SEM). Statistical
outliers were determined as those rats that spent greater than two standard
deviations above or below the mean time spent in any chamber or arm.

Results
Conditioned place preference apparatus: Non-biased vs. biased
Typically, a CPP apparatus consists of two- or three-chambers (three chambers
includes a small, center chamber which connects the two conditioning
chambers); each of which contain distinct contextual cues. Studies used in the
current project used a three-chamber apparatus (Accuscan Instruments, Inc;
Columbus, OH); opaque Plexiglas sliding doors separated the two large
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conditioning chambers (25cm x 30cm x 30cm) from the small center chamber
(13cm x 30cm x 30cm). For rodents, conditioning typically utilizes visual and
tactile cues although other sensory modalities may be used (e.g., olfactory cues).
The conditioning apparatus can be configured such that naïve animals spend
approximately equal amounts of time in each chamber (unbiased apparatus) or
unequal amounts of time in each chamber (biased apparatus).

This

determination is often made prior to initiating the study in order to establish
„baseline‟ behavior, and is termed the pre-test. There is some argument that pretested rodents are slower at acquiring the learned association (Tzschentke,
1998), as this presents an opportunity for the animals to become familiar with the
environment; however, including a pre-test has not impacted the ability of rats to
successfully acquire and express Meth-induced CPP (Chapters IV-IX).

The interpretation of the behavior observed during the pre-test deserves
consideration.

Typically, the rats initially explore the new environments

presented by the CPP box, and then, as they become familiar with the
surroundings, they may elect to spend more time in one environment over the
other. The affinity for a particular context often can be ethologically explained,
i.e., rats prefer dark places and avoid brightly lit places, and the literature
typically refers to this as a “preference” for dark places and an “aversion” to the lit
places. Thus, choice of contextual cues (aversive vs. neutral) may contribute to
the development of a biased vs. a non-biased apparatus. Stimuli such as bright
lights are typically avoided by rodents; light/dark box studies demonstrate that
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rodents will chose to spend more time in a dark environment compared to one
that is brightly lit (Bourin and Hascoet, 2003; Costall et al., 1989; Ramos, 2008).
In a CPP apparatus with black and white walls (e.g., Med Associates CPP
apparatus) the natural tendency of rodents to spend time in the chamber with the
black walls is often deterred by the addition of a bright light in that chamber; thus,
creating an apparatus in which subjects spend approximately equal amounts of
time in each chamber (Carlezon, 2003). In this example, the addition of the
aversive stimuli of the bright light produces a non-biased apparatus. We contend
that use of aversive stimuli in the CPP paradigm may compromise the ability to
interpret behavioral outcomes by introducing the confounding factor of anxiety;
thus the preference that develops following conditioning may reflect a reduction
in anxiety rather than rewarding properties of the drug per se. Thus, a better
approach may be to use contextual cues which are inherently neither preferred
nor aversive in rodents, termed neutral contextual cues.

The use of neutral cues (stimuli which are inherently neither aversive nor
preferred by rodents) such as vertical vs. horizontal stripes and non-noxious
textured floors (see Fig. 1), typically will not produce a group preference for either
chamber; however, individual rats may have a preference for one chamber (Shen
et al., 2006). This point is illustrated in Fig. 2. As a group, 55 rats did not
demonstrate a significant preference for Chamber A (vertical stripes on walls with
a textured floor with an overturned paint dish glued in the middle) or Chamber B
(horizontal stripes on walls with a textured floor with a flat, rectangular piece of
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Plexiglas glued to the center of the floor with only a minimal amount of time being
spent in the center compartment (solid color walls with a smooth slightly raised
platform floor) (Fig. 2A, 818±49s vs. 855±51s; paired t-test, p>0.05); however,
individual rats tended to spend more time in one chamber relatively to the other
(Fig 2B; approximately 65% vs. 27%). As the time spent in one compartment vs.
another was random (i.e., some rats spent more time in chamber A and others in
chamber B, Fig 2B), this behavior is difficult to interpret in ethological terms. One
theory, is that the rats may be exploring the CPP apparatus until they are
sufficiently habituated at which time they stop exploring resulting in significantly
more time being spent in that chamber. While individual rats had a bias for one
chamber or the other, as a group there was no chamber bias; thus, the CPP
apparatus used for studies in this project were conducted in a non-biased
apparatus in the sense that all rats do not prefer one chamber over the other.

The use of a non-biased vs. a truly biased apparatus can significantly impact
behavioral outcomes. For example, Cunningham and colleagues manipulated
the conditioning apparatus such that rats had either no preference (non-biased)
or a strong preference (biased) for one chamber (Cunningham et al., 2003). The
use of either the biased or non-biased apparatus can significantly influence
behavioral outcomes. This factor is discussed below in the use of a non-biased
or biased experimental design.
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Conditioned place preference experimental design: Non-biased vs. Biased
design and other considerations
Non-biased vs. biased CPP design refers to the chamber in which animals are
paired with the drug based on initial chamber preference (determined by a pretest).

One method statistically „neutralizes‟ chamber bias by using a

counterbalanced drug-paired chamber assignment, wherein half of the animals
are assigned to be drug-paired in the initially preferred and others in the nonpreferred chamber (Carlezon, 2003). Counterbalancing creates approximately
equal (not statistically different) times being spent in the drug-paired and nondrug-paired chamber prior to conditioning; however, this approach can introduce
considerable variability when animals have strong unconditioned chamber bias
making it difficult to assess small shifts in preference.

In contrast, a biased

design assigns all animals to be drug-paired in the initially preferred or nonpreferred chamber. This methodology has been thoroughly discussed in several
publications (Brielmaier et al., 2008; Cunningham et al., 2003; Roma and Riley,
2005; Hinson et al., 1991).

The use of a non-biased vs. a biased apparatus and experimental design can
significantly impact behavioral outcomes.

For example, Cunningham and

colleagues manipulated the conditioning apparatus such that rats had either no
preference (non-biased apparatus) or a strong preference (biased apparatus) for
one chamber (Cunningham et al., 2003).

Rats were randomly assigned to

receive ethanol in the non-biased apparatus and either the initially preferred or
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non-preferred chamber in the biased apparatus. This study determined that
ethanol-induced CPP can be produced in the non-biased apparatus, however,
when individual rats express a strong initial preference for a chamber during the
pre-test (defined as a large difference in time spent in one chamber relative to
the other) as occurs in a biased apparatus, significant CPP is achieved only in by
pairing ethanol with the initially non-preferred chamber (Cunningham et al.,
2003). This effect is likely due to the ceiling effect that can occur when a strong,
initial preference is present prior to conditioning. Similar findings are reported
with clonidine (Cervo et al., 1993), cocaine (Nomikos and Spyraki, 1988),
cocaethylene (Schechter, 1995), heroin (Schenk et al., 1985), and nicotine
(Calcagnetti and Schechter, 1994).

Furthermore, conditioned place aversion

(CPA) can only be produced when rats are paired with the hallucinogenic drug
LSD in the initially preferred chamber (Meehan and Schechter, 1998). These
findings have been corroborated by our laboratory with Meth-induced CPP.
Although we do not have a true “biased apparatus” and the rats randomly spent
more time in one chamber or the other (Fig 2B), thus individual rats have a
strong unconditioned bias. Here, rats were pre-tested and assigned to receive
Meth in a counterbalanced manner (wherein half of the rats were assigned to
receive Meth in the initially preferred chamber and others in the initially nonpreferred chamber) and subsequently conditioned for five-days with 1mg/kg Meth
(Fig 3A). Using this non-biased design we observed that conditioning produced
CPP when all rats (n=45) were evaluated as a group; time spent in the Methpaired chamber was significantly greater during the CPP test compared to the

31
same

chamber

during

the

pre-test

(Fig

3B,

designated

Non-Biased

Counterbalanced; n=45, paired t-test, p<0.001). However, splitting these rats
into those paired in the initially non-preferred and preferred chambers revealed
that only those rats Meth-paired in the initially non-preferred chamber
demonstrated significant CPP (time spent in the Meth-paired chamber during the
CPP test compared to the same chamber during the pre-test) (Fig 3B;
designated Biased Non-preferred; n=23; paired t-test, p<0.001).

In contrast,

evaluation of data collected from rats paired in the initially preferred chamber
revealed that time spent in the Meth-paired chamber was decreased, not
increased, after Meth-conditioning (Fig 3B; designated Biased Preferred; n=22;
paired t-test, p<0.05) indicating a ceiling effect that may occur when a strong
unconditioned bias is present. These results indicate that it is not appropriate to
Meth-pair rats in the preferred chamber in a biased apparatus.

It also should

be noted that analyzing this same data set by comparing time spent in the salineand Meth-paired chambers for the non-biased and biased (Biased Preferred and
Biased Non-Preferred) all resulted in positive CPP (Fig 3C). However, it should
be noted that this outcome likely does not reflect learning (CPP) in all treatment
groups.

Rather, the CPP data achieved for the Biased Preferred rats looks

remarkably similar to that achieved during the pre-test thus this reflects the
unconditioned preference rather than a learning phenomenon.

Thus, this

underscores the notion that multiple methods of analysis should be used to verify
CPP results as the use of a non-biased vs. biased apparatus and design may
influence the behavioral outcomes and appropriate methods of analysis.
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A controversial aspect of the biased design is the potential contribution of anxiety
associated with pairing in the initially non-preferred chamber may have on
behavioral outcomes.

These concerns arise as a result of complex issues

regarding the motivational states associated with the initially non-preferred
context (Schenk et al., 1985), especially if the non-preferred context can be
ethologically defined (e.g., in a bright chamber). Data obtained from the biased
design can be interpreted in two ways 1) the preference is the result of the
association between the rewarding properties of the drug or 2) the preference is
achieved as a result of anti-anxiety properties of the drug (i.e., initial anxiety for
the non-preferred chamber is overcome). There are several lines of evidence
that belay the concern that CPP is the result of anxiolytic, rather than rewarding,
properties. Regarding the first concern, psychostimulants are not anxiolytic but
rather are anxiogenic particularly after repeated administration (Cancela et al.,
2001;

Olausson

et al.,

2000).

For example,

the

anxiogenic drugs

methamphetamine, amphetamine, and MDMA induce CPP (Daza-Losada et al.,
2007; Lin et al., 1999; Tzschentke, 1998). We observed that Meth (1mg/kg)
administration did not alter anxiety as measured on the elevated plus maze (time
spent in open vs. closed arms or number of open vs. closed arm entries, Fig 4B
and 4C, time spent in each arm as well as number of arm entries were compared
between Meth- and saline-rats using a Student‟s t-test, p>0.05) when
administered 30min prior to the elevated plus maze test (time during peak
psychomotor effects). Furthermore, assessment of anxiety on the elevated plus
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maze failed to reveal an anxiogenic or anxiolytic effect following repeated
administration of methamphetamine which was sufficient to produce a
conditioned place preference when evaluated within 24hr of the drug-free
conditioned place preference test (Fig 4D & 4E, time spent in each arm as well
as number of arm entries were compared between Meth- and saline-rats using a
Student‟s t-test, p>0.05). The second line of evidence to belay concerns about
the contribution of anxiety is that anxiolytic drugs do not always produce a
preference in the CPP paradigm. Variable doses and paradigms used make it
difficult to directly compare across studies, but the benzodiazepines diazepam
and alprazolam produce CPP in some cases (Gray et al., 1999; Le et al., 2002;
Papp et al., 2002; Walker and Ettenberg, 2003; Walker and Ettenberg, 2001;
File, 1986) but have no effect on conditioning in others (File, 1986; Matsuzawa et
al., 2000; Meririnne et al., 1999). Additionally, serotonergic drugs (venlafaxine
and paroxetine), which are commonly used to treat anxiety disorders (i.e.
anxiolytic effects), do not produce CPP (Deslandes et al., 2002; Subhan et al.,
2000; Tzschentke et al., 2006). Taken together, it is unlikely that a reduction in
anxiety is the main cause of Meth-induced CPP in the protocol employed for the
current studies.

Measuring preference
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There are several methods to evaluate CPP data; including between and within
group comparisons.

The selection of a method of analysis and statistical

approach are dictated by experimental design and hypothesis being tested.
Between group comparisons allow for direct treatment effects to be evaluated.
Illustrated in Figures 5 and 6 are data collected from a six-day conditioning
paradigm (timeline illustrated in Fig 4A) wherein rats were conditioned with either
Meth or saline. Between group analyses revealed the following. Time spent in
the Meth-paired chamber (day 1, 3, 5 chamber for saline conditioned rats, termed
“Meth-like chamber”) was significantly greater in Meth-conditioned rats compared
to saline-conditioned rats (Fig 5A; saline conditioned rats (white bar, n=12);
Meth-conditioned rats (black bar, n=48); Student‟s t-test, p<0.05). The second
method demonstrated that subtracting time spent in the saline-paired chamber
(day 2, 4, 6 chamber for saline conditioned rats, termed “saline-like chamber”)
from the time spent in the Meth-like or Meth-paired chamber demonstrated
significant between group differences as well (Fig 5B; saline-conditioned rats
(white bar, n=12); Meth-conditioned rats (black bar, n=47); Student‟s t-test,
p<0.05). Finally, time spent in the Meth-like or Meth-paired chamber minus time
spent in the same chamber during the pre-test revealed significant between
group differences (Fig 5C; saline-conditioned rats (white bar, n=11); Methconditioned rats (black bar, n=47); Student‟s t-test, p<0.001).

While these

methods of analysis are visually quite different, all demonstrate significant
between group differences indicating that Meth conditioning resulted in significant
CPP. Within group comparisons are generally employed for evaluating shifts in
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preference across time. For example, time spent in the Meth-paired chamber
before and after pharmacological treatments or before and after extinction
training. Among the commonly used methods of analysis to evaluate preference
within an experimental group include comparing time spent in the Meth-paired
chamber vs. time spent in the saline-paired chamber (Fig 6A; n=50; Paired t-test,
p<0.001) and time spent in the Meth-paired chamber across multiple tests for
preference (e.g., pre-test vs. CPP test) (Fig 8B; n=50; Paired t-test, p<0.001).

The majority of studies in this project assess changes in preference across time
(i.e., before and after pharmacological treatments in the home cage and before
and after extinction training); therefore, we chose to evaluate data using a within
subject analysis. For example, within group comparison of rats conditioned in a
five-day conditioning paradigm (Fig 3A) revealed that the Biased Preferred rats
spent significantly more time in the Meth-paired chamber than in the salinepaired chamber (Fig 3B; black bars; n=22; paired t-test, p<0.01); however,
preference evaluated across time (pre-test vs. CPP test) demonstrated that time
spent in the Meth-paired chamber decreased after conditioning (Fig 3A; black
bars; n=22; paired t-test, p<0.05). This observation underscores the importance
of validating behavioral outcomes with more than one statistical approach in
order to avoid type I and type II error. While not presented in this dissertation, all
data sets were analyzed with several different statistical methods to verify the
behavioral outcomes.
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Concluding Remarks
There is a place for the biased design in CPP assessments. Especially when
using a CPP apparatus which engenders a strong, unconditioned bias which will
reduce variability revealing CPP which might otherwise be undetected due to the
ceiling effect which may occur. We contend, and here demonstrate, that the
biased design demonstrates reward-mediated behavior and not necessarily an
anxiety-reducing phenomenon and thus is appropriate to test the proposed
hypothesis in the current project.

Rationale for doses used
Methamphetamine
In the current series of experiments, 1mg/kg Meth reliably produced persistent
CPP in several different experimental paradigms independent of conditioning
protocol used, withdrawal time imposed, or repeated CPP testing. This outcome
is in agreement with published studies demonstrating that Meth-induced CPP is
readily produced with 1mg/kg Meth in both two- and eight-day conditioning
protocols (Kitanaka et al., 2010; Li et al., 2002; Herrold et al., 2009; Schindler et
al., 2002). A dose-response evaluation for Meth-induced CPP was conducted
and demonstrated that Meth-induced CPP was produced by 0.3mg/kg and
1mg/kg (as the base) but not 0.1mg/kg in a six-day conditioning protocol; but, the
persistence of the behavior was more robust in the 1mg/kg conditioned rats (data
collected by Amy A. Herrold).

Indeed, studies contained in this dissertation

demonstrate the enduring behavioral effects (i.e., CPP) established with 1mg/kg
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Meth conditioning (see data contained in Chapters IV-VIII and especially Chapter
IX). Furthermore, this dose and dosing paradigm is below that which induces
neuronal toxicity (e.g., decreased DAT expression and glial fibrillary acid protein
expression) (Krasnova and Cadet, 2009; McDaid et al., 2006a).

GABAB Receptor ligands
Baclofen is a well-characterized drug which has been clinically available since
the 1970‟s. It has been widely employed as a GABABR agonist ((-) baclofen
IC50=33μM; (+) baclofen IC50=0.04 μM) (Bowery et al., 1983). Baclofen has
been tested as an anti-relapse medication in clinical trials (Brebner et al., 2002;
Cousins et al., 2002; Heinzerling et al., 2006; Ling et al., 1998; Shoptaw et al.,
2003); however substantial side effects including sedation and motor impairment
limit the utility of baclofen (Cryan et al., 2004; Heinzerling et al., 2006; Jacobson
and Cryan, 2005; Ling et al., 1998; Shoptaw et al., 2003). The dose selected for
baclofen in the current study (2mg/kg) is below the threshold published in the
literature to produce significant side effects in rodents; baclofen (2.5 & 5mg/kg)
inhibits motor behavior, impairs memory, and induced hypothermia (Cryan et al.,
2004). We have verified that motor performance assessed on the rotarod was
significantly inhibited by 4mg/kg baclofen (For results see Chapter V).
Additionally, while 3mg/kg baclofen produced an impairment in spontaneous
motor activity, the motoric effects of 2mg/kg baclofen did not differ from that of
vehicle (horizontal activity, photobeam breaks over 75min post-injection for
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vehicle (n=7), 2422±189; baclofen 2mg/kg (n=6), 1728±388; baclofen 3mg/kg
(n=6), 1067±258; ANOVA p=0.012, post-hoc Dunnett‟s).

The dose of 2mg/kg baclofen is within the range of doses found to successfully i)
attenuate the development and expression of Meth-induced CPP when
administered 30 min prior to each daily conditioning session or CPP test,
respectively (1.25, 2.5, 5mg/kg, i.p.) (Li et al., 2001) ii) inhibit the reinstatement of
nicotine-induced CPP and self-administration when administered 5 min prior to
testing (0.612, 1.25, 2.5mg/kg, i.p.) (Fattore et al., 2009), iii) reduce cocaine selfadministration when administered 10 min prior to the session (2.5mg/kg, i.p.)
(Smith et al., 2004), iv) reduce amphetamine self-administration (i.e., break point)
when administered 30min prior to testing (1.8, 3.2, 5.6mg/kg, i.p.) (Brebner et al.,
2005), and v) inhibit the maintenance of amphetamine-induced motor
sensitization (2mg/kg, i.p.) (Bartoletti et al., 2004).

Plasma and brain

concentrations of baclofen are reported to be relatively consistent for at least
180min after a single bolus intravenous (i.v.) injection of baclofen in the rat
(50mg/kg) (Deguchi et al., 1995) which aligns with enduring effects of GABAergic
ligands on drug-induced behaviors. Orally administered baclofen (5mg/kg) elicits
centrally-mediated events including hypothermia (Cryan et al., 2004) within one
hour after baclofen administration suggesting that the onset of action is relatively
short.
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To evaluate the involvement of GABABRs in the MDT in the maintenance of
Meth-induced CPP, baclofen was injected directly into the MDT. The dose of
0.5nmol/0.5μl/side baclofen was selected because it is within the range of MDTinjected doses found to be behaviorally relevant to inhibit working memory
(doses used were 0.03-0.3nmol) (Romanides et al., 1999) and influence motor
activity (doses used were 0.003-1.0nmol) (Churchill et al., 1996a).

The

behavioral effects (i.e., motor activity and memory retention) of locally injected
baclofen can be antagonized by co-administration of GABABR antagonists (i.e.,
CGP35348 or saclofen) (Zarrindast et al., 2002; Churchill et al., 1996a) indicating
these behavioral effects are the consequence of baclofen acting at the GABABR.

Fendiline. Fendiline is an L-type Ca++ channel blocker that is used clinically as a
coronary vasodilator (Bayer and Mannhold, 1987; Nawrath et al., 1998; Tripathi
et al., 1993) has recently been discovered to function as a GABABR PAM (Ong
and Kerr, 2005; Ong et al., 2005). While radioligand binding studies to determine
the affinity of fendiline for the GABABR have not been published, fendiline was
found to potentiate baclofen inhibition of neuronal activity (neuronal inhibition
EC50=20μM) (Chen et al., 2005; Ong et al., 2005).

The GABABR positive

allosteric modulator fendiline modulates GABABR signaling without the motor
side effects associated with baclofen as we verified using the rotarod
assessment for motivated motor behavior (Chapter V). While motor performance
was significantly inhibited by 4mg/kg baclofen, the GABABR PAM fendiline
(5mg/kg) did not affect performance (For results see Chapter V).

The ability of
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fendiline to modify psychostimulant-induced behaviors remains unknown but the
dose of 5mg/kg was selected based on studies which show peripheral
cardiovascular effects (Bayer and Mannhold, 1987). Fendiline pharmacokinetics
demonstrate a slow onset of action and a long half-life (Bayer and Mannhold,
1987).

Adverse behavioral effects (including sedation) were observed with

30mg/kg fendiline (unpublished data) thus the dose used for the studies in the
current project was 5mg/kg.

GS39783, and CGP7930. The GABABR PAMs GS39783 and CGP7930 were
selected based on several criteria: 1) They are positive allosteric modulators of
the GABABR but with distinct molecular structures. 2) While radioligand binding
studies to determine the affinity of these ligands for the GABABR have not been
published, they both enhance the binding of GABABR agonists (i.e., baclofen and
GABA), decrease the binding of GABABR antagonists, and potentiate the effects
of baclofen on K+ currents, cAMP production, and neuronal activity (EC50=1μM
for both ligands) (Urwyler et al., 2004; Chen et al., 2005; Olianas et al., 2005). 3)
Lack of significant side effects at even 200mg/kg (p.o.) (Cryan et al., 2004). 4)
The dose of 30mg/kg (i.p.) GS39783 and CGP7930 successfully reduces
cocaine self- administration when administered 10 min prior to the session (Smith
et al., 2004). Finally, 5) while the pharmacokinetics of the PAMs GS39783 and
CGP7930 have not been published, GS39783 (3mg/kg, i.p.), and CGP7930
(30mg/kg, i.p.) significantly reduce cocaine self-administration for at least 10hr,
indicating that these ligands may actively alter brain processes for several hours
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after a single administration (Smith et al., 2004). The dose of 30mg/kg for both
ligands was selected based on their favorable side effect profile and ability to
alter psychostimulant-induced behaviors.
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Figure 1. Illustration of three-chamber CPP apparatus used for studies in the
current project. A. Shows the test procedure before (left) and after (right) the
dividers have been removed.
conditioning.

B.

Shows the chambers (A & B) used for
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Figure 2. Demonstration of pre-test results generated in our three-chamber CPP
apparatus.

A. Time spent in each chamber (sec) as an average of a group of

rats (n=55). Data analyzed as a paired t-test, p>0.05. Center chamber was not
included for statistical analysis and is illustrated for qualitative purposes. B. The
same data illustrated as individual rats.
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Figure 3.

Non-biased vs. biased conditioned place preference experimental

design. A. Timeline illustrating the five-day conditioning protocol. Conditioning
was preceded by a drug-free pre-test followed by five days of conditioning which
consisted of Meth (1mg/kg)-conditioning interposed by saline (1ml/kg)-
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conditioning, concluding in a drug-free CPP test.

Trtmnt, treatment; Meth,

methamphetamine; Sal, saline; Ø, no drug. B. Within group comparison of time
spent in the saline- and Meth-paired chambers during the CPP test. C. Within
group comparison of time spent in the Meth-paired chamber during the CPP test
compared to time spent in the same chamber during the pre-test. Non-biased
Counterbalanced (n=45), Biased Preferred (n=23), Biased Non-Preferred (n=22).
Data were analyzed with a paired t-test for each data set, * p<0.05, ** p<0.01.
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Figure 4. Neither acute Meth nor repeated Meth administration had any effect
on anxiety measured in the elevated plus maze. A. Timeline illustrating testing
and treatment protocol. B & C. Effect of acute saline (1ml/kg) or Meth (1mg/kg)
administration on time spent in the open or closed arms (B) or number of arm
entries into the open or closed arms (C). D & E. Effect of repeated saline
(1ml/kg) or Meth (1mg/kg) administration in the CPP conditioning paradigm when
tested in a drug-free state 24hr after testing for CPP on time spent in the open
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arms (D) or number of arm entries into the closed or open arms (E). Data were
analyzed with a Student‟s t-test, p>0.05.
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Figure 5.

Between group analysis for Meth-induced CPP.

A.

Timeline

illustrating the six-day conditioning protocol. A drug-free pre-test was followed by
conditioning which consisted of Meth (1mg/kg)-conditioning interposed by saline
(1ml/kg)-conditioning, concluding in a drug-free CPP test.

Trtmnt, treatment;

Meth, methamphetamine; Sal, saline; Ø, no drug. B. Illustrates time spent in the
Day 1, 3, 5-paired chamber (saline or Meth) for each group during the CPP test.
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C. Illustrates time spent in the Day 1, 3, 5-paired chamber minus time spent in
the Day 2, 4, 6-paired chamber during the CPP test for each group.

D.

Illustrates time spent in the Day 1, 3, 5-paired chamber during the CPP test
minus time spent in the same chamber during the pre-test for each group. Data
were analyzed with a Student‟s t-test, * p<0.05, *** p<0.001. White bars indicate
saline-conditioned rats (they received saline-pairings on all days); black bars
indicate rats that were conditioned with Meth and learned to associate Meth with
a particular chamber.
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Figure 6. Within group analysis for methamphetamine (Meth) conditioned rats.
A.

Timeline illustrating the six-day conditioning protocol.

Conditioning was

preceded by a drug-free pre-test followed by six days of conditioning which
consisted of Meth (1mg/kg)-conditioning interposed by saline (1ml/kg)conditioning, concluding in a drug-free CPP test.
methamphetamine; Sal, saline; Ø, no drug.

B.

Trtmnt, treatment; Meth,

Illustrates time spent in the

saline- and Meth-paired chambers during the CPP test. C. Illustrates time spent
in the Meth-paired chamber during the CPP test compared to time spent in the
same chamber during the pre-test. Data were analyzed with a paired t-test,
n=55, p<0.001.

CHAPTER IV
REPEATED BACLOFEN ADMINISTRATION INHIBITS THE MAINTENANCE OF
METHAMPHETAMINE-INDUCED CONDITIONED PLACE PREFERENCE
Abstract
Using conditioned place preference (CPP), the present study sought to
determine if post-conditioning, home cage administration of the GABABR agonist
baclofen inhibited the maintenance of methamphetamine (Meth)-induced
associative learning and if this effect depended upon the time period during
which baclofen was administered. Male Sprague Dawley rats were conditioned
with Meth (1mg/kg, i.p.) and saline. Baclofen (2mg/kg, i.p.) was subsequently
administered and CPP was tested as follows: i) Baclofen given for two days
during early withdrawal from Meth conditioning (protocol days 6 & 7); CPP tested
one or 11 days later.

ii) Baclofen administered for two days during more

protracted withdrawal from conditioning (protocol days 16 & 17); CPP tested for
CPP one day later. iii) Baclofen given for 10 days (protocol days 9-18); CPP
tested 3 days later. These studies revealed that post-conditioning administration
of 10 once-daily home cage injections of baclofen inhibited the maintenance and
subsequent expression of Meth-induced CPP.

This inhibitory effect was not

observed when baclofen was administered for two days independent of when
those two injections were administered.

These data indicate that the

maintenance of Meth-induced associative learning can be disrupted by
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pharmacologically augmenting GABABR signaling for 10 days. As a reduction in
the significance of Meth-associated cues is a means to reduce relapse, baclofen
may be of value for addiction therapy in abstinent Meth-abusing humans.

Introduction
Re-exposure to drug-paired cues increases neuronal activity in limbic brain
regions in drug-withdrawn, drug-addicted/dependent humans (Childress et al.,
1999; Childress et al., 2008) and rodents (Brown et al., 1992; Zombeck et al.,
2008; Franklin and Druhan, 2000; Ciccocioppo et al., 2001; Rhodes et al., 2005),
and can elicit drug-craving and drug-seeking even after long periods of
withdrawal (O'Brien et al., 1992; Ehrman et al., 1992). Therefore, disrupting the
maintenance of the drug-cue association may reduce the propensity of cueinduced relapse. Learned associations between the rewarding effects of abused
substances (unconditioned stimulus) and the context in which the drugs were
administered (conditioned stimulus) can be produced in the laboratory using
conditioned place preference (CPP) in humans (Childs and deWit H., 2009) and
rodents (Tzschentke, 2007). Thus, this behavioral paradigm has been widely
employed to investigate processes engaged during associative learning as well
as to help identify potential pharmacotherapies for relapse prevention. There are
currently no FDA-approved treatments for methamphetamine (Meth) addiction
and the mainstay behavioral/cognitive therapies might be improved by adding a
pharmacotherapy. To best model the human scenario, the potential therapies
should demonstrate the capacity to reduce/reverse the drug-conditioned effects.
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Towards that end, we employed Meth-induced CPP in rats and subsequently
administered repeated post-conditioning, home cage injections of baclofen, a
GABABR agonist, to determine if it would inhibit the maintenance of Methinduced associative learning.

Baclofen

has received

considerable

support as a

viable therapy for

psychostimulant abuse (Brebner et al., 2002; Xi and Gardner, 2008; Rose and
Grant, 2008; Vocci and Appel, 2007; Cousins et al., 2002). Neuronal activity is
negatively regulated by the GABABR (Mott and Lewis, 1994; Bowery, 1993); the
GABABR decreases release of several neurotransmitters including glutamate
(Giorgetti et al., 2002; Huston et al., 1990; Bonanno et al., 1997) and dopamine
(Santiago et al., 1993a; Gong et al., 1998; Kalivas, 1993; Smolders et al., 1995;
Santiago et al., 1993c).

Moreover, GABABRs modify downstream effectors,

such as transcription factor activity (Bettler et al., 2004; Mott and Lewis, 1994;
Barthel et al., 1996), which also underlie psychostimulant-induced neuroplasticity
(Chen et al., 2009; Nestler, 2001) and mnemonic processes (Wang et al., 2006;
Quevedo et al., 2004; Bailey et al., 1996; Berke and Hyman, 2000) Therefore
the GABABR is positioned to influence many systems critical for the maintenance
of CPP behaviors.

The

GABABR

is

down-regulated

after

psychostimulant

administration

(Frankowska et al., 2008b; Kushner and Unterwald, 2001; Zhang et al., 2000)
and pharmacologically augmenting GABABR signaling inhibits the development
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and expression of psychostimulant-induced behaviors, including CPP (Li et al.,
2001), motor sensitization (Bartoletti et al., 2005), and self administration (Smith
et al., 2004; Brebner et al., 2005; Filip et al., 2007; Filip and Frankowska, 2007;
Ranaldi and Poeggel, 2002). However, to date only a report from Bartoletti and
colleagues (Bartoletti et al., 2004) has demonstrated that baclofen inhibits the
maintenance of a previously established psychostimulant-induced behavior; i.e.,
the maintenance of amphetamine-induced motor sensitization was inhibited by
baclofen.

Motor sensitization and CPP demonstrate different dose-related

profiles for amphetamine and engage different brain substrates (Shen et al.,
2006; Rademacher et al., 2006; Shoblock et al., 2003). Thus, to extend the
current literature, we determined if baclofen would inhibit the maintenance of
Meth-induced CPP.

The current study evaluated withdrawal time- and duration-dependent effects of
baclofen on the maintenance of Meth-induced CPP.

Withdrawal from

psychostimulants is a dynamic process with different brain states being present
during the hours, days, and weeks following psychostimulant exposure (Zhang et
al., 2001; Ernst and Chang, 2008; McGregor et al., 2005; Camp et al., 1997;
McDaid et al., 2006b; Zhang et al., 2000; Jayaram and Steketee, 2005); thus the
brain substrate on which baclofen will act will vary greatly depending on the
withdrawal time. This includes flux in a number of neurotransmitters (e.g., GABA
and glutamate) and downstream signaling molecules (e.g., the transcription
factor CREB). For example, functional coupling of the GABA BR is decreased in
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the cortex at 14 days withdrawal from repeated amphetamine, an effect that is
not observed at one day withdrawal (Zhang et al., 2000).

Likewise, the

transcription factor CREB is differentially regulated after a sensitizing regimen of
Meth with CREB being elevated at three but not 14 days withdrawal (McDaid et
al., 2006b). Thus, the brain state is highly dynamic and baclofen administered
during one post-conditioning withdrawal time may not necessary be effective
during another.

The current study evaluated the possibility of “windows of

opportunity” for baclofen to be effective as well as the possibility of treatment
duration effects of baclofen on the maintenance of Meth-induced associative
learning.

Materials and Methods
Animals
Male Sprague-Dawley rats (n=94) (Harlan, Indianapolis, IN) weighing 250-300g
at the start of the study were acclimated to the vivarium for at least five days prior
to the onset of the experiments.

Rats were housed in pairs in a climate-

controlled environment (23-25º) on a 12 hr light/dark cycle, and allowed ad
libitum access to food and water.
pharmacological treatments.

Cage mates were given identical

Housing facilities are accredited through the

Association for Assessment and Accreditation of Laboratory Animal Care, and all
experiments were carried out in accordance with the conditions set forth by the
National Institutes of Health Guide for the Care and Use of Laboratory Animals
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(National Research Council, 1996) and with the approval of the Rush University
Institutional Animal Care and Use Committee.

Drugs
(+)Methamphetamine HCl (Sigma, St. Louis, MO) was dissolved in 0.9% sterile
saline and administrated as 1mg/ml/kg as the base; saline was administered as
1ml/kg; baclofen (2mg/kg; Sigma, St Louis, MO), and baclofen vehicle (0.9%
saline; 1ml/kg). All injections were given intraperitoneally (i.p.).

The 2mg/kg dose of baclofen was selected because it was within the range of
doses used in laboratory rats to successfully i) attenuate the development and
expression of Meth-induced CPP when administered 30min prior to each daily
conditioning session or CPP test, respectively (doses tested were 1.25, 2.5,
5mg/kg, i.p.) (Li et al., 2001), ii) inhibit the reinstatement of nicotine-induced CPP
and self-administration when administered 5min prior to testing (0.612, 1.25,
2.5mg/kg, i.p. were used) (Fattore et al., 2009), iii) reduce cocaine selfadministration when given 10min prior to the session (2.5mg/kg, i.p.) (Smith et
al., 2004), iv) reduce amphetamine self administration when administered 30min
prior to testing (doses tested were 1.8, 3.2, 5.6mg/kg, i.p.) (Brebner et al., 2005),
and v) inhibit the maintenance of amphetamine-induced motor sensitization
(2mg/kg, i.p.) (Bartoletti et al., 2004). In addition, we determined in a pilot study
that 3mg/kg baclofen reduced motor activity, but no impairment was observed
with 2mg/kg baclofen (e.g., horizontal activity, over 75min post injection for
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vehicle (n=7), 2422±189; baclofen 2mg/kg (n=6), 1728±388; baclofen 3mg/kg
(n=6), 1067±258; one-way ANOVA p=0.012, post-hoc Dunnett’s showed
significance for 3mg/kg).

Apparatus for Assessing Behavior
The test room was dimly lit (54-108 lux) with white noise continuously present
(white noise generator, San Diego Instruments, San Diego, CA).

The CPP

apparatus (63cm x 30cm x 30cm) consisted of three chambers divided by
Plexiglas sliding doors (AccuScan Instruments, Inc., Columbus, OH); two large
conditioning chambers (25cm x 30cm x 30cm) separated by a small center
chamber (13cm x 30cm x 30cm). Each chamber had distinct visual (vertical vs.
horizontal lines on walls) and tactile (patterned floor with an overturned paint dish
glued to the center of the floor or differently patterned floor with a smooth
rectangle glued to the center of the floor) cues which were randomized for
visual/tactile cue combinations. The center chamber had white, solid colored
walls and a smooth slightly raised platform floor. Time spent in each chamber
and motor activity was monitored via two sets of photobeams (24 in the
horizontal plane and 12 vertical).

Conditioned Place Preference
Rats were transported from the animal housing room to the adjacent test room at
least 30min prior to the start of the experiment. Rats were subjected to a 30min
pre-test at least 72hr prior to initiating conditioning to determine unconditioned
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preference. Pre-test results demonstrated that the box configuration resulted in
rats spending unequal amounts of time in each chamber (n=94; time spent
727±38sec vs. 950±39sec, p<0.05); thus, rats were Meth-paired in the chamber
in which they spent the least amount of time during the pre-test. As illustrated in
the experimental timelines (Figs. 9A, 10A, & 11A), conditioning occurred over five
days; Meth-conditioned rats were given a Meth injection (1mg/kg) every other
day for three days (days 1, 3, & 5) and a saline injection (1ml/kg) on the alternate
two days (days 2 & 4). This five-day conditioning protocol reliably produces
amphetamine- (Shen et al., 2006; Rademacher et al., 2006) and Meth- (Chapters
IV& VII and unpublished data) induced CPP. Moreover, alternating the order of
Meth administration does not influence preference outcomes and the resulting
CPP is similar to that obtained with 6-day conditioning protocol (Chapter VI).
During conditioning, immediately after the injection rats were placed into the
appropriate chamber of the CPP box for 45min.

After conditioning, three

experiment-specific protocols were used to determine withdrawal time and
treatment duration effects of baclofen on Meth-induced CPP, as described below.

Experiment 1: Early Withdrawal (Short vs. Long-Term Maintenance)
This experiment was designed to ascertain the effects of baclofen on the shortterm maintenance of Meth-induced CPP (see Fig. 9A for experimental time line).
Rats were assigned to a treatment group based on pre-test outcomes such that
time spent in each chamber prior to conditioning was approximately equal
between treatment groups. Rats were administered two-once daily home cage
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injections (protocol days 6 & 7) of baclofen (2mg/kg) or baclofen vehicle (1ml/kg);
one day (protocol day 8) or 11 days (protocol day 18) after the last injection rats
were tested for CPP in a drug-free state. For the CPP test, rats were allowed
free access to the entire CPP box and time spent in each chamber was
monitored for 30min.

Experiment 2: Protracted withdrawal (Long-Term Maintenance)
This experiment was designed to ascertain if baclofen effects on the
maintenance of Meth-induced CPP were withdrawal-time dependent (See Fig.
10A for experimental time line). After conditioning, but before the home cage
treatments were initiated, rats were given a drug-free CPP test to verify the
development of the preference (Fig 10A; protocol day 11). Rats that did not
increase time spent in the Meth-paired chamber on CPP Test 1 compared to the
same chamber during the pre-test by at least 10% (180sec) were excluded from
the study. Culling rats based on the strength of learning (Paolone et al., 2009),
helps assure that only those rats that clearly acquired the task were used to
determine the potential for GABABR ligands to subsequently reduce the acquired
preference.

Rats were assigned to a treatment group such that the magnitude

of CPP expressed during CPP Test 1 was approximately equal for both treatment
groups.

Rats were subsequently administered two once-daily home cage

injections (protocol days 16 & 17) of baclofen (2mg/kg) or baclofen vehicle
(1ml/kg). One day after the last home cage injection (protocol day 18), rats were
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tested in a drug-free state in order to ascertain if preference demonstrated during
CPP Test 1 could be disrupted.

Experiment 3: Sub-Chronic Baclofen Administration & the Long-Term
Maintenance of Meth-induced CPP
This experiment was designed to ascertain if a longer duration baclofen
treatment would inhibit the maintenance of Meth-induced CPP (see Fig. 11A for
experimental time line).

Rats were tested in a drug-free state three days after

conditioning (day 8) and culled using the method described previously to ensure
robust initial preference. Rats were assigned to a treatment group such that the
magnitude of CPP expressed during CPP Test 1 was approximately equal for
both treatment groups.

Rats were subsequently administered 10 once-daily

home cage injections (protocol days 9-18) of baclofen (2mg/kg) or baclofen
vehicle (1ml/kg). Three days after the last home cage injection (protocol day 21),
rats were tested in a drug-free state to ascertain if preference demonstrated
during CPP Test 1 could be disrupted. This three-day period was imposed to
allow the sub-chronic baclofen treatment to be cleared from the system prior to
testing so we could determine baclofen effects on memory maintenance.

Statistical Analysis
CPP was defined as spending significantly more time in the Meth- vs. the salinepaired chamber. For Experiment 1, a two-way ANOVA was used (Treatment x
Chamber) to determine the effect of treatment on preference expressed during
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the CPP Test.

A two-way repeated measures ANOVA was employed for

Experiments 2 and 3 (Chamber x Test) to evaluate the changes in preference
that occurred before and after home cage treatments (i.e., CPP Test 1 vs. CPP
Test 2). For all experiments, a post-hoc Newman-Keuls test was conducted.
Similar approaches were used by Stewart and colleagues (Paolone et al., 2009;
Botreau et al., 2006). Time spent in the center compartment was not used for
CPP statistical analysis but we verified that time spent in the center chamber was
not different between treatment groups or during any test within a treatment
group (Student’s t-test or repeated measures ANOVA, respectively). All data are
presented as mean ± standard error of the mean (SEM). Statistical outliers,
determined as those rats that spent greater than two standard deviations above
or below the mean time spent in any chamber, were not included for analysis.

Results
Experiment 1: Early Withdrawal (Short vs. Long-Term Maintenance)
To determine if processes engaged soon after conditioning could be inhibited by
baclofen, two once-daily, post-conditioning, home cage injections of baclofen or
vehicle were administered on protocol days 6 & 7 (Fig. 9A) and the rats were
tested one day later (protocol day 8). Baclofen did not inhibit the maintenance
and subsequent expression of Meth-induced CPP in either protocol. A two-way
ANOVA revealed a significant effect of Chamber (F(1,54)=33.86, p<0.0001) with a
non-significant effect of Treatment (F(1,54)=0, p=0.996) and Treatment x Chamber
interaction (F(1,54)=1.83, p=0.182).

A post-hoc Newman-Keuls test revealed
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significantly more time was spent in the Meth-paired chamber compared to the
saline-paired chamber for vehicle (Fig. 9B, n=14, p<0.001) and baclofen (Fig. 9B,
n=15, p<0.01) treated rats.

Time spent in the middle chamber was not

significantly different between treatment groups (Student’s t-test, p>0.05). Thus,
two injections of baclofen administered on the days soon after Meth conditioning
failed to alter the expression of CPP one day.

To determine if the time between baclofen administration and CPP testing altered
the ability of baclofen to disrupt the preference for the Meth-associated context,
another group of Meth-conditioned rats, administered baclofen (2mg/kg) or
baclofen vehicle (1ml/kg) on days 6 and 7, were tested for the expression of the
preference on day 18. Similar to those tested one day after baclofen, these rats
successfully expressed CPP (time spent Meth-paired chamber, 1141±46sec vs.
time spent in the saline-paired chamber, 455±45sec; paired t-test, p<0.0001).
Findings from these two experiments converge to demonstrate that two injections
of baclofen given soon after conditioning (i.e., protocol days 6 and 7) did not
inhibit the expression of Meth-induced CPP one or 11 days later.

Experiment 2: Protracted withdrawal (Long-Term Maintenance)
In this experiment, CPP Test 1 was incorporated on protocol day 11 (see Fig.
10A) in order to verify that rats successfully developed the preference for the
Meth-paired chamber prior to administration of the home cage treatments and
then to allow identification of the strongest learners to provide a more rigorous
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evaluation of the ability of baclofen to reduce this learning. As a group, the 30
rats tested expressed CPP (time spent Meth-paired chamber, 896±48sec; vs.
saline-paired chamber, 758±48sec; paired t-test, p<0.05); however, six out of 30
rats did not increase time spent in the Meth-paired chamber on CPP Test 1 by
10% (180s) more than time spent in the same compartment during the pre-test,
thus they were not tested for antagonism by baclofen.

To determine if baclofen administered during a later withdrawal time (protocol
days 16 & 17) would disrupt previously acquired place preference when CPP
expression was tested one day later (day 18). Vehicle treated rats (Fig 10B, n=9)
expressed a preference for the Meth-paired chamber before (protocol day 11)
and after the two home cage vehicle injections (protocol day 18).

Two-way

repeated measures ANOVA revealed a significant effect of

Chamber

(F(1,16)=19.832, p=0.0004) as well as a significant Chamber x Test interaction
(F(1,16)=4.528, p=0.049) with no effect of Test (F(1,16)=0.020, p=0.889). A posthoc Newman-Keuls revealed significantly more time was spent in the Methpaired chamber compared to the saline-paired chamber for both tests (p<0.01).
This indicates that the acquired preference demonstrated during CPP Test 1 was
not diminished on CPP Test 2 (day 18); therefore, repeated CPP testing,
intervening home cage injections, or withdrawal time did not alter subsequent
expression of place preference.

The baclofen treatments resulted in similar

outcomes obtained with vehicle; i.e., preference maintained after two once-daily
injections of baclofen (Fig. 10C, n=13). A two-way repeated measures ANOVA
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revealed a significant effect of Chamber (F(1,24)=17.483, p=0.0003) with no effect
of Test (F(1,24)=0.072, p=0.790) or Chamber x Test interaction (F(1,24)=0.122,
p=0.730). A post-hoc Newman-Keuls test revealed significant CPP during CPP
Test 1 (p<0.01) and CPP Test 2 (p<0.05). For each test, time spent in the middle
chamber did not significantly change for either treatment group (Student’s t-test,
p>0.05). Thus, findings from Experiments 1 and 2 indicate that two once-daily
injections of baclofen independent of when they are administered (days 6 & 7 vs.
16 & 17) or tested (day 8 or 18) failed to alter the expression of CPP induced by
a five-day Meth conditioning protocol.

Experiment 3: Sub-Chronic Baclofen Administration & the Long-Term
Maintenance of Meth-induced CPP
As a group, the 32 rats tested expressed CPP during Test 1 (time spent Methpaired chamber, 999±43sec vs. saline-paired chamber, 645±44sec; paired t-test,
p<0.0001); however, four out of 32 did not increase time spent in the Meth-paired
chamber on CPP Test 1 by 10% (180s) more than time spent in the same
compartment during the pre-test thus they were not used to evaluate antagonism
by baclofen.

In this Experiment, a three day period was imposed between the last home cage
injection to allow baclofen to be cleared from the system prior to testing for
preference,

to clearly delineate between baclofen effects on maintenance

(tested in a drug-free state) vs. baclofen effects on expression (baclofen present
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during the CPP test). Post-conditioning administration of the vehicle (days 9-18)
did not impact the ability of rats to express a preference for the Meth-paired
chamber (Fig. 11B, n=12). Two-way repeated measures ANOVA revealed a
significant effect of Chamber (F(1,22)=27.298, p<0.0.0001) but no effect of Test
(F(1,22)=0.051, p=0.823) or Chamber x Test interaction (F(1,22)=0.103, p=0.751). A
post-hoc Newman-Keuls test revealed significant preference for both CPP tests
(Fig. 11B; p<0.01).

This demonstrated that the acquired preference

demonstrated during CPP Test 1 was not diminished on CPP Test 2 (day 21);
therefore, repeated CPP testing, intervening home cage injections, and
withdrawal time did not alter subsequent CPP.

In contrast, CPP that was

observed during CPP Test 1 was not maintained after 10 days of home-cage
baclofen injections (Fig. 11C, n=13).

Two-way repeated measures ANOVA

revealed a significant effect of Chamber (F(1,24)=20.814, p=0.0001) and a
Chamber x Test interaction (F(1,24)=5.742, p=0.025) but no effect of Test
(F(1,24)=0.009, p=0.926).

A post-hoc Newman-Keuls test reveled significant

preference for CPP Test 1 (p<0.01) but not for CPP Test 2 (p>0.05). These
findings demonstrate that sub-chronic treatments with baclofen can disrupt the
maintenance of Meth-induced CPP. The inability of rats to express a preference
for the Meth-paired chamber did not reflect motor deficits engendered by the
repeated baclofen treatment for activity during CPP Test 2 was statistically
indistinguishable between vehicle (n=12) and baclofen (n=13) treated rats.
(Horizontal Activity; vehicle, 3281±291 vs. baclofen, 3390±193, Student’s t-test,
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p>0.05. Vertical Activity; vehicle, 593±76 vs. baclofen, 554±59, Student’s t-test,
p>0.05.)

Discussion
Results from this study revealed that 10 once-daily home cage injections of
baclofen inhibited the maintenance of Meth-induced CPP. The critical feature of
this effect appeared to be the sub-chronic exposure as opposed to time during
which baclofen was administered or when the CPP was tested, for baclofen
given during the first two or last two days of this treatment period were
ineffective, and place preference was sustained whether CPP testing occurred
one or 11 days after the last injection. These findings suggest that persistent
adaptations engendered by repeatedly augmenting GABABR signaling (i.e., for
more than two days) was sufficient to disrupt processes necessary to maintain
Meth-induced associative learning.

Psychostimulant-induced brain adaptations are complex, involving multiple
neurotransmitter systems and downstream signaling molecules (Nestler, 2004;
Nestler, 2001; McDaid et al., 2006b; McDaid et al., 2007). Contributing to the
dysregulated brain state during withdrawal from repeated psychostimulant
administration is a decrease in the expression of GABA BRs (Frankowska et al.,
2008b) as well as a reduction in functional coupling of the receptor to the Gprotein (Zhang et al., 2000; Kushner and Unterwald, 2001). Withdrawal from
repeated psychostimulant exposure is a dynamic process with different brain
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states occurring in the hours, days, and weeks after terminating psychostimulant
administration. For example, functional coupling of the GABABR is decreased in
the nucleus accumbens and increased in the cortex at 14 days withdrawal from
repeated amphetamine, an effect that is not observed at one day withdrawal
(Zhang et al., 2000). The time dependent nature of these changes may translate
into periods of time when the brain is more vulnerable, or sensitive, to
pharmacological interventions.

In the current study, two once-daily injections

administered during the two days following conditioning (protocol days 6 & 7) or
delayed by 10 days (protocol days 16 & 17) were not able to reveal withdrawal
time-dependent effects. This indicates that the brain state during early vs. more
protracted withdrawal does not impact the ability of two once-daily treatments of
baclofen to disrupt the maintenance of Meth-induced CPP. Rather, our findings
point to the duration of the baclofen treatment being a critical factor in disrupting
maintenance previously acquired place preference.

The maintenance of psychostimulant-induced behaviors is relatively unexplored;
the current study has demonstrated for the first time that 10 once-daily injections
inhibit the maintenance of Meth-induced associative learning. To the best of our
knowledge, no literature has demonstrated baclofen effects on memory
maintenance; however, memory acquisition and expression are sensitive to
pharmacological disruption by baclofen (Nakagawa et al., 1995; McNamara and
Skelton, 1996; Castellano et al., 1989; Swartzwelder et al., 1987; Zarrindast et
al., 2002; Zarrindast et al., 2004; Levin et al., 2004; Li et al., 2001; Stackman and
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Walsh, 1994). A single study by Bartoletti and colleagues has demonstrated that
10 injections of 2mg/kg baclofen inhibit the maintenance of amphetamineinduced motor sensitization (Bartoletti et al., 2004).

As a collective, these

findings suggest that 10 injections of baclofen target a mechanism that is
engaged during Meth-induced CPP (current results) and amphetamine-induced
behavioral sensitization (Bartoletti et al., 2004).

Ten once-daily baclofen injections have influenced the expression of these
psychostimulant-induced behaviors by a number of mechanisms.

Repeated

administration of an agonist may result in receptor down-regulation and/or
desensitization. A single baclofen administration (5-30mg/kg) has been reported
to dose-dependently decrease GABABR expression in gerbil brain when
measured 2hr after the injection (Park et al., 2004); however, mRNA expression
of the GABABR is not altered by a tolerance-inducing baclofen administration
protocol (2 x daily 5mg/kg, x 7 days) in rat spinal cord (Sands et al., 2003).
Chronic baclofen administration (10mg/kg x 21 days) can functionally downregulate GABABR responses in rat spinal cord (Malcangio et al., 1995).
Therefore, in the current study we cannot determine if a change in GABABR
expression may have contributed to the observed behavioral results; however
based on previous studies which either blunt or augment neuronal activity it
seems unlikely that reducing inhibitory GABAergic tone would inhibit the
maintenance of Meth-induced CPP. Other candidate mechanisms may involve
downstream consequences of repeated (i.e., > 2 injections) GABABR activation.
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GABABR negatively regulate signal transduction, ion channel function and gene
transcription, via inwardly rectifying potassium channels (GIRKs), calcium
channels, and cAMP (Bettler et al., 2004; Mott and Lewis, 1994; Barthel et al.,
1996). Indeed, increasing the dose and/or duration of baclofen administration
appears to have a more profound effect on the downstream consequences of
GABABR activation.

No changes in neuropeptide gene expression (e.g.,

preprodynorphine and preproenkephalin) were observed with a single systemic
injection of 2.5mg/kg baclofen; however, a single large systemic dose (10mg/kg)
increases c-Fos expression in specific brain regions (van Nieuwenhuijzen et al.,
2009) and seven injections (10mg/kg) alter the expression and activation of the
transcription factor cAMP response element binding protein (CREB) (Yin et al.,
2006). Activation (i.e., phosphorylation) of transcription factors in limbic brain
regions is a molecular consequence of psychostimulant administration (McDaid
et al., 2006b; Carlezon et al., 2005; Olson et al., 2005; Berke and Hyman, 2000;
Chen et al., 2009; Nestler, 2001) and is also involved in learning in memory
processes (Wang et al., 2006; Bailey et al., 1996; Berke and Hyman, 2000;
Alberini, 2009). The GABABR activation pharmacologically antagonizes events
leading to changes in the transcription factor CREB (Yin et al., 2006; Lhuillier et
al., 2007) and also normalizes downstream consequences of changes in gene
transcription including ΔFosB (Lhuillier et al., 2007) and neuropeptide gene
expression (Zhou et al., 2004). Thus, changes in the function of transcription
factors provides an overlapping mechanism by which baclofen can alter the
maintenance of memory and psychostimulant-induced behaviors.
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Conclusion
In summary, we have found that pharmacologically augmenting GABABR
signaling for 10 days inhibited brain mechanisms necessary to maintain and
subsequently express Meth-induced associative learning. The results of these
experiments provide insight into the role of the GABA BR in memory processes
engaged during the maintenance of Meth-induced CPP and may be of value as
an addiction therapy for abstinent, Meth abusing individuals an effect which may
be independent of when the treatment is initiated.
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Figure 7. Maintenance of Meth-induced CPP was not altered by two-once daily
injections of baclofen administered during the early post-conditioning phase. A.
Illustration of Experiment 1 treatment protocol. M, methamphetamine (1mg/kg);
S, saline (1mg/kg); Ø, no drug; V, baclofen vehicle (0.9% saline, 1ml/kg); B,
baclofen (2mg/kg). Data were analyzed with a two-way ANOVA followed by a
post-hoc Newman-Keuls which compared time spent in the Meth- (filled bar) and
saline- (open bar) paired chambers (significance denoted by *** p< 0.001 or ** p<
0.01). The center compartment (hatched bar) was not included for statistical
comparisons.

B.

Rats that received two post-conditioning vehicle injections

expressed a preference for the Meth-paired chamber one day later (protocol day
8, left set of bar graphs; n=14). Rats that received two injections of baclofen also
expressed CPP (right set of bar graphs; n=15).
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Figure 8. Maintenance of Meth-induced CPP was not inhibited by two once-daily
home cage injections of baclofen initiated during the late post-conditioning
phase.

A.

Illustration of Experiment 2 treatment protocol.

M,

methamphetamine (1mg/kg); S, saline (1mg/kg); Ø, no drug; V, baclofen vehicle
(0.9% saline, 1ml/kg); B, baclofen (2mg/kg). Data were analyzed with a two-way
repeated measures ANOVA followed by a post-hoc Newman-Keuls which
compared time spent in the Meth- (filled square) and saline- (open square) paired
chambers (significance denoted by ** p<0.01 or * p<0.05).

The center

compartment (filled triangle) was not included for statistical comparisons.

B.
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Rats assigned to the baclofen vehicle (n=9) expressed CPP on both test days
(CPP Test 1 & CPP Test 2). C. Rats that received baclofen treatment (n=13)
also expressed a preference for the Meth-paired chamber on both test days
(CPP Test 1 & CPP Test 2).
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Figure 9.
baclofen.

Meth-induced CPP was inhibited by 10 once-daily injections of
A.

Illustration of Experiment 3 treatment protocol.

M,

methamphetamine (1mg/kg); S, saline (1mg/kg); Ø, no drug; V, vehicle (0.9%
saline, 1ml/kg); B, baclofen (2mg/kg).

Data were analyzed with a two-way

repeated measures ANOVA followed by a post-hoc Newman-Keuls which
compared time spent in the Meth- (filled square) and saline- (open square) paired
chambers. (significance denoted by ** p<0.01). The center compartment (filled
triangle) was not included for statistical comparisons.

B.

Rats assigned to

receive baclofen vehicle (n=12) expressed CPP during both CPP tests (CPP Test
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1 & CPP Test 2). C. Rats that received baclofen treatments (n=13) expressed a
preference for the Meth-paired chamber during CPP Test 1 but the preference
was no longer evident during CPP Test 2 (p>0.05).

CHAPTER V
POST-CONDITIONING ADMINISTRATION OF THE GABAB RECEPTOR
POSTITIVE ALLOSTERIC MODULATOR / Ca++ CHANNEL BLOCKER
FENDILINE ANTAGONIZES THE MAINTENANCE AND
EXPRESSION OF METHAMPHETAMINE-INDUCED
CONDITIONED PLACE PREFERENCE
Abstract
The current study evaluated the potential of fendiline, a GABABR positive
allosteric modulator and L-type calcium channel blocker, to inhibit the
maintenance and expression of learned associations between methamphetamine
(Meth; the unconditioned stimulus) and a unique environmental context (a
conditioned stimulus).

Meth (1mg/kg)-induced associative learning was

established using a six-day conditioned place preference (CPP) paradigm, and
fendiline or its vehicle was administered at various post-conditioning times. The
dose selected for fendiline (5mg/kg) did not inhibit motivated motor behavior
assessed on the rotarod nor produced rewarding or aversive effects on its own
as determined with the CPP/CPA task.

In rats demonstrating Meth-induced

CPP, two once-daily injections of fendiline did not influence the maintenance of
place preference when tested in a drug-free state regardless of the postconditioning phase or the length of time between terminating the fendiline
treatments and the test for preference when tested. In contrast, 10 once-daily
fendiline treatments were successful in inhibiting the maintenance of the
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preference.

Following re-conditioning, an injection of fendiline administered

immediately prior to the CPP test revealed that expression of Meth-induced CPP
was inhibited in rats with a treatment history of 10 fendiline injections and rats
that received two injections of fendiline corresponding to the last two days of the
10 day treatment.

These experiments reveal duration-dependent effects of

fendiline on the maintenance of Meth-induced CPP and withdrawal time-after
fendiline treatment-dependent effects of fendiline on the expression of Methinduced CPP. As a reduction in the significance of Meth-associated cues is a
means to reduce relapse, fendiline, or other drugs with similar chemical
properties may be of value for addiction therapy in abstinent Meth-addicted
humans.

Introduction
During repeated psychostimulant administration, associations are made between
the rewarding effects of the stimulant and the context in which the drug was
administered.
responsive

to

After terminating the drug treatments, the brain is hypersubsequent

re-exposure

to

psychostimulant-paired

cues

(Hotsenpiller et al., 2001; Rebec and Sun, 2005; Rebec and Sun, 2005;
Hotsenpiller and Wolf, 2002).

This hyper-responsivity may be an underlying

mechanism contributing to cue-induced drug-craving and seeking in humans
(Childress et al., 1999; O'Brien et al., 1998; Childress et al., 1999; Ehrman et al.,
1992) and rodents (Crombag et al., 2008). This behavior can be observed in the
laboratory using conditioned place preference (CPP) (Childs and deWit H., 2009;
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Tzschentke, 2007; Tzschentke, 1998). CPP provides a useful means to explore
the potential for pharmacotherapies to reduce cue-elicited drug-craving and –
seeking in the abstinent addict.
methamphetamine (Meth).

The current study is focused on

Meth is a potent and highly abused psychostimulant

for which no FDA-approved pharmacotherapy is available, therefore; there is a
large unmet need to develop an anti-relapse therapy for Meth addiction.

The maladapted brain state that occurs after repeated psychostimulant
administration is the consequence of several factors, including a down-regulation
of the GABABR system (Frankowska et al., 2008b; Kushner and Unterwald,
2001; Zhang et al., 2000) and an up-regulation of L-type calcium channels
(Shibasaki et al., 2010; Ford et al., 2009; Nasif et al., 2005a; Nasif et al., 2005b;
Hu, 2007). The inhibitory effects of the GABABR are mediated by inhibition of
high voltage-activated Ca++ channels (Mott and Lewis, 1994; Bowery, 1993) thus
this provides a unique opportunity for GABABRs to blunt the neuronal excitability
that occurs as a consequence of the up-regulated Ca++ channels. The GABABR
and the L-type calcium channel have received attention as possible targets for a
pharmacotherapy for addiction (Brebner et al., 2002; Xi and Gardner, 2008; Rose
and Grant, 2008; Vetulani, 2001). The GABABR agonist baclofen inhibits the
maintenance and expression of amphetamine-induced behavioral sensitization
(Bartoletti et al., 2004; Bartoletti et al., 2005), the expression of Meth-induced
CPP (Li et al., 2001), and decreases Meth (Ranaldi and Poeggel, 2002),
amphetamine (Brebner et al., 2005) and cocaine self-administration (Filip et al.,
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2007; Filip and Frankowska, 2007). A drawback to the practical application of
direct acting GABABR agonists, such as the baclofen, is sedation and motor
impairment (Cryan et al., 2004; Ling et al., 1998; Shoptaw et al., 2003;
Heinzerling et al., 2006). Positive allosteric modulators (PAMs) of the GABA BR
selectively augment GABABR-mediated signaling by acting only where
endogenous GABA is already bound to the GABA BR (Bettler et al., 2004; Urwyler
et al., 2001; Gjoni et al., 2006; Urwyler et al., 2005). This action affords PAMs
considerable regional and temporal specificity compared to direct acting agonists
such as baclofen. Consequently, GABABR PAMs present fewer negative side
effects than those associated with direct (orthosteric) acting agonists like
baclofen. Furthermore, the receptor desensitization and down regulation that
occurs with direct agonists is not observed with PAMs (Gjoni and Urwyler, 2008)
which is an additional therapeutic advantage as long-term treatment would likely
be necessary for an anti-addiction therapy. Like baclofen, GABABR PAMs (i.e.,
CGP7930 and GS39783) reduce the maintenance of Meth-induced CPP (Voigt et
al., unpublished data), cocaine self-administration (Smith et al., 2004; Filip et al.,
2007) and cocaine- and cue-induced reinstatement of cocaine-seeking (Filip and
Frankowska, 2007). Attenuation of stimulant-induced behaviors is also observed
with L-type calcium channel blockers which inhibit the expression of nicotine(Biala, 2003), Meth-, and cocaine-induced CPP (Suzuki et al., 1992), cocaineinduced behavioral sensitization (Martin-Iverson and Reimer, 1994), and
attenuates drug-primed reinstatement of nicotine self-administration (Biala and
Budzynska, 2008). Collectively, these studies demonstrate that GABA BR PAMs
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and L-type calcium channel blockers modulate stimulant-mediated behaviors.
The capacity of these targets to modify the maintenance and expression of Methinduced behaviors was to date, unknown, and thus, is the focus of the current
study.

We consider the dual actions of fendiline, a GABA BR PAM (Ong and

Kerr, 2005; Ong et al., 2005; Chen et al., 2005) and L-type calcium channel
blocker (Tripathi et al., 1993; Nawrath et al., 1998; Bayer and Mannhold, 1987) to
be particularly interesting which compelled us to evaluate the ability of fendiline
to mitigate previously acquired CPP.

Psychostimulant administration initiates a cascade of down-stream signaling
events which change over the course of hours, days, and weeks following the
last exposure (Zhang et al., 2000; Zhang et al., 2001; Camp et al., 1997; Ernst
and Chang, 2008; Jayaram and Steketee, 2005; McDaid et al., 2006b). For
example, functional coupling of the GABABR is observed at 14 but not one day
withdrawal from repeated amphetamine administration (Zhang et al., 2000).
Changes such as these are manifested as different phases of withdrawal which
have been observed during the three weeks following the cessation of Meth use
(McGregor et al., 2005). The dynamic brain state present after psychostimulant
administration presents an opportunity during which the brain may be more
sensitive or vulnerable to disruption of mechanisms necessary to maintain and
subsequently express psychostimulant-induced behaviors. The current study,
evaluated the post-conditioning time and duration-dependent effects of fendiline
on the maintenance and expression of Meth-induced CPP.
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Materials and Methods
Animals
Male Sprague-Dawley rats (n=118, Harlan, Indianapolis, IN) weighing 225-250g
at the start of the study were acclimated to the vivarium for at least five days prior
to the onset of the experiments.

Rats were housed in pairs in a climate-

controlled environment on a 12hr light/dark cycle and allowed ad libitum access
to food and water. Cage mates were given identical pharmacological treatments.
Housing facilities are accredited through the Association for Assessment and
Accreditation of Laboratory Animal Care, and all experiments were carried out in
accordance with the conditions set forth by the National Institutes of Health
Guide for the Care and Use of Laboratory Animals (National Research Council,
1996) and with the approval of the Rush University Medical Center Institutional
Animal Care and Use Committee.

Drugs
Conditioning: (+)Methamphetamine HCl (Sigma, St. Louis, MO) was dissolved in
0.9% sterile saline and administrated as 1mg/ml/kg (calculated as the base) and
saline was administered as 1ml/kg. Home Cage Treatment: Fendiline [N-(3,3diphenylpropyl)-α-methylbenzylamine] (Sigma, St. Louis, MO) 5mg/ml/kg or
fendiline vehicle (25% EtOH) 1ml/kg. Rotarod: Fendiline 5mg/ml/kg; fendiline
vehicle 1ml/kg; (+/-)baclofen 4mg/kg/ml (a direct GABABR agonist, Sigma, St.
Louis, MO); baclofen vehicle (0.9% saline) 1ml/kg; and positive control
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pentobarbital 10mg/kg/ml (an agonist of ionotropic GABA A receptors; Ovation
Pharmaceuticals, Inc., Deerfield, IL). All injections were given intraperitoneally
(i.p.).

The 5mg/kg dose of fendiline was selected for CPP experiments based on
literature demonstrating that this dose provides improved cardiovascular function
(e.g., antihypertensive effects) while having a favorable side effect profile in
humans (Bayer & Mannhold 1987) and pilot studies conducted in our laboratory
(a higher dose of 30mg/kg resulted in adverse side effects in rodents).

For

example, 4mg/kg baclofen was selected as a GABA BR positive control for a
rotarod motor-control study because it was within the range of doses previously
used in laboratory rats to successfully attenuate psychostimulant-induced
behaviors including Meth-induced CPP (1.25, 2.5, 5mg/kg, i.p.) (Li et al., 2001)
and amphetamine self-administration (1.8, 3.2, 5.6mg/kg, i.p.) (Brebner et al.,
2005). As another positive control, we conducted a pilot study to verify that the
10mg/kg pentobarbital dose was below that which is necessary to induce
anesthesia or inhibit the righting reflex but was sufficient to induce motor slowing.

Experiment 1: Assessment of motivated motor function
Rotarod assessments were used to ascertain the effects of treatments used in
the CPP protocols on motivated motor function requiring a high degree of motor
coordination. The rotarod apparatus (San Diego Instruments, San Diego, CA)
consisted of four animal lanes (each 11cm wide). The drum (7cm diameter) was
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positioned to achieve a 46cm fall height. The rotating drum was accelerated 540rpm over 5min. Previously Meth-conditioned rats were trained until all rats met
the criterion of remaining on the rotarod for a minimum of 3min. On the test day,
a test compound was administered and latency to fall from the apparatus (sec)
was measured at the following time points: 0 (immediately prior to injection), 20,
40, 60, 180, 360min, and 24hr after the injection. A repeated measures design
was used (all rats were evaluated with each test compound).

Rats were

“retrained” on the apparatus 24hr prior to each test to ensure that minimum
criterion (i.e., had to remain on the rotarod apparatus for a minimum of 3min)
was maintained across multiple tests.

Conditioning apparatus
The test room was dimly lit (54-108 lux) with white noise (white noise generator,
San Diego Instruments, San Diego, CA) continuously present.

The CPP

apparatus (AccuScan Instruments, Inc., Columbus, OH) (63cm x 30cm x 30cm)
consisted of three chambers divided by Plexiglas sliding doors; two large
conditioning chambers (25cm x 30cm x 30cm) were separated by a small center
chamber (13cm x 30cm x 30cm). Each chamber had distinct visual and tactile
cues (chamber A, vertical lines on walls and an overturned paint dish glued to the
center of a randomly patterned floor; chamber B, horizontal lines on walls and a
square patterned floor; center chamber, no stripes on walls and a smooth,
slightly raised platform floor). Time spent in each chamber and motor activity
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was monitored via two sets of photobeams (24 in the horizontal plane and 12
vertical in the vertical plane).

Experiment

2:

Assessment

of

fendiline

in

conditioned

place

preference/conditioned place aversion
This experiment was designed to test rewarding or aversive properties
associated with fendiline. The timeline is illustrated in Fig. 12. The rats were
transported from the animal housing room to the adjacent test room at least
30min prior to the start of the experiment. Rats were subjected to a 30min pretest at least 72hr prior to initiating conditioning to determine unconditioned
preference. Pre-test results verified that the box configuration did not engender a
bias for either chamber; however individual rats tended to spend more time in
one chamber or another other so rats were counterbalanced; half received
fendiline in the initially preferred chamber and half in the initially non-preferred
chamber. This experimental design was employed because it was unclear if
fendiline would produce a preference (CPP) or an aversion (conditioned place
aversion, CPA) the counterbalanced design allows for detection of both;
accordingly rats which spent more than 75% of the pre-test in one chamber were
excluded from further analysis (2 out of 10 rats from the study). Conditioning
occurred over 10 days; two conditioning sessions took place each day. Each
morning, rats were injected with vehicle (25% EtOH 1ml/kg i.p.) and immediately
placed in one CPP chamber for 45min; 4hr later, the other chamber was paired
with fendiline (5mg/kg i.p.) for 45min. Three days following the final conditioning

85
session rats, were given a drug-free CPP test. The three day period between
conditioning and the CPP test was imposed to allow for fendiline to be cleared
from the system prior to testing for preference. For the 30min CPP test, rats
were allowed free access to the entire CPP apparatus and time spent in each
chamber and motor activity was monitored.

Experiments 3-5: Methamphetamine-induced conditioned place preference
Rats were pre-tested as described above, and were paired with Meth in the
chamber in which they spent the least amount of time during the pre-test. As
illustrated in the experimental timelines (Fig. 12B & 12C), conditioning occurred
over six days; Meth-conditioned rats were given a Meth injection every other day
for three days and a saline injection on the alternate three days.

During

conditioning, rats were placed into the appropriate chamber of the CPP box
immediately after the injection (Meth or saline) for 45min. A 30min, drug-free
CPP test was conducted three days after the last conditioning session (day 9).
Rats that did not increase time spent in the Meth-paired chamber on CPP Test 1
compared to the same chamber during the pre-test by at least 10% (180s) were
excluded from the study.

Culling rats based on the strength of learning, as

previously employed (Paolone et al., 2009), helps assure that only those rats that
clearly acquired the task (i.e., made the association between drug and context)
were used to determine the potential for GABABR ligands to subsequently reduce
the acquired preference. Rats were assigned to a treatment group such that the
magnitude of preference expressed during CPP Test 1 was approximately equal
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for all treatment groups. The effects of fendiline on the maintenance (tested in a
drug-free state) and expression (tested immediately after a fendiline injection)
were tested in specific protocols described below.

Experiment 3 was designed to ascertain if early post-conditioning treatments of
fendiline were sufficient to disrupt the short-term maintenance of previously
acquired CPP when measured in a drug-free state. To do so, Meth-conditioned
rats were injected in the home cage, once-daily for two days (on protocol days 10
& 11; refer to Fig 12B) with 5mg/kg fendiline or its vehicle. Rats were tested
three days after the last home cage treatment using the method described
previously. The three day drug-free period was imposed to allow fendiline to be
removed from the system prior to testing for preference.

Experiment 4 was

designed to determine fendiline effects on the long-term maintenance of Methinduced CPP when measured in a drug-free state. For this experiment, Methconditioned rats received one of the following four post-conditioning treatments to
determine the influence of post-conditioning time and treatment duration: (1) 10
days of fendiline vehicle, (2) 10 days of fendiline, (3) two days of fendiline
followed by eight days of vehicle, or (4) eight injections of vehicle followed by two
days of fendiline. Rats were tested for CPP expression in a drug-free state three
days after the last home cage treatment (day 22), as in Experiment 3. We then
used these rats to test the effects of fendiline on CPP expression when tested
immediately after a fendiline injection, as well as to ascertain if a fendiline history
influenced outcomes of this assessment (Experiment 5). To do so, 7-10 days
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after CPP Test 2, the rats were „re-conditioned‟ for four days (protocol days R1R4, Fig 12C) to re-establish preference in all groups and prevent the extinction of
the preference that can occur due to repeated testing. Three days after reconditioning, rats were given a drug-free CPP test (CPP Test 3, protocol day R7)
to verify CPP and the 10% criterion for task acquisition was applied. Three days
later, an acute injection of fendiline was administered immediately prior to CPP
Test 4 (protocol day R10) and preference was determined as in CPP Tests 1-3.
On days when experimental procedures were not conducted (i.e., intervening
days are not indicated on the experimental timelines in Fig. 12A, B, & C), rats
remained undisturbed in the home cage.

Statistical Analysis
Motor Function: Rotarod assessments were conducted using a repeated
measures ANOVA with the within subject factor of time and the between subject
factor of treatment followed by a post-hoc Newman-Keuls for between group
differences at each time point. Motor activity during CPP Test 4 was assessed
using a one-way ANOVA followed by a post-hoc Newman-Keuls. Conditioning:
Preference or aversion was defined as spending significantly more time in the
drug-treated or vehicle-treated chamber, respectively.

This comparison was

accomplished by two-way repeated measures ANOVA (factors were chamber
and CPP Test) followed by a post-hoc Newman-Keuls test for between chamber
differences.

All data are shown as mean ± SEM.

Statistical outliers were

determined as those rats with assessments that were greater than two standard
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deviations above or below the mean. Using this criterion, 14 rats were removed
from the studies for being outliers.

Results
Experiment 1: Effect of fendiline on rotarod performance
The rotarod test was used to determine if fendiline (5mg/kg), or its vehicle (25%
EtOH), induced deficits in motivated motor function task (using the natural fear of
falling as a motivating factor) that requires a high degree of motor coordination.
Baclofen (4mg/kg) and pentobarbital (10mg/kg) were used as positive controls.
All rats (n=10) maintained minimum criterion throughout the repeated testing
design (refer to methods).

Two-way repeated measures ANOVA revealed a

significant effect of Time (F(6,270)=3.357, p=0.003) as well as a significant
Treatment x Time interaction (F(24,270)=3.587, p<0.0001) with a non-significant
factor of Treatment (F(4,45)=1.367, p=0.260). As shown in Fig 13, a post-hoc
Newman-Keuls test revealed that baclofen (p<0.05) and pentobarbital (p<0.01)
administration significantly impaired motivated motor function compared to the
saline treatment at 20 and 40min post injection, an effect that was not observed
with fendiline or its vehicle (p>0.05). These findings indicate that the 5mg/kg
dose used to determine if fendiline could produce CPP or CPA (Experiment 2)
and/or alter the maintenance of Meth-induced CPP (Experiments 3-5) was not
sufficient to alter even a rigorous motor-function task.
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Experiment

2:

Assessments

of

fendiline

in

conditioned

place

preference/conditioned place aversion (Refer to Fig. 12A for timeline)
An important consideration for medication development targeted toward chronic
therapy for addiction is to determine potential abuse liability or aversive side
effects of the putative therapeutic agent. Thus, we evaluated the capacity of
fendiline to produce either a preference or an aversion in the conditioning
protocol using the 5mg/kg dose used in the rotarod task which did not alter motor
function. We designed a conditioning paradigm for fendiline that mimicked the
most robust fendiline treatment protocol to be used to disrupt the maintenance of
Meth-induced CPP, i.e., 10 once daily injections.

Thus, a morning/afternoon

conditioning paradigm was employed where saline-pairings were conducted in
the morning and fendiline-pairings were conducted in the afternoon. Following
10 days of twice-daily conditioning, rats demonstrated neither a preference nor
an aversion for the fendiline-paired chamber (Fig. 14, n=8). That is, a two-way
repeated measures ANOVA revealed no significant

effects of Chamber

(F(1,14)=0.009, p=0.928), Test (F(1,14)=0.004, p=0.949), or Chamber x Test
interaction (F(1,14)=0.600, p=0.452).

Thus, using the fendiline dose (5mg/kg)

identified as having no effects on motivated motor behavior (Fig. 13) or rewarding
or aversive subjective effects (Fig. 14) we sought to determine if postconditioning

administration

of

fendiline

inhibited

subsequent expression of Meth-induced CPP.

the

maintenance

and
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Experiment 3: Effect of fendiline administered during early the postconditioning phase on short-term maintenance of Meth-induced preference
(refer to Fig. 12B for timeline)
Following conditioning with Meth, preference for the Meth-paired chamber was
observed before (CPP Test 1) and after (CPP Test 2) two once-daily treatments
of vehicle (Fig. 15A, n=8) and fendiline (Fig. 15B, n=9). A two-way repeated
measures ANOVA revealed the following. Vehicle-treated rats demonstrated a
significant Chamber effect (F(1,14)=77.807, p<0.0001) with no effect of Test
(F(1,14)=0.017, p=0.898) or Chamber x Test interaction (F(1,14)=0.121, p=0.733). A
post-hoc Newman-Keuls test revealed a significant preference during CPP Test 1
and CPP Test 2 (p<0.01).

Likewise, fendiline-treated rats demonstrated a

significant effect of Chamber (F(1,16)=14.746, p=0.001) with no effect for Test
(F(1,16)=0.120, p=0.733) or a Chamber x Test interaction (F(1,16)=1.734, p=0.207).
A post-hoc Newman-Keuls test revealed a significant preference for the Methpaired chamber during CPP Test 1 (p<0.01) and during CPP Test 2 (p<0.05).
Thus, CPP was expressed independent of treatment history; two days of
fendiline administered during the early post-conditioning phase had no impact on
the short-term maintenance of Meth-induced CPP.

Experiment 4.

Effects of fendiline administration on the long-term

maintenance of Meth-induced CPP (Refer to Fig. 12C for timeline)
To ascertain if increasing the number of fendiline treatments would inhibit the
maintenance of Meth-induced CPP (tested in a drug-free state), the once-daily
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injections of fendiline were increased from two to ten.

To verify that Meth-

induced CPP persisted for the duration of the study, we determined that postMeth conditioning administration of ten once-daily vehicle injections did not
impact the ability of rats to express a preference for the Meth-paired chamber
(Fig. 16A, n=11). That is, a two-way repeated measures ANOVA revealed a
significant effect of Chamber (F(1,20)=63.355, p<0.0001) but a non significant
effect of Test (F(1.20)=0.165, p=0.689) and Chamber x Test interaction
(F(1,20)=0.284, p=0.600). This finding indicates the preference exhibited three
days after conditioning (CPP Test 1) did not diminish for at least 15 days, due to
repeated CPP testing, or with the home cage vehicle treatments. In contrast to
these results, in rats administered ten once-daily treatments of fendiline, the
preference that was evident during CPP Test 1 was no longer maintained during
CPP Test 2 (Fig. 16B, n=12). A two-way repeated measures ANOVA revealed a
significant effect of Chamber (F(1,22)=11.129, p=0.003) and a significant Chamber
x Test interaction (F(1,22)=4.800, p=0.039) but no effect of Test (F(1,22)=0.035,
p=0.853). A post-hoc Newman-Keuls test revealed significant CPP for Test 1
(p<0.01) but not for CPP Test 2 (p>0.05). These results demonstrate that 10
days of fendiline treatment is sufficient to nullify previously established
preference.

The positive outcome with ten-days of fendiline led to the question as to whether
a critical time during this ten-day period could be identified during which the Meth
memories are particularly vulnerable to fendiline-induced disruptions. That is, if
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the behavioral antagonism reflected processes that occurred only at the
beginning or end of the chronic treatment period. Thus, we tested the effects of
two fendiline injections given on days 10 and 11 (2 Day Early Fendiline) or 18
and 19 (2 Day Late Fendiline). Neither 2 Day Early Fendiline (Fig. 16C, n=14) or
2 Day Late Fendiline (Fig. 5D, n=16) influenced the expression of the preference
on CPP Test 2.

For early fendiline-treated rats, a two-way repeated measures

ANOVA revealed a significant effect of Chamber (F(1,26)=47.050, p<0.0001) and
Chamber x Test interaction (F(1,26)=11.056, p=0.003) but no effect of Test
(F(1,26)=0.003, p=0.956). Two-way repeated measures ANOVA of data collected
for the late fendiline-treated rats revealed a significant effect of Chamber
(F(1,30)=44.607, p<0.0001) with no effect of Test (F(1,30)=0.001, p=0.971) or
Chamber x Test interaction (F(1,30)=0.863, p=0.360). A post-hoc Newman-Keuls
test revealed a significant preference for the Meth-paired chamber during CPP
Test 1 and CPP Test 2 for both treatment groups (p<0.01). Thus, while ten days
of once-daily fendiline injections inhibited the maintenance of Meth-induced CPP,
this effect did not appear to reflect any particular post-conditioning phasedependent phenomenon. Thus, it appears that the larger number of treatments
is critical for inhibiting the maintenance of Meth-induced CPP.

To verify the conclusions drawn from the rotarod experiment, we also monitored
motor activity during the CPP Test 2. The fendiline treatment which terminated
three-days prior to CPP Test 2 did not result in any significant changes in motor
activity for any treatment group (one-way ANOVA, F(3,52)=2.55, p=0.07).
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Horizontal activity (horizontal beam breaks); 10 Day Vehicle (n=11) 3649±246,
10 Day Fendiline (n=12) 3373±362, 2 Day Early Fendiline (n=14) 4280±232, 2
Day Late Fendiline (n=16) 4239±190.

Experiment 5:

Effects of fendiline administered during the test for

expression of Meth-Induced CPP (Refer to Fig. 12C for timeline).
Experiment 5 was designed to ascertain if a 5mg/kg fendiline challenge,
administered immediately prior to the CPP test, inhibited CPP expression
regardless of the effects fendiline may have had on maintenance. We also set
out to determine if fendiline treatment history was an important factor in the
effects seen with the fendiline challenge. To accomplish these objectives, all rats
used for Experiment 4 were re-conditioned (refer to Fig. 12C) to ensure that CPP
was maintained and expressed by all groups (i.e., to re-establish CPP in the 10
Day Fendiline-treated group as well as to assure that extinction of the preference
did not occur during repeated CPP testing required for Experiment 4). Thus,
following re-conditioning, all rats were subsequently given a drug-free CPP test
(CPP Test 3) to verify that the preference was present. The 10% criterion for
preference acquisition during CPP Test 3 was applied as described for
Experiments 3 and 4.

This excluded only 6 rats, and these were distributed

approximately equally across treatment groups. Moreover, rats that received the
10 fendiline injections which did not express a preference during CPP Test 2
were not impaired in “re-acquiring” a preference for the Meth-paired chamber
compared to other treatment groups. Rats which met the criterion were tested
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three days later, immediately after an injection of vehicle or fendiline. Methconditioned rats with a vehicle treatment history between CPP Test 1 and CPP
Test 2, and who demonstrated preference for the Meth context during CPP Test
3 (i.e., the 10 Day Vehicle group), also showed preference during CPP Test 4
following an acute challenge of vehicle (Fig. 17A, n=9).

Two-way repeated

measures ANOVA revealed a significant effect of Chamber (F(1,16)=18.780,
p=0.001) with no effect of Test (F(1,16)=0.012, p=0.913) or Chamber x Test
interaction (F(1,16)=0.113, p=0.741).

Indeed, post-hoc Newman-Keuls verified

significant CPP Test 3 and CPP Test 4 (p<0.01). Similarly, rats in the 2 Day
Early Fendiline treatment group expressed preference for the Meth-paired
chamber during both drug-free CPP Test 3 and fendiline challenged CPP Test 4
(Fig. 17C, n=12). Two-way repeated measures ANOVA revealed a significant
effect of Chamber (F(1,22)=14.315, p=0.001) and no effect of Test (F(1,22)=0.280,
p=0.602) or a Chamber x Test interaction (F(1,22)=0.634, p=0.434). A post-hoc
Newman-Keuls verified the significant preference during both CPP tests
(p<0.01). In contrast, rats in the 10 Day Fendiline (Fig. 17B, n=12) or 2 Day Late
Fendiline (Fig. 6D, n=14) treatment groups did not express a preference for the
Meth-paired chamber after an acute challenge of fendiline.

For the 10 Day

Fendiline group, a two-way repeated measures ANOVA revealed a significant
Chamber x Test interaction (F(1,22)=14.483, p=0.001) with non significant effects
of Chamber (F(1,22)=3.063, p=0.094) or Test (F(1,22)=0.011, p=0.916). Likewise, a
two-way repeated measures ANOVA of rats in the 2 Day Late Fendiline group
demonstrated a significance for the effect of Chamber (F(1,26)=7.105, p=0.013)
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and Chamber x Test interaction (F(1,36)=8.574, p=0.007) but no effect of Test
(F(1,26)=0.036, p=0.851).

A Post-hoc Newman-Keuls test revealed significant

preference for the drug-free CPP Test 3 (p<0.01) and no preference during the
fendiline challenged CPP Test 4 (p>0.05) for both groups. Throughout each CPP
test, time spent in the middle chamber did not significantly change in any
treatment group throughout any of the experiments. These findings indicate that
there may be a critical time that is later in the post-conditioning period, when
fendiline causes neuroadaptive alterations that subsequently render an acute
fendiline challenge effective in reducing expression of Meth-induced CPP.

As the CPP study indicated that brain adaptations may have occurred following
fendiline administration, we also examined motor activity measured during the
CPP Test 4 to determine if this behavior also showed changes indicative of
neuronal adaptations.

A between group comparison, Fendiline injection

administered prior to CPP Test 4 significantly altered horizontal motor activity
(horizontal beam breaks; one-way ANOVA, p<0.0001). A post-hoc NewmanKeuls revealed that horizontal beam breaks were significantly decreased for all
fendiline-treated groups (independent of treatment history) compared to the
vehicle treated rats (10 Day and 2 Day Late Fendiline history, p<0.0001; 2 Day
Early Fendiline, p<0.001).

While all groups had significantly reduced motor

activity, it did not impede the capacity of rats to express a preference for the
Meth-paired chamber as rats with a treatment history of 2 Day Early Fendiline
expressed a preference for the Meth-paired chamber in spite of decreased motor
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activity. Illustrated in Fig 17E is horizontal activity but this was representative for
all behaviors including total distance and vertical activity.

Discussion
The current study revealed that three conditioning sessions with Meth (alternated
with three saline-condition sessions) induced a preference for the Meth-paired
chamber that persisted for at least 16 days, and that this preference was not
diminished by the home cage injections or repeated CPP testing. The memory of
this preference was disrupted by repeated fendiline treatment in a durationdependent and post-conditioning time-related manner.

To the best of our knowledge, this is the first evaluation of the ability of fendiline
to alter behavioral effects of a psychostimulant. Consequently, it was prudent to
demonstrate that the dose employed did not alter motivated (i.e., rotarod) motor
behavior in Meth-conditioned rats, and that it was not rewarding or aversive. Ten
days of fendiline treatment proved to be more important than the postconditioning phase during which fendiline was administered, as two, once-daily
injections of fendiline given either at the early or late post-conditioning phase of
the 10 Day protocol failed to diminish the maintenance of Meth-induced CPP.
Furthermore, the duration of time between terminating two days of fendiline
treatment and the test for preference (compare Experiment 3, three days;
Experiment 4, 2 Day Early Fendiline, 11 days) had no effect on the ability of rats
to express a preference for the Meth-paired chamber. The findings may reflect
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sustained

interruptions

of

mechanisms

critical

for

maintenance

and/or

adaptations that only occur with repeated treatments (i.e., >2 treatments and
does not reflect actions of fendiline administered at the beginning or the end of
the 10 day treatment period) of fendiline which serve to weaken the conditioned
response memory.

The maintenance of associative memories involves a variety of neurotransmitter
systems (e.g., dopamine and glutamate receptors) and concomitant changes in
ion channels (e.g., calcium and sodium channels) (Alberini et al., 2006; Bailey et
al., 2004; Wang et al., 2006; Vianna et al., 2000).

Fendiline, acting as a

GABABR PAM (Kerr et al., 2002; Ong et al., 2005; Ong and Kerr, 2005) as well
as an L-type calcium channel blocker (Bayer and Mannhold, 1987; Nawrath et
al., 1998; Tripathi et al., 1993), has dual mechanisms that may serve to alter
memory maintenance. Indeed, augmented GABA BR signaling (via decreased
cAMP/PKA) (Knight and Bowery, 1996; Malcangio and Bowery, 1993) and
calcium

channel

(Rajadhyaksha

blockade

and

(via

Kosofsky,

calcium
2005)

calmodulin
influence

kinase

and

ERK)

CREB-mediated

gene

transcription of proteins that are important for psychostimulant-induced and
neuronal plasticity as well as learning and memory (Berke and Hyman, 2000;
Nestler, 2001; Kelley, 2004). The specific adaptations are dependent on duration
of time after the last psychostimulant administration.

For example, following

repeated Meth administration the activated form of CREB (pCREB) is increased
in the cortex at three and not at 14 days withdrawal. In the current study, we
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were not able to identify post-conditioning withdrawal time dependent effects of
two fendiline injections on the maintenance of Meth-induced CPP when tested in
a drug-free state. Future studies focused on molecular and electrophysiological
consequences of repeated fendiline are needed to verify the mechanisms that
underlie the ability of fendiline to disrupt memory maintenance.

Treatment history is critically important in the ability of an acute fendiline injection
to inhibit the expression of Meth-induced CPP. Here, two (2 Day Late Fendiline)
and ten fendiline injections both terminating on protocol day 19, but not the 2 day
treatment which terminated on protocol day 11, both rendered the acute fendiline
challenge effective in blocking preference expression. One explanation is that
two once-daily fendiline injections is sufficient to induce an adapted brain state
that persists for at least 19 days (2 Day Late Fendiline) but less than 25 days (2
Day Early Fendiline). This adapted brain state is vulnerable to the inhibitory
effects of fendiline on the expression of Meth-induced associative learning. The
fact that fendiline treatments can produce effects which persist is functionally
important,

and

determining

if

this

reflects

pharmacodynamic

and/or

pharmacokinetic mechanisms is another area that will need to be addressed.
The adaptations engendered by two fendiline injections were also maintained
after 10 injections which indicate that desensitization and/or down-regulation has
not occurred over the additional eight fendiline injections; therefore, this
compound may be a viable long-term treatment. Regardless of the underlying
mechanisms, it is clear that fendiline treatment history dictated the capacity of a
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fendiline challenge to inhibit the expression of Meth-induced CPP, and the time
of the treatment, not the number of injections, was the critical factor.

Re-exposure to cues associated with abused substances increases neuronal
activity in a region specific manner in humans (Childress et al., 2008; Childress
et al., 1999; Kilts et al., 2004; Kilts et al., 2001) and rodents (Brown et al., 1992;
Ciccocioppo et al., 2001; Franklin and Druhan, 2000; Zombeck et al., 2008;
Rhodes et al., 2005).

This activation is also observed with memory recall

processes and thus we can infer that blunting neuronal activity may result in an
inability to express Meth-induced CPP. Administration of fendiline prior to the
CPP test may have blunted the hyper-responsive state that occurs during reexposure to Meth-associated contextual cues through mechanism such as
activation of inwardly rectifying potassium channels (GABABR mediated GIRK
activation) and inhibition of L-type calcium channels. Indeed, if neuronal activity
is blunted by augmenting GABA receptor signaling (via administration of gamma
vinyl GABA), the expression of Meth-primed reinstatement of CPP is blunted
(DeMarco et al., 2009).

However, the treatment history dependent effects

suggest that prior fendiline-induced adaptations must have occurred in order for
the acute fendiline successfully inhibit the expression of the behavior.

An alternative explanation is that the later post-conditioning time (protocol days
18 & 19) is vulnerable to fendiline-induced effects whereas the early postconditioning time (protocol days 10 & 11) are not. Withdrawal is a dynamic
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process with different brain states occurring in the days and weeks following
psychostimulant administration. For example, functional coupling of the GABABR
is decreased in the nucleus accumbens and increased in the cortex at 14 days
withdrawal from repeated amphetamine, an effect that is not observed at one day
withdrawal (Zhang et al., 2000). Similarly, cocaine-induced sensitization induced
subunit-specific and withdrawal-time dependent effects on L-type calcium
channel expression and distribution in the cortex; the increase was more
profound at 21 days than at three days withdrawal (Ford et al., 2009). Thus,
fendiline administered during the different withdrawal time may have different
effects on brain function and this factor may have contributed to the effects of
treatment history on fendiline inhibition of the expression of Meth-induced CPP.

The goal of this study was to evaluate the ability of fendiline, an L-type Ca++
channel blocker and GABABR PAM, to disrupt mnemonic processes necessary to
maintain and subsequently express the learned associations established during
CPP.

The results suggest that fendiline successfully disrupted the learned

associations between the drug and the cues which is of value as an antiaddiction therapy; both long-term and recent fendiline treatment appears to
provide a protective effect in reducing the salience of drug-associated cues
and/or the maintenance of the associative memory.

Fendiline is clinically

available in Europe as a coronary vasodilator and therefore may be repurposed
and rapidly translated into the clinic as an anti-addiction therapy.
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Figure 10. Illustration of treatment protocols. A. Fendiline conditioned place
preference/conditioned place aversion. For the pre-test (day -1), drug-free rats
were allowed to explore the apparatus for 30min; these data were used to
counterbalance rats based on unconditioned preference. Conditioning occurred
twice daily for 10 days; fendiline vehicle was paired with one chamber in the
morning and fendiline was paired in the opposite chamber in the afternoon.
Three days after the last conditioning session (day 13), drug-free rats were
tested for rewarding or aversive subjective effects of fendiline. B & C. Rats were
pre-tested as described previously, and assigned to receive Meth in the chamber
in which the least amount of time was spent during the pre-test. Conditioning
occurred for six days; Meth was paired with one chamber on days 1, 3, & 5, and
saline-paired in the opposite chamber on days 2, 4, & 6. Three days later (day
9), rats were tested to confirm the development of CPP (CPP Test 1). Rats were
then assigned to one of the following treatment groups.

B. Experiment 1
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evaluated the effects of two home cage injections (days 10 & 11) of fendiline or
its vehicle on the maintenance of Meth-induced CPP. Three days after the home
cage treatments (day 14), drug-free rats were tested for the expression of Methinduced CPP (CPP Test 2). C. Experiment 2 evaluated the effect of fendiline on
the maintenance of Meth-induced CPP by administering 10 once-daily home
cage injections (days 10-19): 10 injections of vehicle (10 Day Veh), 10 injections
of fendiline (10 Day Fend), two injections of fendiline followed by eight injections
of vehicle (2 Day Early Fend), or eight injections of vehicle followed by two
injections of fendiline (2 Day Late Fend). Rats were subsequently tested in a
drug-free state three days after the last home cage injection (CPP Test 2, day
22). Experiment 3 evaluated the effects of an acute fendiline injection on the
expression of Meth-induced CPP. Rats were re-conditioned to re-establish CPP
and prevent extinction of the behavior that can occur due to repeated testing.
CPP Test 3 was used to verify that rats expressed CPP. Three days later, rats
were given an injection of fendiline and immediately tested for the expression of
Meth-induced CPP (CPP Test 4). Ø, no drug; V or Veh, vehicle (1ml/kg); F or
Fend, fendiline (5mg/kg), M, Meth (1mg/kg); S, saline (1ml/kg).
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Figure 11. Motivated motor behavior assessed on the rotarod was not inhibited
by 5mg/kg fendiline. Rats were trained on the rotarod to meet minimum criterion
for inclusion in the study; a repeated measures design was employed such that
each rat (n=10) was tested with each ligand or it‟s vehicle (i.e., saline, fendiline
(5mg/kg), fendiline vehicle (25% EtOH, 1ml/kg), baclofen (4mg/kg), and
pentobarbital (10mg/kg).

Latency to fall from the rotating drum (which was

accelerated from 5-40rpm over 5min) was recorded at the following times 0
(immediately prior to injection), 20, 60, 60, 180, 360min, and 24hr. Two way
repeated measures ANOVA followed by a post-hoc Newman-Keuls revealed that
the positive controls, baclofen (p<0.05, filled square) and pentobarbital (p<0.01,
star), significantly impaired motivated motor function compared to saline treated
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rats (open square) at 20 and 40min post injection; an effect that was not
observed for fendiline (p>0.05, filled triangle) or fendiline vehicle rats (p>0.05,
open

triangle).
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Figure 12. Fendiline (5mg/kg) was neither rewarding nor aversive. Time spent
in each chamber was recorded before (Pre-Test) and after 10 days of fendiline
(5mg/kg) conditioning (CPP/CPA test). Two-way repeated measures ANOVA
followed by a post-hoc Newman-Keuls revealed no significant changes between
time spent in each chamber during the Pre-Test and the test for preference (n=8,
p>0.05) (center chamber was not included in the statistical analysis).

Filled

diamonds, time spent in the fendiline-paired chamber; open square, time spent in
the fendiline vehicle-paired chamber; filled triangle, time spent in the center
chamber.
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Figure 13. Fendiline administered during the early post-conditioning phase did
not inhibit short-term memory maintenance.

After six days of conditioning a

CPP test was conducted to verify the development of CPP (CPP Test 1); home
cage injections were then administered and a drug-free test was subsequently
conducted (CPP Test 2). A. Rats administered two fendiline vehicle injections
(25% EtOH, n=8) expressed CPP on both test days (CPP Test 1 & 2). B. Rats
that received two once-daily fendiline injections (4mg/kg, n=9) also expressed a
preference for the Meth-paired chamber during both tests. Two-way repeated
measures ANOVA followed by a post-hoc Newman-Keuls test was used to
determine between chamber differences (center chamber not included in the
statistical analysis), ** p<0.01, * p<0.05. Filled diamond, time spent in the Methpaired chamber; open square, time spent in the saline-paired chamber; filled
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triangle,

time

spent

in

the

center

chamber.
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Figure 14.

The maintenance of Meth-induced CPP was inhibited by 10

injections but not two post-conditioning injections of fendiline. After six days of
conditioning a CPP test was conducted to verify the development of CPP (CPP
Test 1); home cage injections were then administered and a drug-free test was
subsequently conducted (CPP Test 2). A. Rats administered 10 fendiline vehicle
injections (25% EtOH, n=11) expressed CPP on both test days (CPP Test 1 & 2).
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B. Rats administered 10 once daily fendiline injections (n=12) did not express a
preference for the Meth-paired chamber on CPP Test 2. Rats administered 2
once-daily injections of fendiline corresponding to the first two days (C, n=14) or
the last two days (D, n=16) of the 10 day treatment expressed CPP during both
CPP Test 1 and CPP Test 2. Two-way repeated measures ANOVA followed by
a post-hoc Newman-Keuls test was used to determine between chamber
differences (center chamber not included for statistical analysis), ** p<0.01.
Filled diamonds, time spent in the Meth-paired chamber; open squares, time
spent in the saline-paired chamber; filled triangles, time spent in the center
chamber.
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Figure 15. The expression of Meth-induced CPP was inhibited by a fendiline
injection administered immediately prior to the CPP test only in rats with a
treatment history of 10 injections and two injections corresponding to the last two
injections of the 10 day treatment.

Rats were re-conditioned to prevent the

extinction that can occur after repeated testing and re-establish CPP in the 10
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Day Fendiline treated group. CPP Test 3 was conducted drug-free state to verify
the expression of CPP. Three days later rats were tested for the expression of
Meth-induced CPP after an acute injection of fendiline (5mg/kg) or fendiline
vehicle (25% EtOH, 1ml/kg). A. Rats with a treatment history of 10 fendiline
vehicle injections (n=9) expressed CPP during the drug-free test and after a
fendiline vehicle injection (CPP Test 3 & 4). C. Likewise, rats with a treatment
history of two once-daily fendiline injections corresponding to the first two days of
the 10 day treatment expressed CPP during both tests (n=12). In contrast, rats
with a treatment history of 10 once daily fendiline injections (B, n=12) as well as
rats with a treatment history of two once-daily injections of fendiline
corresponding to the last two days of the 10 day treatment (D, n=14) expressed
CPP during the drug-free test (CPP Test 3) but not after the acute fendiline
injection (CPP Test 4). Two-way repeated measures ANOVA followed by a posthoc Newman-Keuls test was used to determine between chamber differences
(center chamber not included for statistical analysis), ** p<0.01. Filled diamonds,
time spent in the Meth-paired chamber; open squares, time spent in the salinepaired chamber; filled triangles, time spent in the center chamber. E. Horizontal
Activity assessed during CPP Test 4 revealed that fendiline injection,
independent of treatment history, significantly decreased motor activity. Oneway ANOVA followed by post-hoc Newman-Keuls, ## p<0.001, # p<0.01.

CHAPTER VI
ADMINISTRATION OF GABAB RECEPTOR POSITIVE ALLOSTERIC
MODULATORS GS39783 AND CGP7930 BUT NOT BACLOFEN
INHIBIT THE MAINTENANCE OF PREVIOUSLY
ESTABLIHSED METHAMPHETAMINEINDUCED CONDITIONED PLACE
PREFERENCE
Abstract
Little is known about the role of GABABR in the maintenance of memories
associated with abused substances. The current study determined if baclofen,
and/or GABABR positive allosteric modulators, GS39783 and CGP7930, could
negate previously established conditioned place preference (CPP) induced by
methamphetamine. Post-conditioning, home-cage treatments with GS39783 or
CGP7930 antagonized the expression of methamphetamine-induced CPP but
baclofen did not.

These data indicate that selectively augmenting GABA BR

signaling in areas where GABA is endogenously released after repeated
methamphetamine administration may reduce the maintenance and/or the
salience of drug-associated cues.

Introduction
Cues associated with the use of abused substances can activate limbic brain
regions (Childress et al., 1999; Childress et al., 2008) and elicit drug-craving and
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drug-seeking behavior (O'Brien et al., 1992; Ehrman et al., 1992). This powerful,
long-lasting associative learning process that occurs in addicts is modeled in
rodents using conditioned place preference (CPP) with high face, construct, and
predictive validity (Childs and deWit H., 2009; Tzschentke, 1998; Tzschentke,
2007).

The current study evaluated CPP induced by the psychostimulant,

methamphetamine (Meth).

There is no FDA-approved pharmacotherapy for psychostimulant addiction.
However, literature suggests that the GABABR system is a viable target (Brebner
et al., 2002; Xi and Gardner, 2008).

Administration of the GABABR agonist

baclofen inhibits the development and expression of CPP induced by Meth (Li et
al., 2001) as well as the development and expression of amphetamine-induced
motor sensitization (Bartoletti et al., 2004; Bartoletti et al., 2005). Baclofen also
decreases several aspects of Meth (Ranaldi and Poeggel, 2002), amphetamine
(Brebner et al., 2005) and cocaine self-administration (Filip et al., 2007) in
rodents and cocaine-primed reinstatement of cocaine-seeking in baboons
(Weerts et al., 2007).

These data demonstrate that baclofen prevents the

development of psychostimulant-induced behaviors and subsequent stimulantseeking.

Moreover, imaging studies indicate that baclofen blunts the limbic

activation associated with visual drug cues in drug-addicted humans (Brebner et
al., 2002). Clinical studies also demonstrate the efficacy of baclofen to reduce
cocaine craving (Ling et al., 1998) and reduce cocaine (Shoptaw et al., 2003)
and Meth use (Heinzerling et al., 2006). While the use of GABABR agonists as a
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therapy for addiction has considerable support (Xi and Gardner, 2008; Rose and
Grant, 2008), the side effects associated with agonist administration (e.g.,
sedation and motor impairment) is a drawback to their practical application
(Cryan et al., 2004; Ling et al., 1998; Shoptaw et al., 2003; Heinzerling et al.,
2006; Jacobson and Cryan, 2005). Positive allosteric modulators (PAMs) of the
GABABR provide an alternative means to augment GABAergic signaling. GABABR

PAMs do not directly activate receptors; instead they increase the efficacy of

endogenous GABA (Bettler et al., 2004; Urwyler et al., 2001; Gjoni et al., 2006;
Urwyler et al., 2005).

While GABABRs are located throughout the brain,

expression levels differ greatly among regions with high expression levels found
in brain regions important for reward and motivated behavior (e.g., ventral
tegmental area, substantial nigra, and the thalamus) (Margeta-Mitrovic et al.,
1999). The differential expression of GABABRs and the temporal and regional
specificity of GABA release afford PAMs considerable therapeutic discretion
compared to GABABR agonists.

Recent reports reveal the ability of GABABR PAMs to reduce reward-mediated
behaviors. The PAM CGP7930 reduces cocaine self-administration (Smith et al.,
2004; Filip et al., 2007) and both cocaine- and cue-induced reinstatement of
cocaine-seeking (Filip and Frankowska, 2007).

The PAM GS39783 blunts

locomotion induced by acute cocaine, blocks the development of cocaineinduced motor sensitization, and normalizes molecular adaptations resulting from
repeated cocaine administration (Lhuillier et al., 2007).

These studies
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demonstrate the capacity of GABABR PAMs to modulate cocaine-mediated
effects; yet, the capacity of PAMs to modify Meth-induced behaviors is unknown.

Administration of GABAergic ligands during the development and expression
phases of reward-mediated behaviors provides insight into the role of the
GABABR system in these behaviors; however, there are limited therapeutic
applications for these treatment protocols.

A more relevant approach is to

administer a potential therapy after the brain and behavioral adaptations have
taken place.

Using this treatment strategy, baclofen successfully inhibits the

expression of previously established amphetamine-induced motor sensitization
(Bartoletti et al., 2004). We have revealed that a similar strategy with the atypical
antidepressant mirtazapine which inhibits the expression of Meth-induced CPP
(Herrold et al., 2009) and Meth-induced motor and cellular sensitization (McDaid
et al., 2007).

These studies illustrate the feasibility of post-conditioning

treatments to nullify previously established Meth-induced behavioral effects. The
current study used this approach to determine if baclofen and/or PAMs would
inhibit the expression of Meth-induced CPP when administered after the
development of the behavior.

The GABA system undergoes many temporal and region specific adaptations
following psychostimulant administration including changes in GABA turnover
and receptor-mediated function. These adaptations are influenced by neuronal
phenotype, number of drug exposures, and withdrawal duration. During early
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withdrawal (<10 days) the GABABR system is down-regulated which includes
decreased receptor expression (Frankowska et al., 2008b; Frankowska et al.,
2008a), uncoupling of the GABABR from the G-protein (Kushner and Unterwald,
2001), and increased extracellular GABA concentrations (Jayaram and Steketee,
2005; Jayaram and Steketee, 2005; Bustamante et al., 2002). In the current
study,

the

GABABR ligands baclofen, GS39783,

and

CGP7930

were

administered during the early withdrawal phase (days 5 and 6) and we
hypothesized that augmenting GABABR signaling during this phase would reduce
the salience of Meth-associated cues.

Materials and Methods
Animals
Male Sprague-Dawley rats (n=73, Harlan, Indianapolis, IN) weighing 250-300g at
the start of the study were acclimated to the vivarium for at least one week prior
to the onset of the experiments.

Rats were housed in pairs in a climate-

controlled environment on a 12 hr light/dark cycle and allowed ad libitum access
to food and water. Cage mates were given identical pharmacological treatments.
Housing facilities at Rush University are accredited through the Association for
Assessment and Accreditation of Laboratory Animal Care, and all experiments
were carried out in accordance with the conditions set forth by the National
Institutes of Health Guide for the Care and Use of Laboratory Animals (National
Research Council, 1996) and with the approval of the local Institutional Animal
Care and Use Committee.
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Drugs
Conditioning: (+)Methamphetamine HCl (Sigma-Aldrich, St. Louis, MO) was
dissolved in 0.9% sterile saline and administrated as 1mg/ml/kg.

We have

demonstrated that this dose (as opposed to, e.g., 0.1mg/kg) reliably produces an
enduring CPP (unpublished data). Saline was administered as 1ml/kg. Home
cage injections: baclofen (2mg/kg; Sigma, St Louis, MO), baclofen vehicle (0.9%
saline; 1ml/kg), GS39783 and CGP7930 (30mg/kg; gift from Novartis Pharma
AG, Basel, Switzerland), PAM vehicles (10% propylene glycol in sterile water;
1ml/kg). All injections were given intraperitoneally (i.p.).

Doses of GABAergic ligands were selected based on the following behavioral
endpoints in laboratory rats.

The dose of 30mg/kg GS39783 and CGP7930

successfully reduces cocaine self administration when administered 10 min prior
to the session (Smith et al., 2004) (3, 10, 30mg/kg i.p.). The dose of 2mg/kg
baclofen was selected because it was within the range of doses found to
successfully i) attenuate the development and expression of Meth-induced CPP
when administered 30min prior to each daily conditioning session or CPP test,
respectively (doses tested were 1.25, 2.5, 5mg/kg, i.p.) (Li et al., 2001), ii) inhibit
the reinstatement of nicotine-induced CPP and self-administration when
administered 5min prior to testing (0.612, 1.25, 2.5mg/kg, i.p.) (Fattore et al.,
2009), iii) reduce cocaine self-administration when administered 10min prior to
the session (2.5mg/kg, i.p.) (Smith et al., 2004), iv) reduce amphetamine self-
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administration break point when administered 30min prior to testing (doses
tested were 1.8, 3.2, 5.6mg/kg, i.p.) (Brebner et al., 2005), and v) inhibit the
maintenance of amphetamine-induced motor sensitization (2mg/kg, i.p.)
(Bartoletti et al., 2004). In addition, we determined that motivated motor behavior
assessed on the rotarod was inhibited by 4mg/kg baclofen (20 and 40min
collapsed results were as follows; latency to fall 209±24sec (n=5), vs. 355±29sec
for vehicle (n=11); Student’s t-test, p<0.01). Additionally, while 3mg/kg baclofen
produced an impairment in spontaneous motor activity, 2mg/kg baclofen resulted
in no difference from vehicle (horizontal activity, photobeam breaks over 75min
post injection for vehicle (n=7), 2422±189; baclofen 2mg/kg (n=6), 1728±388;
baclofen 3mg/kg (n=6), 1067±258; ANOVA p=0.012, post-hoc Dunnett’s).

Apparatus
The apparatus used to monitor activity consisted of three chambers divided by
opaque Plexiglas sliding doors (AccuScan Instruments, Inc., Columbus, OH); two
large conditioning chambers (25cm x 30cm x 30cm) separated by a small center
chamber (13cm x 30cm x 30cm). Each chamber had distinct visual (horizontal or
vertical stripes or a solid color wall) and tactile cues (textured floors). Motor
activity and time spent in each chamber was monitored via two sets of
photobeams (24 horizontal and 12 vertical).
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Conditioned Place Preference
The behavioral testing room was dimly lit (54-108lux) with white noise
continuously present. The rats were transported from the vivarium to the test
room (located across the hall, in the same animal facility suite) at least 30min
prior to the start of the experiment. The protocol consisted of four phases (refer
to Figure 18): pre-test, conditioning, home-cage intervening treatments, and a
CPP test. A 30min pre-test, verified that the box configuration did not result in a
significant group preference for either chamber (time spent left: 789±42s, time
spent right: 883±42s, p=0.265). Individual rats tended to spend unequal amounts
of time in each chamber; thus, for conditioning, rats were administered Meth in
the chamber in which they spent the least amount of time during the pre-test.
Conditioning occurred over 6 days. During the conditioning phase, rats were
given a Meth injection (1mg/kg, i.p.) every other day (days 1, 3, and 5) and
immediately placed into the appropriate chamber for 45min. On the alternate
days (2, 4, and 6), rats were given a saline injection (1ml/kg, i.p.) and
immediately placed into the opposite chamber for 45min. In half the rats, the
order of Meth or saline pairing occurring first was switched such that saline was
administered on days 1, 3, and 5 and Meth on days 2, 4, & 6. A drug-free CPP
test was performed on day 9, (termed CPP Test 1) to confirm that the preference
developed. This was accomplished by placing rats into the center chamber and
the sliding doors were immediately removed allowing free access to the entire
CPP box. The test session lasted 30min and time spent in each chamber was
determined. There were no differences between those rats which received the
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Meth or the saline pairing first thus they were pooled for the analysis. Rats that
did not increase time spent in the Meth-paired chamber on CPP Test 1 compared
to the same chamber during the pre-test by at least 10% (180s) were excluded
from the study. This culling procedure, as previously shown by others (Paolone
et al., 2009) helps assure that only those rats that clearly acquired the task were
used to determine the potential for GABABR ligands to subsequently reduce the
acquired preference. Based on the results generated during CPP Test 1, rats
were assigned to one of the following once-daily home cage treatments (days 10
& 11) such that the expression of the preference was approximately equal across
all treatment groups which included: vehicle, baclofen, GS39783, or CGP7930.
Selection of the early withdrawal time treatment (days 10 & 11) was based on
literature demonstrating that the GABABR system is down-regulated during early
withdrawal times (Frankowska et al., 2008b; Kushner and Unterwald, 2001) and
therefore might benefit from augmented GABABR signaling.

While the

pharmacokinetics of GS39783 and CGP7930 are unknown, orally administered
baclofen (5mg/kg) elicits centrally mediated events including hypothermia (Cryan
et al., 2004) within one hour after baclofen administration suggesting that the
onset of action is relatively short. Plasma and brain concentrations of baclofen
are reported to be relatively consistent for at least 180min after a single bolus i.v.
injection of baclofen in the rat (50mg/kg) (Deguchi et al., 1995) which aligns with
enduring effects of GABAergic ligands on drug-induced behaviors.

Baclofen

(2.5mg/kg), GS39783 (3mg/kg), and CGP7930 (30mg/kg) significantly reduce
cocaine self administration for at least 10 hours, indicating that these ligands may
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actively alter brain processes for several hours after a single administration
(Smith et al., 2004). Therefore, in the current study the administration of ligands
once-daily for two days likely altered GABAergic signaling for a sustained period
of time. Three days after the home cage treatments (day 14), rats were tested
for the expression of CPP in a drug-free state (termed CPP Test 2). This period
aided in clearing the GABABR compounds from the rat prior to CPP testing to
avoid any potential influences of residual drug on the expression of CPP. Thus,
this approach allowed us to more confidently interpret the effects of GABA BR
ligands in terms of memory maintenance.

Statistical Analysis
CPP was defined as spending significantly more time in the Meth-paired vs.
saline-paired chamber. This was accomplished by two-way repeated measures
ANOVA (factors were Chamber and CPP Test) followed by post-hoc NewmanKeuls for between chamber differences for each test. All data are shown as
mean ± SEM.

Statistical outliers were determined as those rats that spent

greater than two standard deviations above or below the mean time spent in any
chamber.

Results
The 6 day conditioning protocol resulted in a significant preference for the Methpaired chamber. As a group, the 73 rats tested expressed CPP on Test 1 (day 9)
(time spent Meth-paired chamber, 970±33sec; time spent saline-paired chamber,
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675±32sec; paired t-test: p<0.0001); however, 13 rats were not tested for
antagonism by GABABR ligands because time spent in the Meth-paired chamber
on CPP Test 1 was not least 10% (180s) more than time spent in the same
compartment during the pre-test. This culling procedure helped assure that only
those rats that clearly acquired the task were used to determine the potential for
GABABR ligands to subsequently reduce the acquired preference (see Materials
& Methods).

Post-conditioning administration of the vehicle solutions did not impact the ability
of drug-free rats to express a preference for the Meth-paired chamber (Figure 19,
Baclofen Vehicle (n=9): Chamber, F(1,16)=23.850, p=0.0002; Test, F(1.16)=0.0001,
p=0.994; Chamber x Test Interaction, F(1,16)=2.572, p=0.128. Figure 20, PAM
Vehicle (n=14): Chamber, F(1,26)=18.759, p=0.0002; Test, F(1,26)=0.065, p=0.801;
Chamber x Test Interaction, F(1,26)=2.05, p=0.164). This demonstrated that the
acquired preference demonstrated three days after conditioning did not diminish
for at least five days, due to repeated CPP testing, or with the intervening home
cage injections.

Rats administered baclofen as an intervening treatment maintained CPP (Figure
19, Baclofen (n=8): Chamber, F(1,14)=25.326, p=0.0002; Test, F(1,14)=0.055,
p=0.818; Chamber x Test Interaction, F(1,14)=6.167, p=0.026).

In contrast,

administration of the GABABR PAMS, GS39783 and CGP7930 nullified
previously established preference; i.e., the preference for the Meth-paired
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chamber observed on CPP Test 1 was no longer evident on CPP Test 2 (Figure
3. GS39783 (n=11): Chamber, F(1,20)=11.141, p=0.003; Test, F(1,20)=0.0002,
p=0.989; Chamber x Test Interaction, F(1,20)=6.947, p=0.016. CGP7930 (n=9):
Chamber, F(1,16)=3.506, p=0.080; Test, F(1,16)=0.002, p=0.965; Chamber x Test
Interaction, F(1,16)=9.108, p=0.008.)

Throughout each test, (Pre-Test, CPP Test 1, CPP Test 2) time spent in the
middle chamber did not significantly change in any treatment group (Figures 19 &
20).

These data reveal the unique ability of post-conditioning injections of the
GABABR PAMS (administered while the rats remained in the home cage) to
diminish the expression of the previously established preference.

Discussion
This study revealed that GABABR PAMs administered to rats in the neutral
environment of the home cage was sufficient to nullify the previously expressed
preference for the Meth-paired chamber. This outcome was not obtained with
the direct GABABR agonist, baclofen.

At the dose selected, GS39783 and

CGP7930 are thought to act only at GABABRs that are occupied by endogenous
GABA (Gjoni et al., 2006; Urwyler et al., 2001).

Therefore, these findings

indicate that augmenting the efficacy of occupied GABA BRs during early phases
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of withdrawal is sufficient to disrupt the maintenance of the acquired salience for
the Meth-associated context.

There are numerous studies demonstrating the efficacy of baclofen, GS39783,
and CGP7930 to modulate the development and expression of behaviors
induced by psychostimulants when administered during conditioning, or within
30min prior to testing (Li et al., 2001; Bartoletti et al., 2005; Filip et al., 2007; Filip
and Frankowska, 2007; Weerts et al., 2007; Smith et al., 2004; Lhuillier et al.,
2007; Brebner et al., 2005; Fattore et al., 2009). However, to date only Bartoletti
and colleagues (Bartoletti et al., 2004) have demonstrated efficacy of a GABABR
ligand to modify the maintenance of a previously established psychostimulantinduced behavior. These authors report that the maintenance of amphetamineinduced motor sensitization is blunted when 10 administrations of 2mg/kg
baclofen were initiated 36 days after the behavior developed and terminated 20
days prior to the amphetamine challenge. Our research efforts are expanding
this literature by evaluating GABABR influences on the maintenance of place
preference memory induced by Meth. The inhibitory effects previously observed
for baclofen on the maintenance of amphetamine-induced motor sensitization
were not observed in the current study for the maintenance of Meth-induced CPP
when 2mg/kg baclofen treatments were initiated 4 days after Meth, and given
once-daily for two days after conditioning.

This discrepancy may be due to

several factors including different behavioral endpoints (motor sensitization vs.
CPP), different psychostimulant (amphetamine vs. Meth), different treatment
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duration, and/or different withdrawal time for initiating the baclofen treatment (36
days vs. 4 days). Thus, the possibility still remains that a different treatment
regimen might afford a viable window of opportunity by which baclofen may be
able to interrupt the maintenance of place preference memories for Meth.

The PAMs GS39783 and CGP7930 successfully inhibited the maintenance of
previously established CPP.

As PAMs act by positively modulating GABA-

occupied receptors, this suggests that during the early withdrawal period, regions
that endogenously release GABA have a sufficient number of functional
GABABRs to allow PAMs to inhibit the maintenance of place preference memory.
This conclusion is consistent with the recent demonstration that enhancing GABA
levels (via reducing its metabolism with gamma vinyl GABA, an irreversible
inhibitor of GABA transaminase), inhibits the expression of Meth-primed
reinstatement of CPP (administered 2.5hr prior to the Meth challenge) (DeMarco
et al., 2009). Thus, it may be that augmenting GABABR signaling in brain regions
where GABA is tonically released is particularly important for disrupting memory
maintenance.

Several laboratories report region specific changes in GABA turnover, GABABR
expression, and receptor-mediated function during the early days following
repeated psychostimulant exposure.

Examples of increased GABAergic tone

occurring within the first seven days of withdrawal include increased extracellular
GABA levels in the medial prefrontal cortex after repeated cocaine administration
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(Jayaram and Steketee, 2005) and enhanced substantia nigra and striatum K +evoked GABA release after repeated Meth administration (Bustamante et al.,
2002).

These observations may be the consequence of the brain attempting to

maintain homeostasis (i.e., blunt the neuronal hyper-excitability associated with
psychostimulant use). Possibly contributing to the hyper-excitability associated
with psychostimulant administration, GABABRs are reduced throughout the brain
of rats after cocaine self-administration (Frankowska et al., 2008b) and in the
ventral tegmental area a decrease in the functional coupling of GABA BRs is
observed (Kushner and Unterwald, 2001).
contribute

to

the

hyper-excitable

state

psychostimulant withdrawal (Hu, 2007).

Changes such as these may
of

the

brain

observed

during

Behavioral observations made the

current study suggest that the “new brain state’ induced by Meth conditioning
includes GABA-occupied GABABRs in regions critical for the maintenance of
Meth-associated memories that are selectively enhanced by PAMs.

The

negative findings for baclofen then suggest that activating GABABRs throughout
the brain (regardless of endogenous GABAergic tone) overrides the selective
augmentation of occupied GABABRs achieved by administration of the PAMs.

The current study focused on the short-term maintenance of Meth-associated
memories, a phase of mnemonic processing that is not widely studied with
regard to GABABR influences.

In contrast, there is ample literature

demonstrating that administration of baclofen alters other mnemonic processes
including acquisition (Nakagawa et al., 1995; McNamara and Skelton, 1996),
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consolidation (Castellano et al., 1989; Swartzwelder et al., 1987; Castellano et
al., 1989; Zarrindast et al., 2002; Zarrindast et al., 2004), and expression
(Stackman and Walsh, 1994; Stackman and Walsh, 1994; Levin et al., 2004; Li et
al., 2001) of spatial and/or associative learning tasks. We determined that a
dose of baclofen that was subthreshold to impairing motor function was not
sufficient to inhibit the maintenance of CPP when given as two once-daily
injections.

Therefore, while moderate doses of baclofen effectively inhibit

memory acquisition, consolidation, and expression it does not appear to be
effective to inhibit memory maintenance during the first few days of withdrawal.
Phase-dependent effects also observed with the PAM GS39783 which was
shown to inhibit the acquisition but not the expression of nicotine-induced CPP
(Mombereau et al., 2007).

The current work extended this literature by

demonstrating that selective positive modulation of activated GABABRs by
GS39783 and CGP7930 can also inhibit the early phase maintenance of drugassociated memories.

In summary, we have identified two structurally distinct GABABR PAMs,
GS39783 and CGP7930, which inhibit the expression of Meth-induced CPP
when administered during the early withdrawal phase. This information allows us
to infer that GABABR expressing neurons in regions that have endogenous
GABAergic tone are critical for the maintenance of the associative memory that
forms during Meth-induced CPP.

Thus, GABABR PAMs may be a viable
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therapeutic alternative to direct acting GABABR agonists for the treatment of
psychostimulant addiction.
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Figure 16.

Illustration of the treatment protocol.

A drug-free pre-test was

conducted and rats were assigned to receive Meth (1mg/kg, i.p.) in the initially
non-preferred chamber. Conditioning occurred on days 1–6. A drug-free CPP
test was conducted on day 9 to verify the development of CPP (CPP Test 1).
Vehicle, baclofen, or a PAM was administered in the home cage on days 10 &
11.

A final drug-free CPP test (CPP Test 2) was conducted on day 14 to

determine the capacity of GABAergic ligands to influence the expression of Methinduced CPP. M, methamphetamine (1mg/kg), S, saline (1mg/kg), Veh, vehicle
(1ml/kg), Bac, baclofen (2mg/kg), PAM, positive allosteric modulator: GS39783
(30mg/kg), CGP7930 (30mg/kg)
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Figure 17.

Meth-induced CPP was not inhibited by post-conditioning

administration of baclofen.

Rats assigned to the baclofen vehicle (0.9% saline)

group (n=9) expressed CPP on both test days (CPP Test 1 & 2). Rats that
received baclofen treatment (2mg/kg; n=8) also expressed a preference for the
Meth-paired chamber on both test days. Post-hoc Newman-Keuls test was used
to determine between chamber differences (center chamber not included for
statistical analysis), ** p<0.01. Solid line, time spent in the Meth-paired chamber;
dashed line, time spent in the saline-paired chamber; grey line, time spent in the
center chamber
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Figure 18. Meth-induced CPP is inhibited by post-conditioning administration of
the PAMs GS39783 and CGP7930.

Rats assigned to the PAM vehicle (10%

propylene glycol) group (n=14) expressed CPP on both test days (CPP Test 1
&2). Rats administered GS39783 (n=11) or CGP7930 (n=9) as an intervening
treatment did not express a preference for the Meth-paired chamber on CPP
Test 2. Post-hoc Newman-Keuls test was used to determine between chamber
differences (center chamber not included for statistical analysis), ** p<0.01. Solid
line, time spent in the Meth-paired chamber; dashed line, time spent in the
saline-paired chamber; grey line, time spent in the center chamber

CHAPTER VII
POST-CONDITIONING ADMINISTRATION OF BACLOFEN INTO THE MEDIAL
DORSAL THALAMUS INHIBTS METHAMPHETAMINE-INDUCED
CONDITIONED PLACE PREFERENCE
Abstract
The medial dorsal nucleus of the thalamus (MDT) is connected to brain regions
important in the regulation of psychostimulant-induced behaviors and mnemonic
processes.

However, the role of the MDT in the maintenance of

psychostimulant-induced associative learning is unclear. The MDT expresses
moderate to high levels of GABABR; which modulate psychostimulant-induced
neurotransmitter release and downstream molecular adaptations. The present
study evaluated the role of GABABRs in the MDT in the maintenance of
methamphetamine (Meth)-induced associative learning using conditioned place
preference (CPP). After the development of Meth (1mg/kg)-induced CPP, rats
were administered two once-daily injections of baclofen (0.5nmol/0.5μl/side) or
vehicle into the MDT, or the overlying hippocampus (HC) which served as a site
control. The following day, place preference was determined for drug-free rats
by comparing time spent in the Meth-paired chamber during the CPP test to the
same chamber during the pre-test. Intra-MDT administration of vehicle and intraHC administration of either the vehicle or baclofen did not impact the ability of
rats to demonstrate significant CPP. In contrast, rats that received intra-MDT
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injections of baclofen did not show CPP. These results implicate GABA BRs in
the MDT as regulators of short term processes that allow for subsequent
expression of Meth-induced CPP.

Introduction
When psychostimulants are administered in a unique context or environment,
that context may become associated with the positive attributes of the stimulant.
Once this drug-context association is made, re-exposure to the context, in the
absence of the drug, can increase in neuronal activity in limbic brain regions
(Childress et al., 1999; Childress et al., 2008; Rhodes et al., 2005; Brown et al.,
1992; Zombeck et al., 2008; Franklin and Druhan, 2000; Ciccocioppo et al.,
2001) and induce drug-craving, drug-seeking during cue re-exposure which can
lead to relapse to drug use (Ehrman et al., 1992; Hartz et al., 2001; O'Brien et al.,
1992).

The enhanced salience of drug-associated cues can be studied in the

laboratory with conditioned place preference (CPP) paradigms (Childs and deWit
H., 2009; Tzschentke, 1998; Tzschentke, 2007). CPP measures the tendency to
spend more time in an environmental context previously coupled with the
rewarding effects of an unconditioned stimulus. Methamphetamine (Meth) is a
potent

and

highly

abused

psychostimulant

with

no

FDA-approved

pharmacotherapies available. Drug-associated cues can hinder abstinence in
addicts; therefore, understanding the brain circuits and transmitter systems that
are involved in responsiveness to these cues might help identify targets for
relapse reduction pharmacotherapy.
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Though largely ignored by the addiction field, the MDT is connected with regions
known to regulate drug-induced behaviors and mnemonic processes (Kalivas et
al., 1999; Kalivas et al., 2001). Through glutamatergic (Pirot et al., 1994; Kuroda
et al., 1995; Kuroda et al., 1998; Giguere and Goldman-Rakic, 1988; Pirot et al.,
1995) and GABAergic (Churchill et al., 1996b; Groenewegen, 1988; Mogenson et
al., 1987; Zahm et al., 1996) connections, the MDT modulates the medial
prefrontal cortex (mPFC) (Ferron et al., 1984) and ventral pallidum (VP)
(Churchill et al., 1996b; Churchill et al., 1996a; Churchill and Kalivas, 1999),
respectively. Given the involvement of the mPFC in associative learning it is not
surprising that neuronal activity in the MDT is correlated with associative learning
tasks (Oyoshi et al., 1996); lesions of the MDT disrupt the acquisition of sucroseinduced associative learning (McAlonan et al., 1993), blockade of mu-opioid
receptors in the MDT inhibits the acquisition of morphine-induced associative
learning (Guo et al., 2008b), and baclofen administration into the MDT inhibits
working memory (e.g., short-term memory) (Floresco et al., 1999; Romanides et
al., 1999).

Based on these observations, we sought to determine the yet

unexplored role of the MDT in the maintenance of Meth-induced associative
learning.

Systemic

administration

of

the

GABABR

agonist baclofen

inhibits

the

development and expression of Meth-induced behaviors including CPP (Li et al.,
2001) and self-administration (Ranaldi and Poeggel, 2002).

GABABRs are
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located throughout the brain (Margeta-Mitrovic et al., 1999; Charles et al., 2003);
however, moderate to high expression levels are observed in the thalamus,
including the MDT (Margeta-Mitrovic et al., 1999; Charles et al., 2003). Thus,
effects of systemically administered baclofen likely reflect, at least in part,
activation of GABABRs in the MDT. Indeed, activating GABABRs within the MDT,
via intra-cerebral injections of GABABR agonists, disrupts working memory
(Floresco et al., 1999; Romanides et al., 1999) and GABABR expression within
the MDT is significantly decreased following cocaine self-administration
(Frankowska et al., 2008b; Frankowska et al., 2008a). The current project was
designed to expand this literature to ascertain if activating MDT GABA BRs can
reduce the maintenance of place preference memory that was induced by Meth.

Materials and Methods
Animals
Forty male Sprague-Dawley rats (Harlan, Indianapolis, IN) weighing 250-275g at
the start of the study were acclimated to the vivarium (a climate-controlled
environment on a 12hr light/dark cycle), for at least one week prior to the onset of
the experiments. Rats were housed in pairs and allowed ad libitum access to
food and water. Cage mates were given identical pharmacological treatments.
The rat housing room was in the same animal facility suite as, and adjacent to,
the behavioral testing room.

Loyola University Medical Center and Rush

University Medical Center housing facilities are accredited through the
Association for Assessment and Accreditation of Laboratory Animal Care, and all
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experiments were carried out in accordance with the conditions set forth by the
National Institutes of Health Guide for the Care and Use of Laboratory Animals
(National Research Council, 1996) and with the approval of the Loyola University
Medical Center and Rush University Medical Center Institutional Animal Care
and Use Committee.

Drugs
(+)Methamphetamine HCl (Sigma, St. Louis, MO) was dissolved in 0.9% sterile
saline and the dose, 1mg/ml/kg, was calculated as the salt and administered
intraperitoneally

(i.p.).

Vehicle

(0.9%

saline;

0.5μl/side)

or

baclofen

(0.5nmol/0.5μl/side; Sigma, St Louis, MO) were administered via intracerebral
(i.c.) injections. The dose of baclofen selected was because it is within the range
of MDT-injected doses found to be behaviorally relevant to inhibit working
memory (doses used were 0.03-0.3nmol) (Romanides et al., 1999) and influence
motor activity (doses used were 0.003-1.0nmol) (Churchill et al., 1996a) .

Surgical Procedures for intracerebral implantation of guide cannula
To allow direct delivery of vehicle or baclofen into the MDT of awake, behavior
rats, the rats were surgically fitted with guide cannulae overlying the MDT prior to
initiating the study. To do so, 41 rats were allowed one week of acclimation to the
vivarium, and then were anesthetized with pentobarbital (50mg/kg, i.p., Ovation
Pharmaceuticals, Inc., Deerfield, IL) and placed in a stereotaxic apparatus (David
Kopf Instruments, Tujunga, CA). After the skull was exposed, guide cannulae

137
(28 gauge, 1.2mm wide, 11.4mm long) were lowered into the brain 1.2mm
posterior to bregma, +/- 0.6mm off the midline, and 4.4mm below dura
(Pellegrino et al., 1979) as has been used previously (Churchill et al., 1996a).
For placement controls, guide cannulae were implanted into the hippocampus
(HC) which is dorsal to the MDT that was 2.4mm below dura (2mm dorsal to the
MDT). Stainless steel mounting screws and dental acrylic were used to fix the
cannulae to the skull. The skin incision was closed with sutures. Each guide
cannula was fitted with dummy cannula (33 gauge, which did not extend below
the tip of the implanted guide cannula), and was changed daily to prevent
obstruction of the cannula and to acclimate the rats to having the cannula
manipulated. At least five days of recovery were allowed between the surgery
and the initiation of the experiment.

Behavioral Evaluations
The behavioral test room was dimly lit (54-108lux) with white noise (San Diego
Instruments, San Diego, CA) continuously present. The small animal activity box
used for CPP (AccuScan Instruments, Inc., Columbus, OH) was 63cm x 30cm x
30cm and consisted of three chambers divided by Plexiglas sliding doors; two
large conditioning chambers (25cm x 30cm x 30cm) separated by a small center
chamber (13cm x 30cm x 30cm). Each chamber had distinct visual and tactile
cues. Chamber A had vertical stripes on the walls and a textured floor with an
overturned paint dish glued to the center, the opposite, chamber B, had
horizontal stripes and a textured floor with a flat rectangle glued to the center,
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and the center chamber had solid color walls and a smooth, slightly raised
platform floor. Time spent in each chamber and motor activity was monitored via
two sets of photobeams (24 in the horizontal plane and 12 vertical).

The rats were transported from the animal housing room to the adjacent test
room at least 30min prior to the start of the experiment for habituation. Rats
were subjected to a 30min pre-test (refer to the timeline in Fig.21A) which verified
that there was not a significant preference for either chamber (data presented in
Results); however, individual rats tended to spend more time in one chamber
compared to the other.

Thus, for conditioning, rats were administered Meth

(1mg/kg) in the chamber in which they spent the least amount of time during the
pre-test. Conditioning occurred over five days; Meth was paired with one of the
chambers on days 1, 3, & 5 and a saline (1ml/kg) was paired in the opposite
chamber on days 2 & 4. Pairing occurred immediately after each injection and
lasted for 45min. During the withdrawal period after conditioning, baclofen or
vehicle was administered in the home cage, once-daily for two days (days 6 & 7).
One day later (day 8), rats were tested for expression of CPP in a drug-free
state. To do so, the rats were placed into a small neutral, center chamber and
the sliding doors were immediately removed allowing the rats free access to the
entire CPP box. The test session lasted 30min and time spent in each chamber
was determined.

Intracerebral Microinjection Procedure
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For the intracerebral injections (which occurred in the housing room), dummy
cannulae were removed and injectors which extended 1.0mm below the guide
cannulae were inserted. The injectors were connected to a Hamilton syringe
(Reno, NV) via polyethylene tubing, and the syringes were held in a CMA/100
microinjection pump (Carnegie Medicine, Stockholm, Sweden).

Baclofen

(0.5nmol/0.5μl/side, dose based on (Churchill et al., 1996a; Romanides et al.,
1999)) or vehicle (0.5μl/side) was administered to behaving, unrestrained rats at
a rate of 0.1µl/min for 5min for a total volume of 0.5μl/side. Injectors were left in
place for 1min to allow for diffusion of the drug away from the injector tip after
which time the injectors were removed, dummy injectors were replaced, and rats
returned to the home cage.

Histology
After the completion of behavioral testing, pontamine sky blue (Sigma, St. Louis,
MO) was injected to allow for visualization of injector tip placement. The brains
were removed, fresh frozen and cut in 50µm sections. Sections were mounted
on subbed slides and stained with pyronin-Y or cresyl violet. The intracerebral
infusion site (marked by blue dot or lesion) was agreed on by two treatment-blind
observers using light microscopy and reconstructed onto a rat stereotaxic brain
map (Paxinos and Watson, 1998) (Fig. 22)

Statistics
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A two-way repeated measures ANOVA (treatment x test) was employed to
determine shifts in chamber preference across time (pre-test vs. CPP test).
Post-hoc Newman-Keuls was used to identify between test differences. All data
are presented as mean ± SEM. Statistical outliers were determined as those rats
that spent greater than two standard deviations above or below the mean time
spent in any chamber during the pre-test or CPP Test.

Results
Results of the 30min pre-test demonstrated that, before conditioning, there was a
significant group preference for chamber A (n=41, time spent in chamber A,
1025±45sec vs. chamber B 643±44sec; paired t-test, p<0.001, center chamber
time was 133±8sec). Based on pre-test results, rats were assigned to receive
Meth in the chamber in which the least amount of time was spent during the pretest such that time spent in the chamber to be paired with Meth was
approximately equal across all treatment groups. Rats were assigned to one of
the following Meth-conditioned treatment groups: HC vehicle, HC baclofen, MDT
vehicle, or MDT baclofen.

Figure 22 shows the injection sites within the MDT and HC for the intracerebral
injections administered during the post-conditioning period; out of the total of 41
rats used for the study one was excluded due to the cannula blockage and four
for placement outside of the MDT and HC.

Rats receiving HC injections

demonstrated significant CPP independent of treatment history (i.e., vehicle or
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baclofen) (Fig. 23A), a two-way repeated measures ANOVA revealed a
significant effect of Test (F(1,11)=22.068, p=0.001) and no effect of Treatment
(F(1,11)=0.467, p=0.508) or Treatment x Test interaction (F(1,11)=1.274, p=0.283).
A Post-hoc Newman-Keuls test showed that time spent in the Meth-paired
chamber during the CPP test (day 8) was significantly increased from time spent
in the same chamber during the pre-test (day -1) for both treatment groups (HC
vehicle, n=8; HC baclofen, n=5; p<0.05).

In contrast, treatment history

significantly impacted CPP outcomes for MDT injected rats (Fig. 23B), a two-way
repeated measures ANOVA revealed a significant effect of Test (F (1,21)=26.822,
p<0.0001) and a Treatment x Test interaction (F(1,21)=4.614, p=0.044) but no
effect of Treatment (F(1,21)=1.327, p=0.262).

A Post-hoc Newman-Keuls test

revealed that time spent in the Meth-paired chamber during the CPP test (day 8)
was significantly increased from time spent in the same chamber during the pretest (day -1) for the MDT vehicle treated rats (n=13, p<0.01) but not for those rats
which received MDT baclofen (n=10, p>0.05).

Discussion
Repeated pairing of Meth with a unique context results in robust associations
between Meth (unconditioned stimulus) and the context in which it is
administered (conditioned stimulus) (Tzschentke, 1998; Tzschentke, 2007). In
the current study, preference for the Meth-paired chamber was not disrupted by
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intra-cerebral vehicle injections into the MDT or HC indicating that the injection
procedure did not impact the preference for the Meth context.

Baclofen

administered into the MDT, and not the overlying HC, inhibited the expression of
Meth-induced CPP when tested in a drug-free state 24hr after the last
intracerebral injection.

These findings demonstrate that pharmacological

augmentation of GABABR signaling in the MDT disrupted the processes
necessary to maintain and subsequently express a preference for the Methpaired chamber.

Prior work has demonstrated that the GABABR agonist, baclofen, modifies the
development

(administered

immediately

after

training)

and

expression

(administered as a pretreatment prior to behavioral testing) of mnemonic
processes including spatial memory (Levin et al., 2004; McNamara and Skelton,
1996; Nakagawa et al., 1995) and fear conditioning (Castellano et al., 1989;
Swartzwelder et al., 1987; Zarrindast et al., 2004). Baclofen also antagonizes
the expression of conditioned behaviors; baclofen administered as a pretreatment prior to testing for the expression of Meth-induced CPP (Li et al., 2001)
or amphetamine-induced conditioned motor sensitization (Hotsenpiller and Wolf,
2003) inhibits the expression of these behaviors.

The current study

demonstrated that intra-MDT administration of baclofen in Meth-conditioned rats
resulted in a reduction of CPP drug-free rats one day after the last MDT
treatment an effect which was not observed with two once-daily systemic
injections of 2mg/kg baclofen (Chapter VI) indicating a selective influence of the
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MDT on the maintenance of Meth-induced CPP rather than globally activating
GABABRs via systemic baclofen administration. The behavioral effects of locally
injected baclofen can be antagonized by co-administration of GABABR
antagonists (i.e., CGP35348 or saclofen) (Zarrindast et al., 2002; Churchill et al.,
1996a) indicating the involvement of the GABABR in the observed behavioral
phenomenon; however, future studies with a GABABR antagonist will be
necessary to validate the involvement of GABA BRs in the observed behavioral
effects.

The MDT expresses moderate to high levels of GABABRs (Margeta-Mitrovic et
al., 1999; Charles et al., 2003); therefore, it is possible that augmented GABABR
signaling within the MDT may be responsible, at least in part, for mediating the
effects of the systemically administered ligands.

The MDT is important for

learning and memory processes; neuronal activity in the MDT is enhanced during
the recall of associative tasks (Oyoshi et al., 1996), lesions of the MDT inhibit the
acquisition of sucrose-induced associative learning (McAlonan et al., 1993) as
well as working memory (Floresco et al., 1999), morphine-induced associative
learning is disrupted by blockade of μ-opioid receptors in the MDT (Guo et al.,
2008b), and baclofen administered into the MDT disrupts working memory
(Romanides et al., 1999). We have now demonstrated that the maintenance of
associative memories is regulated by the MDT. The current study demonstrated
that intra-MDT administration of baclofen in Meth-conditioned rats inhibited the
maintenance of CPP when drug-free rats were tested one day after the last MDT
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treatment.

As this outcome was not obtained when the overlying HC was

exposed to the same treatment this helped verify that the effect of baclofen
reflected actions within the MDT, and not via back diffusion of baclofen up the
cannulae track to more dorsal structures.

Although the HC has long been

implicated in learning and memory processes (Jarrard, 1993); the current study
found that augmenting GABABR signaling in the HC 24 and 48hr after
conditioning had no effect on memory maintenance.

When baclofen was

administered into the HC immediately after passive avoidance training
subsequent expression of the behavior was inhibited, this observation is
consistent with the involvement of the HC in early memory mnemonic events
(<24hr) (Arolfo et al., 1998; Bourtchouladze et al., 1998; Packard and Teather,
1997).

Taken together, these studies suggest that augmenting GABA BR

signaling within the MDT, but not the HC, during the early phases after Methconditioning is sufficient to weaken the maintenance of Meth-induced associative
learning.

The MDT is anatomically positioned to influence a number of brain regions that
are known to influence drug-induced behaviors and mnemonic processes; one
such region is the medial prefrontal cortex (mPFC) which receives dense
glutamatergic projections from the MDT (Kuroda et al., 1995; Churchill et al.,
1996b; Kuroda et al., 1998; Pirot et al., 1994; Groenewegen, 1988). Glutamate
in the mPFC is a critical regulator of memory processes (Wang et al., 2006) and
neuronal activity in the mPFC is increased by electrical stimulation of the MDT

145
(Ferron et al., 1984; Bubser et al., 1998). Thus a decrease in MDT (e.g., due to
administration of baclofen as in the current study) activity might be expected to
reduce glutamate release in the mPFC and blunt neuronal activity. This effect
may account for inhibiting working memory (Romanides et al., 1999) and
disrupting the maintenance of Meth-induced associative memory in the current
study.

In conclusion, these results implicate GABABRs in the MDT as critical regulators
of processes that are necessary to maintain and subsequently express Methinduced CPP.
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Figure 19. Illustration of treatment the protocol. For the pre-test (day -1), drugfree rats were allowed to explore the entire CPP box for 30min. Conditioning
occurred for five days; Meth was paired with one chamber on days 1, 3, & 5, and
the saline was paired with the opposite chamber on days 2 & 4).

Baclofen

(0.5nmol/0.5μl/side) or its vehicle (0.9% saline, 0.5μl/side) was administered on
days 6 and 7. One day later (day 8), rats were tested for the expression of Methinduced CPP in a drug-free state. M, methamphetamine (1mg/kg); S, saline
(1mg/kg); Ø, no drug.
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Figure 20. Brain map Illustrating location of intra-cerebral injection sites. A.
Illustration of the injector tip location for all intra-cerebral sites tested. Stereotaxic
maps were adapted from the atlas of Paxinos and Watson (Paxinos and Watson,
1998). The numbers refer to the coronal level of the section, in mm relative to
bregma.

B.

Representative photomicrographs of Nissl-stained coronal brain

sections showing injector tips into the medial dorsal thalamus.
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Figure 21. The maintenance of Meth-induced CPP was inhibited by two-once
daily injections of baclofen into the medial dorsal thalamus (MDT). Data were
analyzed with a two-way repeated measures ANOVA followed by a post-hoc
Newman-Keuls test to identify between test (pre-test vs. CPP test) differences.
Post-hoc test values are illustrated, * p<0.05, ** p<0.01, ns, not significant. The
dashed line indicates 900sec; 50% of the total CPP test time (1800sec).

B.

Intra-hippocampus (HC) injections of vehicle (open bars, n=8, p<0.05) or
baclofen (filled bars, n=5, p<0.05) did not impact the ability of rats to demonstrate
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CPP.

C.

Rats that received intra-MDT injections of vehicle demonstrate a

significant CPP (open bars, n=13, p<0.01), whereas those rats which received
baclofen did not (filled bars, n=10, p>0.05).

CHAPTER VIII
ANALYSIS OF GABAB RECEPTOR EXPRESSION AND DISTRIBUTION USING
THE CROSS-LINKING TECHNIQUE IN RAT BRAIN FOLLOWING
REPEATED METHAMPHETAMINE ADMINISTRATION
Abstract
Repeated psychostimulant administration creates persistent molecular, cellular,
and circuit adaptations which are manifested as altered neuronal function and
behavior. These adaptations are the consequence of adaptations in a number of
neurotransmitter systems including the inhibitory GABABR system; however, little
is known about the GABABR at a time when psychostimulant-induced behaviors
are expressed. To provide an ex vivo snap-shot of an in vivo brain state we
applied the bis(sulfosuccinimidyl)suberate (BS3) cross-linking technique to
assess GABABR expression and distribution, the first time that such an
evaluation has been conducted with a metabotropic receptor in psychostimulanttreated brain tissue. Using this technique, we evaluated GABABR expression
and distribution within brain regions involved in psychostimulant-induced
behaviors at a time when methamphetamine (Meth)-induced conditioned place
preference (CPP, Experiment 1) and motor sensitization (MS, Experiment 2)
were expressed. For CPP, we used a six-day conditioning protocol (Meth-paired
on days 1, 3, & 5 and saline-paired on days 2, 4, & 6) which was sufficient to
induce CPP and MS. Brain tissue was harvested one day after rats
150
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demonstrated Meth-induced CPP (day 10). In spite of the robust behavioral
effects, we observed no significant changes in the expression or distribution of
the GABABR in the medial prefrontal cortex (mPFC), nucleus accumbens (NAc),
ventral pallidum, or medial dorsal thalamus. Likewise, 14 days after three oncedaily Meth injections, at a time when rats expressed Meth-induced MS, GABABR
expression or distribution was unaltered in the mPFC and NAc.

Thus, we

conclude that in the expression of Meth-induced CPP and MS in the current
studies was not dependent on a change in the expression and or distribution of
the GABABR in limbic brain regions evaluated.

However, future studies

evaluating downstream mediators of the GABABR and/or receptor function will be
of value to determine if there is a down-regulation of the GABABR system
contributing to the psychostimulant-induced behaviors such as CPP and motor
sensitization. These studies also suggest that the BS 3 cross-linking technique
will likely be of value to assess a wide variety of surface proteins.

Introduction
Psychostimulants, including methamphetamine (Meth), induce long-lasting
changes in neuronal function (Chen et al., 2009; Nestler, 2001; McDaid et al.,
2007).

These adaptations are highly dynamic and paradigm-specific, with

different brain states occurring during the hours, days, and weeks following
psychostimulant administration (Kalivas and Hu, 2006). While the basal brain
state is highly variable, it is clear that brain regions/neurons that are withdrawn
from repeated exposure to psychostimulants are hyper-responsive to re-
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exposure to cues which are associated with drug-administration (Brown et al.,
1992; Zombeck et al., 2008; Franklin and Druhan, 2000; Ciccocioppo et al.,
2001; Rhodes et al., 2005; Childress et al., 1999; Childress et al., 2008; Lin et al.,
2007) as well as subsequent psychostimulant administration (Robinson et al.,
1988; Kazahaya et al., 1989; Nishikawa et al., 1983; McDaid et al., 2006b;
McDaid et al., 2007).

This hyper-excitable brain state can be observed

behaviorally in the laboratory using conditioned place preference (CPP) and
motor sensitization (MS).

These behaviors model different aspects of

psychostimulant-induced brain adaptations but both behaviors indicate persistent
alterations

in

neuronal

function

that

persist

long-after

psychostimulant

administration.

The GABABR modulates neuronal excitability, signal transduction, and protein
expression; thus, changes in the GABABR system will significantly affect brain
function and resulting behavior. Effects on neuronal excitability are mediated by
G-protein dependent activation of inwardly rectifying K+ channels and inhibition of
high voltage activated Ca++ channels (Mott and Lewis, 1994; Bowery, 1993); the
GABABR regulates neuronal activity and the release of a neurotransmitters
including dopamine (Gong et al., 1998; Kalivas et al., 1993; Santiago et al.,
1993a; Santiago et al., 1993c; Smolders et al., 1995). Indeed, pharmacological
augmentation of GABABR signaling blunts stimulus-evoked release of dopamine
(Fadda et al., 2003) and glutamate (Hotsenpiller and Wolf, 2003). In addition,
GABABRs also mediate effects on protein expression and signal transduction via
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a G-protein dependent mechanism (e.g., cAMP) to regulate the activity of the
transcriptional regulator cAMP response element binding protein (CREB). Thus,
a down-regulation in GABABR system function may contribute to neuronal hyperresponsivity observed after repeated psychostimulant administration. Indeed, the
GABABR system is down-regulated after robust psychostimulant administration
protocols including decreased GABABR expression following a minimum of six
days of stable cocaine self-administration (average of 15-18mg/kg/day)
(Frankowska et al., 2008b; Frankowska et al., 2008a) and functional coupling of
the receptor to the Gi/o G-protein is reduced after chronic cocaine (Kushner and
Unterwald, 2001) and after a sensitizing regimen of amphetamine (Zhang et al.,
2000). Furthermore, these effects are withdrawal time dependent; which makes
it of value to determine withdrawal time dependent effects on the GABA BR
system which may contribute to the development, maintenance, and/or
expression of Meth-induced behaviors.

Thus, the current study sought to

determine the expression and distribution of the GABABR at a time when Methinduced CPP and MS are expressed.

Trafficking of GABABRs is a dynamic process that can profoundly influence
stimulant-medicated behaviors and learning and memory. Several methods have
been used to determine the cellular distribution of GABABRs including
biotinylation (Fairfax et al., 2004), α-bungarotoxin tag (Wilkins et al., 2008), and
florescent protein tags (Fairfax et al., 2004). However, each of these techniques
has aspects which make them less than ideal. The cross-linking technique used
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in the current study, pioneered by Boudreau and Wolf (Boudreau and Wolf, 2005)
to evaluate the surface expression of AMPA receptor subunits, provides an ex
vivo snapshot of an in vivo brain state and is an efficient method to determine the
distribution and expression of surface proteins. The membrane impermeable
cross-linking agent bis(sulfosuccinimidyl)suberate (BS3) binds to extracellular
basic residues (via an amide bond) of proteins inserted into the membrane
resulting in a high molecular weight aggregate that is easily differentiated from
the intracellular protein by using an antibody for protein detection targeted to the
carboxy-terminal region of the receptor. In order for the cross-linking technique
to work there must be an adequate number of extracellular basic resides for BS 3
to bind to in the extracellular domain. The GABA BR is part of the Class C family
of receptors which has a very large extracellular domain (Brauner-Osborne et al.,
2007) making it amenable to the cross-linking procedure. Using this technique,
we were able to successfully evaluate the expression and distribution of
GABABRs in brain regions critical for regulating psychostimulant-induced
behaviors (i.e., medial prefrontal cortex, mPFC; nucleus accumbens, NAc;
ventral pallidum, VP; and medial dorsal thalamus, MDT) at a time when Methinduced CPP and MS are demonstrated. These experiments demonstrate, for
the first time, that the cross-linking procedure can be used to assess expression
and cellular distribution of a metabotropic receptor in brain tissue. Applying this
technique, these experiments were designed to assess behavior- (CPP vs. MS)
and/or withdrawal-time (4 or 14 days after the last Meth administration)
dependent effects on the GABABR.

155

Materials and Methods
Animals
A total of 70 male Sprague-Dawley rats weighing between 250-275g at the start
of the study were acclimated to the vivarium for at least one week prior to the
onset of the experiment.

Rats were housed in pairs in a climate-controlled

environment on a 12hr light/dark cycle and allowed ad libitum access to food and
water. Cage mates were given identical treatments.

Housing facilities were

accredited through the Association for Assessment and Accreditation of
Laboratory Animal Care, and all experiments were carried out in accordance with
the conditions set forth by the National Institutes of Health Guide for the Care
and Use of Laboratory Animals (National Research Council, 1996) and with the
approval of the Loyola University Medical Center and Rush University Medical
Center Institutional Animal Care and Use Committee.

Drugs
(+)Methamphetamine HCl (Meth; Sigma, St. Louis, MO) was dissolved in 0.9%
sterile saline and the dose, 1mg/ml/kg, was calculated as the base (Experiment
1) or as the salt (Experiment 2). Meth and Meth vehicle (0.9% saline) were given
at a volume of 1ml/kg via subcutaneous (s.c.) or intraperitoneal (i.p.) injection, as
indicated.

Conditioned Place Preference Apparatus
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The test room was dimly lit (54-108lux) with white noise (white noise generator,
San Diego Instruments, San Diego, CA) continuously present.

The CPP

apparatus (63cm x 30cm x 30cm) consisted of three chambers divided by
Plexiglas sliding doors (AccuScan Instruments, Inc., Columbus, OH); two large
conditioning chambers (25cm x 30cm x 30cm) were separated by a small center
chamber (13cm x 30cm x 30cm). Each chamber had distinct visual and tactile
cues. Chamber A, vertical stripes on walls and an overturned paint dish glued to
the center of a patterned floor; Chamber B, horizontal stripes on walls and a grid
floor; Center chamber, solid color walls and a smooth, slightly raised platform
floor. Time spent in each chamber and motor activity was monitored via two sets
of photobeams (24 horizontal and 12 vertical).

Behavioral Experiment 1: Repeated Meth administration, four days postconditioning
The rats were transported from the animal housing room to the adjacent test
room at least 30min prior to the start of the experiment. The behavioral paradigm
consisted of three phases: pre-test, conditioning, and CPP test (Fig. 24A). Rats
were given a 15min pre-test to determine, initial, unconditioned chamber bias
(time spent Chamber A, 348±26s vs. time spent Chamber B, 459±24s, Student’s
t-test, p=0.034). Rats were assigned to one of two treatment groups (i.e., Meth
or saline conditioned) such that unconditioned preference was approximately
equal for each group. For conditioning, rats were counterbalanced wherein half
of the rats were assigned to receive the day 1 pairing in the chamber in which
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they spent the greatest amount of time during the pre-test and the other half were
assigned to receive the day 1 pairing in the chamber in which they spent the
least amount of time during the pre-test. Rats were subsequently conditioned for
six days; Meth (1mg/kg, as the base, i.p.) administered on days 1, 3, & 5 and
saline on the alternate days (termed Meth conditioned group; Meth Grp) or saline
was administered on days 1-6 (saline conditioned group; Sal Grp).

During

conditioning, rats were injected (Meth or saline) and were immediately placed
into the appropriate chamber of the CPP box for 45min; motor activity was
assessed during this time (illustrated is vertical time which represent sensitized
motor activity induced by psychostimulants including Meth, Figs. 24B & C). The
rats were evaluated for chamber preference three days after the last conditioning
session (day 9). To do so, rats were placed into the center chamber and sliding
doors immediately removed allowing free access to the entire CPP box. The test
session lasted 15min and time spent in each chamber was evaluated to
determine preference. Brain tissue was harvested one day after the CPP test as
described below.

Behavioral Experiment 2: Repeated Meth administration, 14 days postadministration
The rats were transported from the animal housing room to the behavior room at
least 30min prior to the start of the experiment.

The behavioral paradigm

consisted of three phases: repeated treatment, withdrawal, and motor
sensitization test (Fig. 25A). For the repeated treatment (days 1-3), rats were

158
administered a once-daily injection of Meth (1mg/kg, as the salt, s.c.) or vehicle
(1ml/kg) and placed into a chamber of the CPP box (which was used to measure
motor activity and not used for conditioning) and motor activity was monitored for
60min. During the 14 day withdrawal period, rats remained in the home cage
undisturbed. To ascertain if motor sensitization was expressed on day 17, rats
were given an acute challenge of Meth (1mg/kg, as the salt, s.c.) immediately
prior to being placed into the CPP box for 60min.

Vertical activity reliably

represents sensitized motor activity induced by psychostimulants including Meth,
illustrated are vertical beam breaks and vertical time. Brain tissue was harvested
(described below) from a separate group of rats on the same day as the
behavioral sensitization test (day 17).

Biochemical assessments
Tissue Preparation
The surface receptor cross-linking method was adapted from that of Boudreau
and Wolf (Boudreau and Wolf, 2005). Rat mPFC, VP, NAc, and MDT tissues
were harvested one day after the CPP test (Fig. 3). After being dissected, each
brain region was chopped into 400µm slices with a McIlwain tissue chopper
(Mickle Laboratory Engineering Co. LTD, Goose Green, UK) and immediately
placed

into

artificial

cerebrospinal

fluid

(aCSF)

with

2mM

Bis(sulfosuccinimidyl)suberate (BS3; Thermo Scientific, Rockford, IL). The crosslinking reaction took place for 30min with gentle agitation at 4°C and the reaction
was terminated by administration of 100mM glycine (10min at 4°C). The tissue
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pellet was separated from the supernatant by centrifugation at 14,000rpm for
2min (4oC); supernatant was removed and the pellet was re-suspended in lysis
buffer containing: 25mM HEPES, 500mM NaCl, 2mM EDTA, 20mM NaF, 0.1%
Nonidet P-40, 1mM DTT, 1mM PMSF, protease inhibitor cocktail (Calbiochem,
La Jolla, CA), phosphatase inhibitor cocktail I (Sigma-Aldrich), and phosphatase
inhibitor cocktail II (Sigma-Aldrich).

Cellular membranes were disrupted by

sonication. Tissues were spun at 14,000rpm for 2min at 4°C and subsequently
aliquoted and frozen at -80°C for future use.

Protein concentrations were

determined via the Bradford method (Bradford, 1976).

Non-cross-linked samples (Non CL, Fig. 27A) were hand dissected and
immediately fast-frozen on dry ice then kept at -80°C until tissue preparation. For
tissue preparation, brain regions were Dounce homogenized and sonicated in
homogenation/lysis buffer (25mM HEPES, 1mM EGTA, 1mM EDTA, 100nM
okadaic acid, 1mM sodium orthovanadate, 100μM PMSF, 10µg/ml of pepstatin,
leupeptin & aprotinin in cocktail form). Protein concentrations were determined
via the Bradford method (Bradford, 1976) and samples were prepared with
sample buffer (NuPAGE LDS Sample Buffer, Invitrogen, Carlsbad, CA) and
reducing agent (NuPAGE Sample Reducing Agent, Invitrogen), aliquoted and
frozen until use at -80°C.

Immunoblotting
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Tissue homogenate samples for cross-linking experiments were prepared with in
1:1 dilution of Laemmli sample buffer (Bio-Rad, Hercules, CA) with βmercaptoethanol (volume determined based on protein assay result) and
subsequently heated to 100°C for 3-5min. Protein (20µg) was loaded into a 415% Tris-HCl linear gradient gel (Bio-Rad) and electrophoresed at 200V for
45min. The gels were then transferred to a Hy-Bond PVDF membrane (GE
Healthcare Limited, Buckinghamshire, UK) for 1.5hr at a current of 1.25 amperes.
Nonspecific binding was blocked by incubation of the membrane with TBST
(0.05% Tween 20, Sigma-Aldrich), 1% normal donkey (GABABR1-R20) or 1%
normal goat (GABABR1-R300) serum for at least 1hr. Membranes were then
incubated with GABABR1-R20 (1:300 in TBST, Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA), GABABR1-R300 (1:500 in TBST, Santa Cruz Biotechnology,
Inc., Santa Cruz, CA), or actin (1:20,000 in TBST and 5% non-fat dry milk, Santa
Cruz Biotechnology, Inc., Santa Cruz, CA) primary antibody overnight at 4°C with
gentle agitation.

Membranes were washed repeatedly with TBST and then

incubated with the appropriate HRP-conjugated secondary antibody for
GABABR1-R20 (donkey anti-goat 1:50,000 in TBST; Jackson ImmunoResearch,
West Grove, PA), GABABR1-R300 (goat anti-rabbit 1:15,000 in TBST; Jackson
ImmunoResearch, West Grove, PA), or actin (goat anti-rabbit 1:20,000 in TBST
and 5% non-fat dry milk; Santa Cruz Biotechnology, Inc., Santa Cruz, CA).
Membranes were subsequently washed with TBST, TBS, and distilled water.
Chemiluminescent substrate (SuperSignal West Pico, Thermo Scientific,
Rockford, IL) was applied to the membrane to visualize protein of interest by light
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sensitive film (HyBlot CL, Denville Scientific, Inc., Metuchen, NJ). Optical density
was determined via densitometric analysis with Un-Scan-It Software (Silk
Software,Inc., Orem, UT).

Preabsorption Assay
Immunoblotting was conducted as stated above with the following adaptations.
The PVDF membrane was cut in half. One half was incubated with antibody plus
the blocking peptide (pre-incubated for 1hr at room temperature) and the other
half was processed as described previously; membranes were incubated
overnight at 4°C. The GABABR blocking peptide (1:60 in 1xTBST; Santa Cruz
Biotechnology, Inc., Santa Cruz, CA) specific to the epitope of the antiGABABR1-R20 goat immunoaffinity purified IgG primary antibody (1:300 in
1xTBST; Santa Cruz Biotechnology, Inc., Santa Cruz, CA). Immunoblots were
subsequently washed, incubated with the appropriate secondary antibody and
developed as described previously.

Quantification and Data Summary
Optical density of the high molecular weight aggregate (>400kD) corresponding
to receptors located at the neuronal surface (S), the intracellular components (I)
which were located at the expected molecular weights (GABAB1aR ~130kD,
GABAB1bR ~100kD), and actin (A, ~43kD) were determined. Using these data
the following were calculated: 1) the ratio of surface to intracellular protein (S/I
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ratio), 2) total surface protein (S/A), 3) total intracellular protein (I/A), and 4) total
protein ((S+I)/A).

Statistics
All data are represented as mean ± SEM. Statistical outliers were determined as
more than two standard deviations above or below the mean for any data set.

Behavior
Conditioned place preference: Significant preference was achieved when a
significantly greater amount of time was spent in the Meth-paired compared to
the saline-paired chamber during the CPP test as assessed with a paired t-test
(Bonferroni adjustment set significance at p<0.025).

Development of motor

sensitization: A within group comparison of vertical activity between the first and
the last Meth treatment (Paired t-test, p<0.05). Expression of motor sensitization:
A between groups analysis of vertical activity following a Meth challenge (saline
vs. Meth) (Student’s t-test, significance set at p<0.05).

Immunoblotting
The surface to intracellular ratio (S/I ratio), total protein, surface (S), and
intracellular (I) values were normalized to the average saline within each gel and
multiplied by 100 to determine optical density as a % Average Saline. Student’s
t-tests (significance set at p<0.05) were used to determine differences between
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GABABR distribution and expression in Meth and saline treatment groups for S/I
ratio, total protein, S, and I.

Results
Experiment 1: Repeated Meth administration, four days post-conditioning
(Refer to Fig. 24A for conditioning protocol)

Meth-conditioned rats demonstrated a significant preference for the Meth-paired
chamber (n=16, p=0.0004; Fig. 24C) while saline-conditioned rats did not show
preference for either chamber (n=16, p=0.304, Fig. 24B).

The conditioning

procedure was also sufficient to induce motor sensitization; vertical time
(p=0.040) was significantly greater on day 5 compared to first conditioning day
(day 1) which was representative of other vertical parameters as well. Saline
conditioned rats demonstrated a significant decrease in vertical time (p<0.001)
when comparing the first and last conditioning days which is consistent with
habituation to the environment and the conditioning procedure. Together these
data indicate that the Meth administration protocol induced brain adaptations
which were sufficient to induce Meth-induced associative learning and MS; thus
to determine the status of the GABABR at a time when the behavior was
expressed brain tissue was harvested one day after the CPP test.

No

differences in GABABR expression or distribution were observed in any brain
region comparing Meth-conditioned rats which expressed a preference for the
Meth-paired chamber when compared to saline-conditioned rats (representative
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blots in Fig. 27C; Table 1); this was true when evaluating the GABAB1aR (130kD)
and GABAB1bR (100kD) isoforms separately (data not shown) or when included
together

(100+130kD).

Meth

conditioning

did

not

alter

GABABR

surface/intracellular ratio, total protein, surface, or intracellular in the mPFC, NAc,
VP, or MDT (Table 1). Furthermore, the magnitude of the preference was not
correlated with biochemistry outcomes.

Experiment 2: Repeated Meth administration, 14 days post-administration
(Refer to Figure 25A for repeated treatment protocol) (Behavioral data,
collected by Amanda Mickiewicz, Ph.D.)

These data revealed that three once-daily treatments of 1mg/kg Meth
(administered as the salt, s.c.) was sufficient to induce brain changes that
manifested themselves as the development (Figs. 25B & C) and expression (Fig.
25D) of Meth-induced MS.

Vertical parameters (which reliably represent the

profile of psychostimulant motor sensitization in rodents) including vertical time
(time spent in the vertical position) which was significantly increased during the
repeated treatment period (day 1 vs. day 3) for rats which received repeated
Meth (Fig. 25C, n=8, paired t-test, p=0.005) but not for those repeatedly
administered saline (Fig. 25B, n=8, paired t-test, p=0.527).

In addition,

significant between group differences were observed on day 17 following a Meth
challenge injection; with the Meth repeated treatment rats spending more time in
the vertical position (Student’s t-test, p=0.018). Analysis of tissue collected on

165
day 17 revealed no differences in GABABR expression or distribution in the
mPFC or NAc when comparing rats repeatedly treated with saline or Meth
(representative blots in Fig. 27D; Table 2); this was true when evaluating the
GABAB1aR (130kD) and GABAB1bR (100kD) and 130kD isoforms separately (data
not shown) or when included together (100+130kD).

Repeated Meth

administration sufficient to induce behavioral sensitization did not alter GABA BR
expression or distribution (i.e., surface/intracellular ratio, total protein, surface, or
intracellular) in the mPFC or NAc (Table 2).

Cross-linking of the GABAB receptor
The GABABR was identified as the first receptor to function as an obligate
heterodimer (Kaupmann et al., 1998; White et al., 1998; Jones et al., 1998;
Kuner et al., 1999); the receptor is comprised of a ligand-binding GABAB1R
(Kaupmann et al., 1998) (which has two isoforms (GABAB1aR & GABAB1bR)
which differ from one another by the presence of a sushi domain repeat )
(Kaupmann et al., 1997) and a GABAB2R which couples to the G-protein (Gi/o)
(Bettler et al., 2004; Pin et al., 2004). In addition, the dimerization is critical for
the trafficking of the functional receptor to the neuronal surface; the binding of the
GABAB2R masks the endoplasmic reticulum retention signal located on the
GABAB1R (Couve et al., 1998; Kaupmann et al., 1997). For the current study,
evaluation of the GABAB1R would be expected to mirror changes that also
occurred for the GABAB2R; thus, it is appropriate to evaluate the GABAB1R in the
current study.
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Using the cross-linking technique we have been able to differentiate between the
high molecular weight aggregate corresponding to receptor inserted into the
neuronal membrane bound to BS3 (>400kD) and the intracellular protein which
ran at the expected molecular weight (~130 & 100kD) in the same tissue sample.
This is illustrated in Fig. 27A which demonstrates the difference between
Western blot results obtained from cross-linked (CL) and non-cross-linked (Non
CL) samples. The high molecular aggregate is not present in the Non CL tissue.
The ability to cross-linked receptor proteins is not ubiquitous, the inwardly
rectifying potassium channel (GIRK, a major downstream mediator of the
GABABR) could not be cross-linked due to a relatively small extracellular domain,
and resulting lack of basic amino acid residues for BS 3 to bind to (data not
shown).

Using antibodies targeting toward the intracellular portion of the

receptor we were able to reliably assess expression and distribution of the
GABABR.

We then validated that the antibodies used were specific for the

GABABR using a blocking peptide which inhibited all antibody binding (illustrated
in Fig. 27B).

Results obtained in this assay revealed small inter-sample

variability making the results highly reproducible.

Discussion
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In the current study, the cross-linking technique revealed no changes in the
expression or distribution of the GABABR at a time when Meth-induced CPP and
MS are expressed. This result conflicts with the decreased GABA BR-selective
radioligand binding observed throughout the brain, including regions evaluated in
the current study (i.e., cortex, NAc, MDT) of rats repeatedly self-administered
cocaine (Frankowska et al., 2008b; Frankowska et al., 2008a); however, the
amount of cocaine that was administered (15-18mg/day for more than 6 days) far
exceeded the Meth administered (1mg/kg/day for 3 days) in the current study.
Our possibility to account for the divergent results between our study and the
previous self-administration study, a more robust psychostimulant administration
paradigm might be required to obtain significant changes in GABABR expression
and/or distribution. Our findings are in agreement with an earlier study which
demonstrated that during a time when amphetamine-induced behavioral
sensitization was expressed (14 days after 5mg/kg x 5 days) GABABR density
was unchanged although there was a change in the functional coupling of the
receptor to the G-protein (Zhang et al., 2000). This is not the first report to
demonstrate that GABABR expression does not always correlate with GABABR
function (Enna and Bowery, 2004). Based on these data, we may conclude that
adaptations in GABABR expression and distribution are not necessary for the
expression of psychostimulant-induced behaviors or an alternative conclusion
may be that there was a functional down-regulation of the GABABR system which
was not detected in these assays. Our laboratory has previously demonstrated
that the inhibitory effects of GABA are diminished in the VP following a
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sensitizing regimen of Meth (McDaid et al., 2005) which may reflect a change in
the functional coupling of the GABABR to the G-protein or one of the downstream
mediators of the GABABR including the expression or function of GIRKs and/or
Ca++ channels (Bettler et al., 2004; Mott and Lewis, 1994; Barthel et al., 1996).
Taken together psychostimulant-induced behaviors which appear to not involve
alterations in GABABR expression or distribution may be the consequence of a
functional down-regulation of the GABABR system.

Further analysis will be

required to validate this possibility.

These findings indicate that one day after the expression of Meth-induced CPP
the expression and distribution of the GABABR are not altered in rats that learned
to associate the rewarding properties of Meth with the contextual cues of the
chamber. Likewise, 14 days after repeated Meth administration, at a time when
Meth-induced behavioral sensitization is expressed, the expression and
distribution of the GABABR were unaltered. While we were not able to identify
changes in GABABR expression or distribution at a time when Meth-induced CPP
or MS were expressed, this report describes a re-purposing of a technique to
assess changes in cellular distribution of a metabotropic receptor for the first
time.

This technique allows for a reliable and efficient means to assess

expression and distribution of surface proteins which may be applied to a wide
variety of proteins inserted into the neuronal surface.
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Figure 22.

A six-day conditioning protocol was sufficient to induce

methamphetamine-induced

conditioned

place

preference

and

behavioral

sensitization. A. Illustration of treatment protocol. A drug-free Pre-test was
conducted (day 0) and rats were counterbalanced (half were given the day 1
treatment in chamber in which rats spent the least amount of time during the Pre-
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test and the other half in the chamber in which the greatest amount of time was
spent during the Pre-test).

Conditioning occurred on days 1–6; saline

conditioned group was administered saline on days 1-6 (n=16) and the Meth
conditioned group was administered Meth on days 1, 3, & 5 and saline on the
alternate days (n=16). A drug-free CPP test was conducted on day 9 to verify
the development of CPP (CPP Test 1) and tissue was collected from drug-free
rats one day later (day 10).

Sal Grp, saline conditioned group; Meth Grp,

methamphetamine conditioned group; M, methamphetamine (1mg/kg, as the
base); S, saline (1mg/kg); Ø, no drug. During conditioning, the saline group
exhibited a significant decrease in time spent in the vertical position (s) (day 1 vs.
day 5) consistent with habituation (B; Paired t-test, p<0.001) whereas the Meth
group had a significant increase in time spent in the vertical position (seconds)
when comparing the first to the last Meth injection (day 1 vs. day 5)
demonstrating the development of behavioral sensitization (C; Paired t-test,
p<0.05).

The drug-free CPP test conducted on day 9 revealed that saline

conditioned rats had no preference for either chamber (D; Paired t-test, p>0.05)
while the Meth-conditioned rats demonstrated a significant preference for the
chamber paired with Meth (E; Paired t-test, p<0.01). S, saline-paired chamber;
M, methamphetamine-paired chamber.
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Figure 23. Three once-daily injections of methamphetamine induced behavioral
sensitization which was expressed at 14 days withdrawal.
treatment protocol.

A.

Illustration of

Three once-daily injections of saline or vehicle were

administered (day 1-3) and 14 days later (day 17) rats were either given an acute
challenge or tissue was harvested from drug-free rats. Sal Grp, saline repeated
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treatment group; Meth Grp, methamphetamine repeated treatment group; M,
methamphetamine (1mg/kg, as the salt); S, saline (1mg/kg); Ø, no drug. During
repeated treatment, the saline-treated rats did not exhibit a significant change in
vertical time (seconds spent in the vertical position) (day 1 vs. day 3) (B; Paired ttest, p>0.05) whereas the Meth group had a significant increase in time spent in
the vertical time when comparing the first to the last Meth injection (day 1 vs. day
3) demonstrating the development of behavioral sensitization (C; Paired t-test,
p<0.01). On day 17, rats with a treatment history of Meth (n=20, filled bars) had
significantly higher motor activity than rats repeatedly administered saline (n=18,
open bars) over the 60min post Meth injection time period. D. Vertical time;
Student’s t-test, p<0.05.
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Figure 24.

Anatomical illustration of the brain regions dissected for

immunoblotting. Sections were redrawn from Paxinos and Watson (1998) and
the numbers illustrate the distance in millimeters from Bregma. mPFC, medial
prefrontal cortex; NAc, nucleus accumbens; VP, ventral pallidum; MDT, medial
dorsal thalamus.
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Figure 25. Validation of the cross-linking technique and GABAB receptor antibody specificity. A. Immunoblotting of cross-linked (CL) and non-cross-linked
(Non CL) mPFC tissues demonstrated a high molecular weight aggregate
(~400kD) which corresponds to BS3 bound GABABR inserted into the neuronal
membrane in the CL tissue which is not present in the Non CL tissue. Bands
corresponding to receptors contained in the intracellular compartment were found
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at the expected molecular weights of the two isoforms, GABA B1aR (~130kD) and
GABAB1bR (~100kD) in CL and Non CL samples. A band corresponding to the
dimerized receptor (GABAB1R & GABAB2R) was also observed in CL and Non CL
samples. B. Pre-incubation of the antibody with blocking peptide inhibited all
antibody binding, indicating antibody specificity. Representative blots from CL
tissue used for quantification in behavioral studies. C. Experiment 1 (GABABR1R20), tissue was collected one day after the test for chamber preference in which
Meth (1mg/kg, as the base, i.p.) conditioned rats demonstrate a preference for
the Meth-paired chamber and saline (1ml/kg) conditioned rats did not.

D.

Experiment 2 (GABABR1-R300), tissue was collected 14 days after three once
daily treatments of saline (1ml/kg) or Meth (1mg/kg, as the salt, s.c.). mPFC,
medial prefrontal cortex; NAc, nucleus accumbens; VP, ventral pallidum; MDT,
medial prefrontal cortex; M, methamphetamine treated rats; S, saline treated
rats.
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Table 1. There were no significant changes in GABAB receptor expression
or distribution after Meth conditioning (Experiment 1).
Student’s t-test
Saline Conditioned
Meth Conditioned
Surface/Intracellular Ratio: S/I
mPFC
100±6, n=15
115±6, n=15
p=0.077
NAc
100±4, n=11
96±6, n=12
p=0.583
VP
100±3, n=9
110±6, n=11
p=0.202
MDT
100±5, n=14
98±8, n=13
p=0.804
Total Protein: (S+I)/A
mPFC
100±3, n=12
94±5, n=13
p=0.338
NAc
100±4, n=7
101±7, n=7
p=0.930
VP
100±4, n=10
107±6, n=11
p=0.353
MDT
100±3, n=13
94±3, n=10
p=0.182
Surface: S/A
mPFC
100±4, n=13
104±7, n=15
p=0.636
NAc
100±3, n=7
105±9, n=7
p=0.625
VP
100±4, n=11
102±8, n=9
p=0.859
MDT
100±2, n=14
100±6, n=13
p=0.944
Intracellular: I/A
mPFC
100±4, n=14
89±5, n=15
p=0.100
NAC
100±8, n=8
103±8, n=7
p=0.824
VP
100±3, n=10
109±6, n=7
p=0.139
MDT
100±4, n=14
96±4, n=13
p=0.543
Table 2. There were no significant changes in GABAB receptor expression
or distribution 14 days after repeated Meth administration (Experiment 2).
Student’s t-test
Saline Repeated
Meth Repeated
Treatment
Treatment
Surface/Intracellular Ratio: S/I
mPFC
100±5, n=8
98±6, n=9
p=0.839
NAc
100±8, n=7
92±7, n=5
p=0.529
Total Protein: (S+I)/A
mPFC
100±9, n=9
92±6, n=8
p=0.459
NAc
100±5, n=10
101±3, n=9
p=0.839
Surface: S/A
mPFC
100±6, n=7
101±6, n=9
p=0.955
NAc
100±4, n=11
98±3, n=10
p=0.653
Intracellular: I/A
mPFC
100±7, n=7
106±10, n=8
p=0.619
NAc
100±5, p=12
105±6, n=10
p=0.465

CHAPTER IX
BACLOFEN FACILITATES THE EXTINCTION OF
METHAMPHETAMINE-INDUCED CONDITIONED
PLACE PREFERENCE IN RATS
Abstract
Exposure to cues associated with abused drugs can trigger drug-craving,
seeking and relapse in the abstinent addict.

The powerful, long-lasting

association between the rewarding effects of a drug and contextual cues
associated with drug administration can be studied in laboratory rats using
conditioned place preference (CPP). Extinction therapy is based on the concept
that repeated exposure to drug-associated cues in the absence of the drug
reduces the significance of cues and the likelihood of cue-induced relapse.
Extinction processes engage multiple brain systems that are modulated by GABA
and baclofen, the GABABR agonist, which has been shown to facilitate the
extinction of morphine-induced CPP in mice. The current study extended this
work

by

determining

if

baclofen

could

enhance

the

extinction

of

methamphetamine (Meth)-induced CPP in rats.

Meth-induced CPP was

established using a six day conditioning protocol.

Rats were subsequently

administered baclofen (2mg/kg i.p. or its vehicle) in conjunction with six oncedaily extinction training sessions followed by a CPP test (collectively termed an
extinction training cycle). Our results demonstrate that CPP persisted for at least
four extinction cycles in vehicle-treated rats. In contrast, the expression of Meth177
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induced CPP was completely inhibited following the first extinction training cycle
in which baclofen was administered immediately after each daily extinction
training session. These data indicate that Meth-induced CPP was resistant to
extinction, but extinction training combined with baclofen administration rapidly
extinguished the preference for the Meth-paired chamber.

These findings

converge with the prior demonstration of baclofen facilitating the extinction of
morphine-induced CPP indicating that GABABR actions are independent of the
primary (unconditioned) stimulus (i.e., the opiate or the stimulant) and likely
reflect mechanisms engaged by extinction learning processes per se.

Thus,

baclofen administered in conjunction with extinction training may be of value for
addiction therapy in abstinent addicted humans regardless of the class of drug
being abused.

Introduction
Methamphetamine (Meth) is a highly abused psychostimulant. Even after long
periods of abstinence, cues associated with the rewarding properties of
psychostimulants can elicit drug-craving and seeking (O'Brien et al., 1992;
Ehrman et al., 1992; Hartz et al., 2001). Thus, relapse to drug use remains a
major challenge for psychostimulant-addicted individuals. These responses are
attributed at least in part to the robust associative learning that occurs between
contextual cues (conditioned stimulus) and the rewarding effects of abused
substances (unconditioned stimulus) as well as the enduring nature of the drugcontext memory.

This long-lasting association can be demonstrated in the
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laboratory with conditioned place preference (CPP) (Childs and deWit H., 2009;
O'Brien et al., 1998; Tzschentke, 1998; Tzschentke, 2007).

Unwanted

associative memories can be disrupted by purposefully employing extinction
learning procedures.

For example, extinction procedures can reduce anxiety

associated with post traumatic stress disorder in humans (McCleery and Harvey,
2004; Brunet et al., 2008). However, extinction of reward-related memories is
not particularly efficacious in reducing relapse in abstinent drug-dependent
humans (Conklin and Tiffany, 2002) or in rodent models of addiction (Crombag
and Shaham, 2002; Di Ciano P. and Everitt, 2004); but there is evidence that
combining extinction therapy with a pharmacotherapy may reduce cue-elicited
relapse in humans (O'Brien et al., 1990) and mice (Heinrichs et al., 2010).

Currently there are no FDA-approved pharmacotherapies for Meth addiction;
however, the GABABR has received considerable attention as a potential
pharmacotherapeutic target (Xi and Gardner, 2008; Rose and Grant, 2008;
Brebner et al., 2002). GABABRs negatively regulate neurotransmitter systems
important for reward-mediated behaviors and mnemonic processes, including
glutamate (Yamada et al., 1999; Lei and McBain, 2003; Porter and Nieves, 2004;
Harte and O'Connor, 2005) and dopamine (Santiago et al., 1993c; Santiago et
al., 1993b; Smolders et al., 1995; Westerink et al., 1996). Cues associated with
drug reward activate limbic brain regions in drug-addicted humans (Childress et
al., 1999; Childress et al., 2008) and rodents (Brown et al., 1992; Zombeck et al.,
2008; Franklin and Druhan, 2000; Ciccocioppo et al., 2001; Rhodes et al., 2005).
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This activation is attributed to the hyper-responsiveness of glutamatergic (Bell et
al., 2000; Hotsenpiller et al., 2001) and dopaminergic (Lin et al., 2007) systems.
Imaging studies indicate that baclofen, a GABABR agonist, blunts the limbic
activation associated with visual drug cues in drug-addicted humans (Brebner et
al., 2002).

Baclofen also inhibits the expression of many psychostimulant-

induced behaviors in rodents including CPP (Li et al., 2001), conditioned motor
sensitization (Hotsenpiller and Wolf, 2003), motor sensitization (Bartoletti et al.,
2004; Frankowska et al., 2009; Lhuillier et al., 2007), and self-administration
(Ranaldi and Poeggel, 2002; Brebner et al., 2005; Campbell et al., 1999; Filip et
al., 2007; Roberts and Andrews, 1997; Smith et al., 2004; Weerts et al., 2007). It
is clear that baclofen can alter learning and memory process.

Particularly

relevant to the current study is the recent demonstration that baclofen
administered immediately after extinction training facilitated the extinction of
morphine-induced CPP (Heinrichs et al., 2010).

As baclofen modulates

neurotransmitter systems that are critical for the expression of psychostimulantinduced behaviors as well as the extinction of opiate-induced CPP, we sought to
determine the efficacy of baclofen to facilitate the extinction of Meth-induced
associative learning.

This experimental endeavor also determined if the

baclofen

with

effect

seen

psychostimulant Meth.

Materials and Methods
Animals

morphine-induced

CPP

generalized

to

the
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Forty male Sprague-Dawley rats (Harlan, Indianapolis, IN) weighing 250-300g at
the start of the study were acclimated to the local vivarium (a climate-controlled
environment on a 12hr light/dark cycle) for at least one week prior to the onset of
the experiments. Rats were housed in pairs and allowed ad libitum access to
food and water. Cage mates were given identical pharmacological treatments.
Rush University Medical Center housing facilities are accredited through the
Association for Assessment and Accreditation of Laboratory Animal Care, and all
experiments were carried out in accordance with the conditions set forth by the
National Institutes of Health Guide for the Care and Use of Laboratory Animals
(National Research Council, 1996) and with the approval of the Rush University
Medical Center Institutional Animal Care and Use Committee.

Drugs
(+)Methamphetamine HCl (Sigma, St. Louis, MO) was dissolved in 0.9% sterile
saline, and the dose, 1mg/ml/kg, was administered as the base. Baclofen was
also dissolved in 0.9% saline and administered at a dose of 2mg/ml/kg (Sigma,
St Louis, MO).

Saline vehicle injections were administered as 1ml/kg.

All

injections were given intraperitoneally (i.p.).

The baclofen dose of 2mg/kg is within the range of doses used in laboratory rats
to successfully attenuate psychostimulant-induced behaviors, including Methinduced CPP (1.25, 2.5, 5mg/kg, i.p.) (Li et al., 2001), cocaine self-administration
(2.5mg/kg, i.p.) (Smith et al., 2004), break point of amphetamine self-
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administration (1.8, 3.2, 5.6mg/kg, i.p.) (Brebner et al., 2005), and amphetamineinduced motor sensitization (2mg/kg, i.p.) (Bartoletti et al., 2004). In addition, in
pilot studies, we determined that motivated motor behavior assessed on the
rotarod (San Diego Instruments, San Diego, CA) was inhibited by 4mg/kg
baclofen and spontaneous motor activity was decreased by 3mg/kg baclofen but
not by 2mg/kg (unpublished data).

Apparatus for Assessing Behavior
The test room was dimly lit (54-108lux) with white noise (San Diego Instruments,
San Diego, CA) continuously present. The CPP apparatus (63cm x 30cm x
30cm) consisted of three chambers divided by Plexiglas sliding doors (AccuScan
Instruments, Inc., Columbus, OH); two large conditioning chambers (25cm x
30cm x 30cm) separated by a small center chamber (13cm x 30cm x 30cm).
Each chamber had distinct, yet neutral, visual and tactile cues. Chamber A had
white vertical stripes and chamber B had white horizontal stripes on walls. These
chambers were randomly fitted with floors that were either a textured surface with
an overturned paint dish glued to the center or different textured floor with a
smooth, flat rectangle glued to the center. The center chamber had white walls
and a smooth, slightly raised platform floor. Time spent in each chamber and
motor activity was monitored via two sets of photobeams (24 in the horizontal
plane and 12 vertical).

Conditioned Place Preference
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The rats were transported from the animal housing room to the adjacent test
room at least 30min prior to the start of the experiment for habituation. Rats
were subjected to a 30min pre-test (refer to the timeline in Fig.28A) which verified
that there was not a significant preference for either chamber (data presented in
Results); however, individual rats tended to spend more time in one chamber
compared to the other.

Thus, for conditioning, rats were administered Meth

(1mg/kg) in the chamber in which they spent the least amount of time during the
pre-test. Conditioning occurred over six days; Meth was paired with a unique
context (i.e., chamber) on days 1, 3, & 5 and a saline (1ml/kg) was paired with a
different context on days 2, 4, & 6. Pairing occurred immediately after each
injection and lasted for 45min. In order to confirm that the preference developed,
a drug-free CPP test was conducted on day 9 (termed CPP Test 1; Fig. 28A).
For this test, rats were placed into the center chamber and the sliding doors were
immediately removed allowing free access to the entire CPP box.

The test

session lasted 30min and time spent in each chamber was determined. Rats
that did not increase time spent in the Meth-paired chamber on CPP Test 1
compared to the same chamber during the pre-test by at least 10% (180s) were
excluded from the studies. This culling procedure, as previously shown by others
(Paolone et al., 2009) helps assure that only those rats who clearly acquired the
task were used to determine the potential of the GABA BR agonist baclofen to
facilitate the extinction of CPP. Rats were assigned to either the baclofen or
baclofen vehicle treatment group such that the magnitude of the preference
during CPP Test 1 was approximately equal between the two groups. Each
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extinction cycle consisted of six consecutive once-daily forced extinction
sessions (45min) followed by a CPP test three days later (referred to as the
“Extinction Test”, Ext Test; Fig. 28A). The once-daily forced extinction sessions
consisted of pairing a saline (1ml/kg) treatment with each chamber for 45min
(termed “Pre-Training Injection”; Fig. 28A), alternating between the previously
Meth- or saline-paired chamber (as done during conditioning), a commonly used
approach for forced extinction training (Mueller and Stewart, 2000; Heinrichs et
al., 2010; Schroeder and Packard, 2004). Immediately after each daily extinction
session, baclofen vehicle (1ml/kg) or baclofen (2mg/kg) was administered
(termed “Post-Training Injection”; Fig. 28A) and rats were returned to the home
cage.

Four extinction cycles (each including six once-daily forced extinction

sessions and the Ext test) were conducted (Fig. 28A).

Statistical Analysis
A two-way repeated measures ANOVA was employed using the within group
factor of chamber and the repeated measure of test. Post-hoc Newman-Keuls
was used to identify between chamber differences; significant preference was
achieved when time spent in the Meth-paired chamber was significantly greater
than time spent in the saline-paired chamber for any CPP/Ext Test.

This

approach has been used by Stewart and colleagues for similar evaluations
(Paolone et al., 2009; Botreau et al., 2006). All data are presented as mean ±
SEM. Statistical outliers were determined as those rats that spent greater than
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two standard deviations above or below the mean time spent in any chamber
during any of the CPP or Ext tests.

Results
Results of the 30min pre-test demonstrated that, before conditioning, rats spent
approximately equal amount of time in each chamber (time spent in chamber A,
868±64s vs. chamber B 810±63s; paired t-test, p=0.652 center chamber time
was 122±9s; n=40). After conditioning (CPP Test 1, day 9), rats expressed a
significant preference for the Meth-paired chamber compared to the saline-paired
chamber (time spent in the Meth-paired chamber, 958±41s vs. time spent saline
chamber 672±43s; paired t-test, p=0.0003; center chamber time was 170±8sec;
n=40). Of these rats, 28 met the learning criteria detailed in the methods, and
these rats with a strong preference for the Meth-chamber (i.e., robust learners)
were subsequently assigned to receive either baclofen or baclofen vehicle in
order to assess the ability of baclofen to facilitate the extinction of Meth-induced
CPP. As detailed in the methods, rats that were outliers for any of the tests (CPP
Test-Ext Test 4) were excluded (n=7) thus a total of 10 and 11 rats were included
in the baclofen vehicle and baclofen groups, respectively.

Significant preference was expressed on CPP Test 1 and it persisted through
four extinction cycles when vehicle was administered in conjunction with
extinction training (n=10, Fig. 28B).

A two-way repeated measures ANOVA

revealed a significant effect of Chamber (F(1,18)=15.966, p=0.001) but no effect of
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Test (F(4,72)=0.022, p=0.999) and no Chamber x Test interaction (F(4,72)=1.011,
p=0.407). A post-hoc Newman-Keuls test revealed significant CPP (significantly
greater amount of time spent in the Meth-paired than the saline-paired chamber)
for the CPP test and all subsequent extinction tests (Fig. 1B; p<0.05 or p<0.01).
In contrast, baclofen administered immediately after each daily extinction session
during extinction cycle 1 nullified preference for the Meth-paired chamber during
all subsequent preference tests (n=11; Fig. 28C, Ext Test 1-4).

A two-way

repeated measures ANOVA revealed a significant Chamber x Test interaction
(F(4,80)=2.799, p=0.031) with no effect of Chamber (F(1,20)=2.950, p=0.101) or Test
(F(4,80)=0.057, p=0.994).

A post-hoc Newman-Keuls test revealed significant

preference for the Meth-paired chamber compared to the saline-paired chamber
only during CPP Test 1 (p<0.01). Although time spent in the center chamber was
not included in the statistical analyses reported above, we verified that time spent
in the center chamber did not significantly change for either treatment group
during any of the preference tests (CPP Test-Ext 4) (one-way ANOVA; vehicle
treated rats F(4,45)=1.300, p=0.284, baclofen treated rats F(4,50)=1.185, p=0.329).

Motor activity was monitored during each of the preference tests (CPP and Ext
Tests).

Examination of these data revealed no significant between group

differences during any test for horizontal or vertical activity (Student’s t-test,
p>0.05; Table 1).

Discussion
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The Meth-induced preference observed in the current study was highly resistant
to extinction; repeated re-exposure to the chambers over four extinction cycles
did not extinguish the Meth-induced preference in vehicle treated rats.

In

contrast, baclofen administered immediately after chamber re-exposure inhibited
the preference for the Meth-paired chamber after the first extinction cycle
(Extinction Test 1).

This inhibitory effect was produced even in rats which

demonstrated robust preference during CPP Test 1 (see culling procedure in
Methods).

Motor activity was not significantly altered by repeated baclofen

treatment; thus, the place preference results do not reflect a change in the
capacity of rats to successfully execute the task. These findings indicate that
augmenting GABABR signaling facilitates the extinction of Meth-induced CPP.

These results corroborate the recent publication by Heinrichs and colleagues
which demonstrates that baclofen facilitates the extinction of morphine-induced
CPP in mice (Heinrichs et al., 2010). This suggests that baclofen is working via
an overlapping mechanism(s) engaged during the extinction of morphine- and
Meth-induced CPP.

During extinction training, rats were re-exposed to

contextual cues (i.e., the conditioning chambers) that were previously associated
with Meth- as well as those paired with saline. Re-exposure to cues associated
with Meth (Rhodes et al., 2005; Chiang et al., 2009) and morphine (Guo et al.,
2008a; Schroeder et al., 2003; Schroeder and Kelley, 2002; Schroeder et al.,
2000) increases neuronal activity (e.g., amygdala and orbitofrontal cortex). This
may reflect hyper-responsive glutamatergic (Bell et al., 2000; Hotsenpiller et al.,
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2001) neurotransmission.

Indeed, blocking glutamatergic AMPA receptors

inhibits the increase in Fos expression that occurs during re-exposure to cocaine
cues in limbic and cortical brain regions (Zavala et al., 2007). In the current
study, blunting the cue-induced brain hyperactivity immediately after re-exposure
to the Meth-paired context is a credible candidate mechanism by which baclofen
facilitates the extinction of Meth-induced CPP with the same argument holding
true for the extinction of opiate-induced CPP.

If true, this indicates that the

persistence of drug-induced associative memories is dependent on hyperresponsive glutamate neurotransmission in the time period after re-exposure to
contextual conditioning cues which influences protein expression and neuronal
structure.

Extinction of a memory is believed to involve new learning; the new memory
becomes stronger than the previously established memory resulting in a different
conditioned response (Quirk and Mueller, 2008).

For example, memory

consolidation can be facilitated by augmenting glutamatergic neurotransmission
(Ungerer et al., 1998); the extinction of cocaine-induced CPP is enhanced by
administering a mGluR5 positive allosteric modulator prior to extinction training
(Gass et al., 2009) or a NMDA receptor agonist immediately after extinction
training (Botreau et al., 2006).

In the current study, baclofen was administered

immediately after each daily extinction session (i.e., after re-exposure to the
saline- or Meth-paired chamber), thus the extinction enhancing effects of
baclofen may be due to enhanced consolidation of the extinction memory likely
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involving mechanisms including PKA and CREB. Although not typically thought
of as memory enhancing, the GABABR agonist baclofen has been reported to
improve passive avoidance learning when administered immediately after
training (Georgiev et al., 1988; Saha et al., 1993) and recognition memory
deficits induced by repeated Meth administration when administered prior to
training (Arai et al., 2009). GABABRs blunt glutamatergic (Yamada et al., 1999;
Lei and McBain, 2003; Porter and Nieves, 2004) and dopaminergic (Santiago et
al., 1993c; Santiago et al., 1993b; Smolders et al., 1995; Westerink et al., 1996)
neurotransmission and this effect would serve to inhibit rather than facilitate
memory consolidation. Antagonism of NMDA glutamate receptors impairs the
extinction of fear conditioning (Liu et al., 2009) as well as the extinction of
cocaine self-administration (Feltenstein and See, 2007) and similar impairing
effects on the extinction of fear conditioning are observed with dopamine
receptor antagonisms (Holtzman-Assif et al., 2010; Hikind and Maroun, 2008).
Therefore, while baclofen has been reported to have positive influences on
memory consolidation, the negative regulation of glutamate and dopamine does
not account for the extinction facilitating effects observed in the current study.

Extinction of a previously established memory can occur when a memory is
recalled (which makes the memory labile and sensitive to disruption) but not
successfully reconsolidated (McGaugh, 2000; Tronson and Taylor, 2007; Taylor
et al., 2009; Bevilaqua et al., 2008). Inhibiting reconsolidation as a practical
means to reduce cue-induced cocaine seeking has been successfully
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demonstrated (Lee et al., 2006; Lee et al., 2005). GABABR-induced decrease in
glutamatergic neurotransmission (Yamada et al., 1999; Lei and McBain, 2003;
Porter and Nieves, 2004; Harte and O'Connor, 2005) should serve to blunt
memory reconsolidation as administration of an NMDA receptor antagonist
inhibits reconsolidation of cocaine-induced CPP memory (Brown et al., 2008;
Itzhak, 2008). Dopamine receptor antagonism has been reported to have both
no effect on the extinction of cocaine CPP (Yim et al., 2009) but has been
reported to facilitate the extinction of conditioned fear (an effect that may be
attributed to the disruption of re-consolidation mechanisms) (Ponnusamy et al.,
2005).

In the current protocol, we cannot determine if baclofen enhanced

extinction learning or inhibited memory re-consolidation, a task made more
difficult by the fact that these processes have many overlapping mechanisms
(Alberini, 2005), these avenues need further exploration to determine how
baclofen facilitated the extinction of Meth-induced CPP.

Baclofen effects on memory maintenance, independent of re-exposure to the
conditioning cues, should also be considered for the current behavioral
outcomes. To date only Bartoletti and colleagues (Bartoletti et al., 2004) have
demonstrated efficacy of baclofen to modify the maintenance of a previously
established psychostimulant-induced behavior. These authors reported that the
maintenance of amphetamine-induced motor sensitization is diminished by 10
home cage administrations of 2mg/kg baclofen. In the current study, baclofen
may have inhibited memory maintenance independent of re-exposure to the
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conditioning cues. However, while we have observed that the maintenance of
Meth-induced CPP was not inhibited with two once-daily baclofen treatments
(2mg/kg) (Chapter VI) the maintenance of the behavior can be inhibited by two
once-daily injections of negative allosteric modulators of the metabotropic
glutamate receptor subtype 5 (mGluR5).

Likewise, 10 administrations of

baclofen in the home cage inhibited the maintenance of Meth-induced CPP
(Chapter IV); however, we contend that the inhibitory effects of baclofen on the
maintenance of Meth-induced CPP may be more therapeutically efficacious by
combining baclofen treatment with extinction training.

In summary, we have found that baclofen administered in conjunction with
extinction training resulted in rapid and complete extinction of Meth-induced
CPP. While the mechanism is unclear this exciting study provides insight into the
role of the GABABR in memory processes engaged after re-exposure to salient
drug-associated contextual cues and may be of value as an addiction therapy for
abstinent, Meth-addicted individuals.
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Table 3. Motor activity recorded during testing revealed no significant
differences between vehicle- (n=10) and baclofen- (n=11) treated rats.
CPP Test
Ext Test 1 Ext Test 2 Ext Test 3 Ext Test 4
1
Horizontal Activity
Vehicle
4242±226 3306±115 3098±198 3296±356 2876±152
Baclofen
4003±259 3291±252 3239±263 2899±201 2773±126
Vertical Activity
Vehicle
746±51
528±44
519±49
446±33
406±32
Baclofen
757±82
569±62
527±60
380±32
398±26
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Figure 26.

Extinction of Meth-induced CPP was facilitated by baclofen.

A.

Illustration of treatment protocol. A drug-free pre-test was conducted and rats
were assigned to receive Meth in the chamber in which the least amount of time
was spent during the pre-test. Conditioning occurred on days 1–6. A drug-free
CPP test was conducted on day 9 to verify the development of CPP. Daily
extinction sessions consisted of a saline injection prior to being placed into either
the previously saline- or Meth-paired chamber.

Immediately following each

extinction training session, baclofen vehicle or baclofen was administered before
the rats were returned to the home cage. Each six-day extinction cycle was
followed by a drug-free test for preference three-days after the last extinction
session (denoted Ext Test 1-4, on days 18, 30, 46 and 55).

M,

methamphetamine (1mg/kg); S, saline (1mg/kg); Veh, vehicle (0.9% saline,
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1ml/kg); Bac, baclofen (2mg/kg); Ø, no drug. B. Meth-induced CPP established
by 6 days of conditioning and subsequently expressed during CPP Test 1 was
not altered by post-conditioning administration of vehicle; significant CPP was
expressed on CPP Test 1 through Ext Test 4 (Vehicle, n=10). C. CPP Test 1
validated that rats expressed a preference prior to initiating extinction training.
The preference evident during CPP Test 1 was not present after the first
extinction cycle with baclofen (Baclofen, n=11). Post-hoc Newman-Keuls was
used to determine between chamber differences ** p<0.01. Solid line, time spent
in the Meth-paired chamber; dashed line, time spent in the saline-paired
chamber; grey line, time spent in the center chamber.

CHAPTER X
GENERAL DISCUSSION
Relapse to drug use is a major problem for abstinent drug-addicted individuals;
cues associated with drug use can precipitate drug-craving, -seeking, and –
relapse (Childress et al., 1993; Ehrman et al., 1992; O'Brien et al., 1998). Thus,
a mechanism to functionally ‘uncouple’ the cue from the response (i.e., drugcraving and –seeking) may reduce the propensity of individuals to relapse to drug
use. Towards that end, this dissertation project explored the role of the GABA BR
in the maintenance of Meth-induced CPP. The maintenance of CPP, compared
to the development and expression phases, is a relatively unexplored area which
has significant clinical applications, for it is those individuals who are already
addicted who require treatment and will struggle with the consequences of being
re-exposed to drug-associated cues. Thus, disrupting processes necessary to
maintain the previously acquired drug-cue association may be of value as an
anti-relapse therapy.

This dissertation project was developed to assess if

augmenting GABABR signaling was sufficient to alter brain circuits necessary to
maintain and subsequently expresses Meth-induced CPP. The collective results
from this project demonstrate that the maintenance of Meth-induced learned
associations are sensitive to disruption by augmenting GABABR signaling.
GABABRs regulate the development and expression of drug-induced behaviors
195

196
(e.g., CPP and MS) as well as learning and memory; however, the influence of
these receptors in the maintenance of drug-induced behaviors is largely
unexplored. To date, only Bartoletti and colleagues have demonstrated that 10
once-daily injections of baclofen administered after the development of
amphetamine- (Bartoletti et al., 2005) or morphine- (Bartoletti et al., 2007)
induced motor sensitization inhibits the subsequent expression of the behavior
and Heinrichs and colleagues have demonstrated that baclofen facilitates the
extinction of morphine-induced CPP (Heinrichs et al., 2010). Findings from the
current project extend these previous results by revealing that i) 10 once-daily
systemic injections of baclofen or fendiline, ii) two once-daily systemic injections
of GS39783 and CGP7930, iii) two once-daily intra-MDT injections of baclofen
administered in the context of the home cage altered brain processes necessary
to maintain Meth-induced CPP, and iv) six systemic injections of baclofen
administered in conjunction with extinction training accelerated the disruption of
the preference.

GABABR activation influences neuronal function via several

different mechanisms which may disrupt Meth-induced CPP; below, I have
overviewed the most plausible theories that help define these mechanisms and
which dovetail into the findings from the current project.

Repeated administration of psychostimulants has significant effects on neuronal
excitability. Studies overwhelmingly support the notion that the brain is hyperexcitable during re-exposure to drug-associated cues.

This hyper-excitability

was measured as an increase in i) Fos expression (Brown et al., 1992;
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Ciccocioppo et al., 2001; Franklin and Druhan, 2000; Rhodes et al., 2005;
Zombeck et al., 2008; Miller and Marshall, 2005), ii) neuronal firing (Rebec and
Sun, 2005) iii) metabolic activity (Childress et al., 2008; Childress et al., 1999),
and iv) extrasynaptic concentrations of neurotransmitters glutamate (Bell et al.,
2000; Hotsenpiller et al., 2001; Hotsenpiller and Wolf, 2002) and dopamine (Lin
et al., 2007). These studies consistently demonstrate neuronal hyper-excitability
within the amygdala, thalamus, and PFC (especially the anterior cingulate and
the orbitofrontal cortices) when the psychostimulant withdrawn individual is reexposed to drug-associated stimuli. Both the amygdala and the thalamus send
glutamatergic projections to the PFC; therefore, the PFC may be a site of
convergence for multiple brain circuits which respond to drug-associated stimuli.
Thus, restoring the inhibitory/excitatory balance in the PFC (which plays an
important role in learning/memory processes as well as executive function) and
associated circuits may reduce the maintenance and subsequent expression of
Meth-induced CPP. Outcomes obtained in Chapter VIII indicate that any putative
adaptations did not involve the level of expression or cellular distribution of the
GABABR, in several limbic regions at times when Meth-induced behaviors (which
presumably involve neuronal hyper-excitability) were expressed (i.e., cueinduced hyper-responsivity (CPP) and drug-induced hyper-excitability (MS)).
Thus, it does not appear that changes in GABABR expression and/or distribution
are responsible for rats to demonstrate Meth-induced behaviors, and that downregulation of some other component of the GABA BR system may have occurred.
For example, decreased G-protein expression is observed after chronic cocaine
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(Nestler et al., 1990) and functional coupling of the GABABR to the G-protein
after a sensitizing regimen of amphetamine (Zhang et al., 2000) or chronic
cocaine (Kushner and Unterwald, 2001). It might be that overt changes in the
expression of the GABABR only occur with robust psychostimulant exposure (>
10 days, 15-18mg/kg i.v. cocaine/day) as was observed previously (Frankowska
et al., 2008b; Frankowska et al., 2008a) and not with the more modest Methtreatment protocols which induced CPP and MS (1mg/kg x 3 days). Although no
changes were observed in the current project, a previous report has
demonstrated that GABABR expression does not predict function of the GABABR
system (Enna and Bowery, 2004). Determination of such changes in GABABR
system function at a time when Meth-induced behaviors are observed will require
further study. Independent of the status of the GABABR system, this project has
demonstrated that augmenting GABABR signaling inhibited the maintenance of
Meth-induced CPP.

Activating GABABRs inhibits Ca++ influx via high voltage activated Ca++ channels
(Gong et al., 1998; Kalivas, 1993; Santiago et al., 1993c; Santiago et al., 1993b;
Smolders et al., 1995; Westerink et al., 1996; Harte and O'Connor, 2005; Lei and
McBain, 2003; Porter and Nieves, 2004; Yamada et al., 1999; Bonanno et al.,
1997; Huston et al., 1990; Amico et al., 1995; Cardozo and Bean, 1995; Mintz
and Bean, 1993; Scholz and Miller, 1991; Takahashi et al., 1998). This effect
would oppose the enhanced excitatory response to drug-stimuli (i.e., subsequent
drug exposure or re-exposure to cues) caused by repeated psychostimulant
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administration which increases the expression of L-type Ca++ channels
(Shibasaki et al., 2010; Ford et al., 2009; Nasif et al., 2005a; Nasif et al., 2005b;
Hu, 2007).

Whether attenuated inhibition or augmented excitation underlies

maintenance, increasing GABABR signaling effectively disrupted mechanisms
necessary to maintain and subsequently express Meth-induced CPP.

Baclofen administered in conjunction with extinction training rapidly disrupted the
Meth-induced preference beyond that achieved with extinction training alone
(Chapter IX). This experimental protocol highlights events which occur during reexposure to Meth-associated cues; it suggests that blunting neuronal activity
and/or down-stream signaling events at a time when neuronal activity was
increased (i.e., during re-exposure to cues) rapidly disrupted the Meth-induced
preference. GABABRs directly influence neurotransmitter release via inhibition of
high-voltage activated Ca++ channels (Gong et al., 1998; Kalivas, 1993; Santiago
et al., 1993c; Santiago et al., 1993b; Smolders et al., 1995; Westerink et al.,
1996; Harte and O'Connor, 2005; Lei and McBain, 2003; Porter and Nieves,
2004; Yamada et al., 1999; Bonanno et al., 1997; Huston et al., 1990; Amico et
al., 1995; Cardozo and Bean, 1995; Mintz and Bean, 1993; Scholz and Miller,
1991; Takahashi et al., 1998), neuronal excitability via activation of GIRKs
(Tabata et al., 2005; Luscher et al., 1997; Nicoll, 2004; Chen and Johnston,
2005; Takigawa and Alzheimer, 1999), and down-stream molecular events via
inhibition of cAMP and CREB (Bettler et al., 2004; Bowery et al., 2002; Bowery,
1993).

Thus, the GABABR has multiple mechanisms that may underlie the
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observed behavioral outcomes.
neurotransmitter

release,

is

GABABR-mediated reduction in excitatory
akin

to

blunting

neuronal

excitation

via

pharmacological antagonism of glutamate receptors; a well documented means
to impair mnemonic processes (i.e., consolidation and reconsolidation) (Liu et al.,
2009; Feltenstein and See, 2007; Brown et al., 2008; Itzhak, 2008; HoltzmanAssif et al., 2010; Hikind and Maroun, 2008; Ponnusamy et al., 2005).

In

addition, GABABR-mediated reduction in cAMP (Bettler et al., 2004) may reduce
the activity of the transcription factor CREB (Barthel et al., 1996; Bettler et al.,
2004; Mott and Lewis, 1994; Lhuillier et al., 2007; Yin et al., 2006). Indeed,
augmenting

GABABR signaling

at

the

same

time

as psychostimulant

administration pharmacologically antagonizes events leading to psychostimulantinduced changes in the transcription factor CREB (Yin et al., 2006; Lhuillier et al.,
2007) and also inhibits downstream consequences of changes in gene
transcription including ΔFosB (Lhuillier et al., 2007) and neuropeptide gene
expression (Zhou et al., 2004). This transcriptional regulation by the GABABR
may also reduce the expression of proteins that regulate mnemonic processes,
e.g., NMDA receptors which are known to be regulated by CREB (Mayr and
Montminy, 2001; McClung and Nestler, 2003). In addition, GABABR mediated
inhibition PKA (via cAMP) would be expected to negatively impact memory
processes as direct inhibition of PKA impairs the maintenance of spatial, fear
conditioned, and recognition memory (Abel and Nguyen, 2008; Wang et al.,
2006) as well as memory consolidation (Bourtchouladze et al., 1998; Quevedo et
al., 2004; Vianna et al., 2000; Isiegas et al., 2006) and reconsolidation (Micheau
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Riedel,
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GABABR

before

G-protein
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after

independent

mechanisms, where transcription factors bind directly to the receptor, may also
be involved (e.g., CREB2) (White et al., 2000; Nehring et al., 2000; Vernon et al.,
2001).

Thus, there are multiple avenues by which augmenting GABABR

signaling can disrupt the cue-activated brain state which may account for the
behavioral inhibition observed when baclofen was administered in conjunction
with extinction training.

In contrast to the cue-activated brain produced during re-exposure to drugassociated cues (e.g., during extinction training) (Brown et al., 1992; Ciccocioppo
et al., 2001; Franklin and Druhan, 2000; Rhodes et al., 2005; Zombeck et al.,
2008; Miller and Marshall, 2005; Rebec and Sun, 2005; Bell et al., 2000;
Hotsenpiller et al., 2001; Hotsenpiller and Wolf, 2002; Lin et al., 2007), the
remaining studies primarily evaluated the effects of baclofen given without reexposure to conditioning cues. Thus, administration of PAMs, which are highly
dependent on extracellular GABA concentrations, may function quite differently in
a cue-activated brain vs. a ‘non-activated’ brain. Although these brain states are
quite different, results from this project demonstrated that augmented GABA BR
signaling during the maintenance period is also sufficient to disrupt processes
necessary to maintain Meth-induced CPP. This effect may be the consequence
of the highly dynamic brain state that exists during the days and weeks following
psychostimulant administration and learning with different kinases, transcription
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factors, and proteins being expressed and activated in a time dependent manner
(Lonze and Ginty, 2002; Selcher et al., 2002; Wang et al., 2006; Bailey et al.,
1996; Nestler, 2001; Chen et al., 2009; Berke and Hyman, 2000; Carlezon et al.,
2005; McDaid et al., 2006b; Ford et al., 2009; Alberini, 2009). Based on results
obtained with the PAMs, regions which are critical for the maintenance of Methinduced CPP express GABABRs and have endogenous GABAergic tone.

While it is difficult to predict what brain regions systemic administration of
baclofen, fendiline, GS39783, or CGP7930 might most influence; guided several
criterion we chose to explore the MDT as a critical mediator of the effects of
systemically administered ligands.

The MDT i) expresses moderate to high

levels of GABABRs (Margeta-Mitrovic et al., 1999; Charles et al., 2003), ii) is
tonically regulated by endogenous GABA (Churchill et al., 1996a), iii) sends a
glutamatergic projection to the PFC which is known to regulate drug-induced
behaviors and mnemonic processes (in fact the orbitofrontal cortex is defined
almost entirely as a projection region of the MDT) (Goldman-Rakic, 1995; Kuroda
et al., 1995; Krettek and Price, 1977; Sesack et al., 1989) which alters PFC
neuronal activity (Bubser et al., 1998; Pirot et al., 1994; Ferron et al., 1984; Gigg
et al., 1992), and iv) studies which demonstrate an involvement of the MDT in
drug-induced behaviors (Churchill and Kalivas, 1999) and mnemonic processes
(Romanides et al., 1999; Floresco et al., 1999; McAlonan et al., 1993; Kalivas et
al., 1999; Kalivas et al., 2001; Oyoshi et al., 1996).

As this anatomical

connectivity would predict, augmenting GABABR signaling in the MDT, which
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should reduce glutamate release in the cortex (Bubser et al., 1998; Pirot et al.,
1994; Ferron et al., 1984; Gigg et al., 1992), was sufficient to disrupt processes
necessary to maintain Meth-induced CPP (Chapter VII). Glutamate in the PFC is
a critical regulator of mnemonic processes (Wang et al., 2006). Administration of
baclofen into other regions which provide significant glutamatergic input to the
PFC would be expected to have similar behavioral outcomes. The HC provides
glutamatergic input to the PFC and intra-HC baclofen inhibits passive avoidance
memory retention (Zarrindast et al., 2002) as well as the acquisition of spatial
memories (Arolfo et al., 1998). In contrast to these results, baclofen injected into
the HC in the current study did not inhibit the maintenance of Meth-induced CPP
(Chapter VII). Thus, intra-HC baclofen does influence mnemonic processes, but
this effect may be a task-specific (i.e., associative learning vs. spatial or passive
avoidance learning), phase specific (i.e., acquisition vs. maintenance), or dosespecific. It is interesting that the HC, which does provide glutamate to the PFC,
was not identified by Rhodes and colleagues as a region which is engaged
during re-exposure to Meth-associated cues in a Meth-CPP protocol (Rhodes et
al., 2005).

Future studies evaluating the amygdala which does provide a

glutamatergic input and is activated during cue re-exposure would be of value in
determining the neurocircuitry underlying the maintenance of Meth-induced CPP.

Our results suggest that brain region-selective augmentation of GABABR
signaling disrupts Meth-induced CPP more rapidly than non-selective activation
of GABABRs throughout the brain. This conclusion is drawn from the observation
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that two once-daily systemic injections of the selective PAMs GS39783 and
CGP7930 (Chapter VI), and local injection of baclofen into the MDT (Chapter
VII),

inhibited

the

maintenance

of

Meth-induced

CPP,

whereas

two

administrations of baclofen (Chapters IV & VI) or the PAM/L-type Ca++ channel
blocker fendiline did not (Chapter V). Thus, global activation of GABA BRs by
baclofen or the global inhibition of L-type Ca++ channels by fendiline may negate
the effects of selectively augmenting GABABRs in areas where GABA is
endogenously released. That is, the GABABR influence on neuronal activity in
particular brain regions appears to have been overridden by global inhibition
throughout the brain. This effect was independent of the post-conditioning time
during which the two once-daily injections of baclofen and fendiline were
administered (i.e., early post-conditioning time vs. a later post-conditioning time).
Although the brain is highly dynamic during the days and weeks following
repeated psychostimulant administration (Camp et al., 1997; Ernst and Chang,
2008; Jayaram and Steketee, 2005; McDaid et al., 2006b; McGregor et al., 2005;
Zhang et al., 2000; Zhang et al., 2001; Giorgetti et al., 2002; Ford et al., 2009)
and memory acquisition (Abel and Kandel, 1998; Alberini, 2009; Bailey et al.,
1996), we did not observe time-dependent effects of baclofen or fendiline on the
maintenance of Meth-induced CPP. Rather, the inhibitory effects of baclofen and
fendiline appeared to be dependent on the number of treatments (i.e., protocol
duration) and not on the post-conditioning withdrawal time during which the
ligands were administered.
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These findings indicate that persistent adaptations engendered by repeated
GABABR activation and/or Ca++ channel inhibition are needed to disrupt the place
memory. Alterations in neuronal function resulting from two fendiline injections
were not sufficiently robust to inhibit maintenance and subsequent expression of
Meth-induced CPP when rats were tested in a drug-free state whereas drug-free
inhibition of the preference was observable after 10 injections.

Reports

underscore that such adaptations are long lasting; e.g., 10 once-daily injections
of baclofen inhibits the expression of amphetamine- and morphine-induced motor
sensitization when evaluated 28 (Bartoletti et al., 2004) and 30 (Bartoletti et al.,
2007) days after the last administration, respectively. Such persistent effects
may reflect long term changes in gene expression which do not occur with two
injections. Evidence for this effect can be found in Chapter V, two once-daily
injections of fendiline rendered the brain vulnerable to an acute injection of
fendiline; however, this effect was only observed for those rats which received
fendiline during the late post-conditioning phase and not when fendiline was
administered during the early post-conditioning phase. This indicates that the
adaptations engendered by two injections of fendiline were not sufficiently robust
(i.e., they are not observable in drug-free rats) nor did they persist (i.e., note
behavioral differences between two injections during the early vs. late postconditioning phase).

It should be noted that we interpret these effects in terms of ‘maintenance of
previously acquired associations’ but the behavioral outcomes also might reflect
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changes in motivation (Ma et al., 2010).

Future studies evaluating the

maintenance of other learned behaviors (e.g., Morris water maze, fear
conditioning, novel object recognition) vs. tasks that more directly assess
motivation (e.g., assess break point) are necessary to conclusively determine the
mechanism underlying the observed behavioral effects. This will be especially
important in light of the observation that in a progressive ratio experiment,
baclofen (3.2mg/kg, i.p.) reduces cocaine self-administration break point when
given 30min prior to the test while having no effect on food self-administration
(Brebner et al., 2000). Thus, it will be informative to conduct a similar test with
GABABR agonists and/or PAMs administered during the post-acquisition phase
on a drug-free test for break point.

While many of the exact underlying mechanisms are conjecture it is clear that the
GABABR is an exciting and highly therapeutically relevant target for an antiaddiction therapy. Results from this project suggest that not only do PAMs have
an improved side effect profile over the agonist baclofen but also that they may
afford significant therapeutic advantage wherein the selective PAMs GS39783
and CGP7930 were able to disrupt the maintenance of CPP with fewer
administrations than baclofen or the non-selective PAM fendiline. Thus, it will
certainly be of value to explore the use of the selective GABABR PAMs GS39783
and CGP7930 as anti-addiction therapies.
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